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Abstract: Ras, p63 and Breast Cancer 
Kathryn Yoh 
 
As a master regulator of the epithelial state, p63 is a family member of the well-
known tumor suppressor p53. It has previously been connected to a cancer-associated 
process, epithelial-to-mesenchymal transition (EMT), and here we find that it can be 
regulated by oncogenes involved in breast tumorigenesis. Specifically, activated forms 
of PIK3CA and H-RAS are able to strongly repress expression of ∆Np63α, which is the 
major p63 isoform in epithelial cells. In mammary epithelial lines, this oncogene 
downregulation occurs at the transcriptional level, and complete repression occurs over 
the course of several days.  
As p63 is repressed, the cells undergo EMT and acquire the ability to invade 
individually through a 3D collagen matrix. Strikingly, even when p63 is suppressed but 
no oncogene action is present, these cells undergo a mesenchymal shift, suggesting 
the importance of this gene in maintaining the epithelial state. Furthermore, it is 
particularly interesting that p63 protein and RNA levels are often low in breast tumors. 
By connecting H-RAS and PIK3CA signaling to p63, it is hypothesized that such 
oncogene suppression could account for tumor progression in cases where p63 levels 
are low. Here, it is proposed that p63 acts in a tumor-suppressive manner, although it 
can be overcome by oncogenes leading to changes in differentiation state and 
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 Women with basal-like breast cancers, which usually have triple-negative status, have 
the worst prognosis among all breast cancer patients. These cancers are aggressive and there 
is a lack of targeted therapies, since the signaling pathways that go awry in these cancers have 
yielded few druggable targets. Herein, I discuss the current situation in this field, including the 
various subtypes, treatments, and common mutations in this tissue. Tumorigenic processes 
such as EMT (epithelial-to-mesenchymal transition) are discussed, along with the circuits 
regulating these pathways. The evidence for cancer stem cells, metastatic niches and 
progenitor cells will be presented. 
 After this, the p53 family is described in depth, which includes homologues p63 and p73. 
The impact of p53 and p63 in governing an array of cellular processes, especially those 
contributing to tumor-related processes, is summarized. As p63 is of great interest, I provide a 
detailed analysis of its history, associated diseases and advances in the understanding of this 
regulator of epithelial tissues. Its impact on target genes, including microRNAs, is analyzed, 
along with any published connections to cancer (including EMT). 
 Following this, the Ras signaling pathway is expounded in detail. Interactions between 
the Ras and p53 families are described, illuminating the interconnectedness of these signaling 
pathways. Finally, our work concerning the regulation of p63 and p53 is detailed in Chapters 2 






Breast Cancer, Current Outcomes and Therapies 
The human breast is thought to have evolved differently from that of other primates, as 
evidenced by the finding that human females have larger deposits of adipose tissue (see review 
by Dixson et al., 2015). Both adipose tissue and connective tissue (consisting the stromal 
tissue) surround a network of ducts that end in a network of terminal ductal lobular units or 
TDLUs (see Figure 1). The terminal end buds are club-shaped outgrowths forming from the duct 
that will eventually form new lobes or alveoli as the mammary gland differentiates. The outer 
layer of each duct or lobe is comprised of basal/myoepithelial cells, characterized by keratins 5 
and 6, as well as p63 expression (Dairkee et al. 1985; Nagle et al. 1986; Trask et al. 1990; 
Nylander et al. 2002). There is also an inner layer of luminal cells, which typically express 
keratins 8, 18 and 19 (Bartek et al. 1985; Taylor-Papadimitriou et al. 1989). Luminal secretory 
cells in the lobes are responsible for producing milk, involving the action of hormones such as 
prolactin and insulin (Borellini & Oka 1989; Qian & Zhao 2014). When a woman is lactating, milk 
is produced there and carried via the ducts to the nipple. Clearly, the breast is a complex and 
important tissue, essential for the wellbeing of human progeny. 
However, breast cancer is one of the leading cancer-related killers of women worldwide 
(Stewart et al., 2014). In the United States alone, it is estimated that around 230,000 women 
were diagnosed in 2015 (Siegel et al., 2015, American Cancer Society, 2015). Nearly 12% of all 
women will be diagnosed with breast cancer at some point in their lifetime, although 89% of 
those women will survive at least 5 years post-diagnosis, up from 75% in 1975 (Howlader N, 
2015). In summary, diagnoses of breast cancer are common in the U.S. and worldwide, so there 
is great incentive to reduce incidence rates and improve standards of care. 
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As with many cancers, early diagnosis is key to improving prognosis. If a mammogram, 
other type of imaging or a physical examination identifies a suspicious lump within the breast, a 
biopsy can be taken and analyzed. One of the least invasive ways to do this is with Fine Needle 
Aspiration (FNA), where cells are taken from a suspicious lump or area of the breast with a very 
thin needle (Willems et al. 2012). It can also be done with the help of MRI or other locating 
technology (stereotactic biopsy). Slightly riskier methods include using a vacuum-assisted 
needle that gathers samples or a hollow core needle (Dahabreh et al. 2014). Of course, it is 
possible to remove some tissue surgically, which might be assisted by needle (wire) or 
radioactive seed localization (Diego et al. 2014). With all of these, there is some risk of false 
negatives, if normal cells are sampled, or along with tumor cells.  
Once biopsies are taken, they can be stained for various proteins and examined under 
the microscope. For example, two hormones that play a role in normal breast development and 
tumor processes are estrogen and progesterone (Graham & Clarke 1997; Platet et al. 2004). 
Quite early on, it was noted that expression of their receptors could be correlated with cancer 
prognosis and/or survival (Pike et al. 1983; McGuire 1978). As an example, testing for Estrogen 
Receptor (ESR1 or simply ER) status predicates whether treatment with the estrogen antagonist 
tamoxifen might be successful (Rutqvist et al. 1989; EBCTCG 1998).  Progesterone Receptor 
(PR) and the oncogene Epidermal Growth Factor Type II Receptor (EGFR2, also known as 
ERBB2/HER2/neu) are the two other receptors routinely tested (Clark et al. 1983; Schechter et 
al. 1984; Bargmann et al. 1986). HER2 amplification/overexpression was a prognostic factor 
and found in 15-20% of breast cancers (Andrulis et al. 1998; Sjogren et al. 1998; Ross & 
Fletcher 1998).  As HER2 signals to a large network of genes regulating processes like growth 
and the cell cycle progression (see Figure 2), deregulation of HER2 has negative consequences 
in various tissues, not just in the breast (Hirsch et al. 2003; Hechtman & Polydorides 2012; Sholl 




Nevertheless, patients with HER2-enriched tumors often have the best prognosis of all 
breast cancer patients, due to treatments like Herceptin and its derivatives. Herceptin 
(trastuzumab) is a monoclonal antibody targeting HER2 used for adjuvant treatment of 
metastatic breast cancers (MBC) overexpressing that gene (Slamon et al. 2001; Slamon et al. 
2011; Romond et al. 2005; Piccart-Gebhart et al. 2005). Herceptin not only suppresses HER2 
activation and downstream Akt kinase phosphorylation; it also induces antibody-dependent 
cellular cytotoxicity (ADCC), stimulating natural killer cells (Arnould et al. 2006; Junttila et al. 
2009). And yet, most patients on this treatment eventually relapse. Potential mechanisms 
include upregulation of IGF-IR, alterations in the cyclin-dependent kinase inhibitor p27kip1, or 
modulation of other signaling pathways, thus subverting the blockade of HER2 (see reviews by 
Fiszman and Jasnis 2011; Robinson et al. 2013).  
Another antibody, Avastin (bevucimab), is an anti-angiogenesis drug that was shown to 
improve progression-free survival in patients (Miller et al. 2007). It was indicated for the 
treatment of MBC, including the HER2-negative type, from 2008 to 2011 when its approval was 
revoked by the FDA. However, Avastin is still being used to treat other types of cancers, and it 
can still be prescribed off-label for MBC. Additionally, Tykerb (lapatinib) is a tyrosine kinase 
inhibitor (TKI) of HER2 and EGFR. It can be used in combination with chemotherapy, hormone 
therapy or Herceptin (Blackwell et al. 2010; Blackwell et al. 2012; Guan et al. 2013).  
Meanwhile, ER-positive tumors have been treated with tamoxifen, an estrogen 
antagonist which competitively binds to estrogen receptors (ESR1/ER-α and ESR2/ER-β). 
These are both expressed in breast and other tissues, however ER-α has a well-established 
role in regulation of breast cancers, whereas the impact of ER-β is less clear (Platet et al. 2004). 
ER-α has two activation function domains, AF-1 and AF-2, found at the N terminus and C 
terminus of the protein. Agonist binding to ER-α allows for conformational changes leading to a 
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transcriptionally active receptor, whereas antagonist binding reduces coactivator binding and 
AF-2-dependent activity (Shiau et al. 1998; Pike et al. 1999). In the case of antagonist binding, 
there is some residual agonist activity, although there is reduced ER-dependent gene 
transcription as compared to when estrogen binds (Berry et al. 1990; Johnston and Dowsett 
2003). Because of this, therapies that fully silence ER transactivation have been developed. 
Currently, the 3rd generation of aromatase inhibitors, so named for the enzyme that converts 
androgen to estrogen, is used as a first-line approach in ER-positive or PR-positive cancers 
(reviewed in Fabian 2007). These do not allow any ER activity, and use of these hormonal 
treatments generally leads to improved outcomes when compared to tamoxifen (Coombes et al. 
2007; EBCTCG 2016). However, some patients develop resistance to endocrine therapy, for 
instance by losing ER expression or activating HER2 signaling (S. R. Johnston et al. 1995; 
Sabnis et al. 2010). Such activation of HER2 signaling might be an alternate technique to 
strengthen AF-1-mediated transactivation, as it is a known ER cofactor (Johnston et al. 1999; 
Schiff et al. 2000).  
An inconvenient truth is that mortality rates differ significantly based on the type of breast 
cancer a woman is diagnosed with (Dawood et al. 2011; Engstrøm et al. 2013). Even today, 
standard chemotherapeutic drugs like Abraxane (paclitaxel) and Halaven (eribulin) are still used 
to treat MBC. There is one targeted treatment, an inhibitor of the kinase mTor, that can be used 
in combination with an aromatase inhibitor to treat ER-positive, HER2-negative MBCs (Baselga 
et al. 2012). However, there are only limited targeted therapies available for triple-negative 
breast cancers, which do not appreciable levels of ER, PR, and HER2. These comprise about 
15% of breast cancers, are considered an aggressive subtype and are associated with poor 
prognosis (see review by Chacon and Costanzo 2010). Therefore, it is of great relevance to 




Breast Cancer: Molecular Subtypes, Grading and Staging, Heterogeneity 
In the last few decades, we have gained the ability to scan for certain cancer-associated 
mutations or to conduct whole genome sequencing of patient tumors. This may add greater 
specificity towards treating individual diseases. Such sequencing of such tumors has generated 
a new categorization of tumors, called ‘molecular’ or ‘intrinsic subtypes’ (Perou et al. 2000; 
Sorlie et al. 2003; Parker et al. 2009; The Cancer Genome Atlas 2012). These include at least 
five subtypes, including basal-like, luminal A, luminal B, HER2-enriched and normal-like 
(Wirapati et al. 2008; Reis-Filho & Pusztai 2011). Luminal A and luminal B had distinct gene 
patterns (the A subtype might have higher ER-α and GATA3 expression) although they could be 
PR-positive or PR-negative. Her2-enriched tumors do not always show receptor positivity based 
on immunohistochemistry (IHC) analysis; however these are correlated with worse prognosis 
(Parker et al. 2009; Haque et al. 2012). Luminal A usually has low proliferation marker (Ki-67) 
expression, while luminal B exhibits high Ki67 - associated with poor prognosis for these 
patients (Domagala et al. 1996; Trihia et al. 2003; Cheang et al. 2009). Also, there is some 
evidence of a claudin-low subtype, which resembles basal-like breast cancer in that it is 
frequently triple-negative (Herschkowitz et al. 2007; Prat et al. 2010; Sabatier et al. 2014). 
These cancers typically have low expression of E-cadherin and claudins such as 3, 4 and 7, and 
high mesenchymal marker expression, although they are less well-defined than the other five 
subtypes. Generally, these molecular-based subtypes are considered more reliable than the 
IHC-based method of receptor staining (reviewed in O’Reilly et al. 2015). 
Basal-like breast cancers comprise about 15-20% of all breast cancers. Most are triple 
receptor-negative, positive for basal keratins, integrin-β4 (ITGB4) and high grade; although 10-
15% do not fit this characterization (Perou et al. 2000; M-J. Kim et al. 2006; Cheang et al. 
2008). In Chapter 2, we examine publically available breast cancer data from The Cancer 
Genome Atlas (TCGA), and the basal marker p63 is low in all cancers (discussed in depth later 
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in this section). But it is especially interesting that they are lost in basal-like cancers, despite 
these cells typically expressing p63. There have been many other reports of low p63 expression 
in breast cancers, although the significance of this is largely unknown (Barbareschi et al. 2001; 
Wang et al. 2002; D. Stefanou et al. 2004; Matos et al. 2005; Tse et al. 2007; Hanker et al. 
2010). As basal-like cancers resemble TNBCs, only more heterogeneous, they are also hard to 
treat effectively. It is obvious that we must strive to understand the signaling pathways that can 
be targeted in these cancers. 
Although sequencing of tumors has become more routine, pathology-based analysis of 
cancer is still a main source of clinical information about cancers. A standard is pathological 
grading of the tumor, relying on a point system for characteristics such as degree of 
differentiation or tubule formation. One such system that was used historically is Bloom-
Richardson, describing Grades I-III in a large cohort of breast cancer patients (Bloom & 
Richardson 1957). A recent paper modified this system (now called Nottingham or Elston-Ellis) 
and confirmed that grading is correlated to prognosis in a long-term study (Elston & Ellis 1991). 
Specifically, grade I (well-differentiated) patients have the longer survival and event-free times, 
whereas grade III (low differentiation) is associated with the worst prognosis. 
Clinical staging is a different classification that takes the location and spread of the 
cancer into account, relying on pathology and imaging technology (see AJCC 7th edition). These 
are graded on the TNM system, standing for Tumor, Node, and Metastases. T0-T4 describes 
the primary tumor, whether it is ductal or lobular (DCIS or LCIS), how large it is and whether it 
reaches the skin or the chest wall (in which case, it is T4). T4d is inflammatory breast carcinoma 
(IBC), which is the most aggressive type and may contain dermal lymphatic metastases, also 
known as tumor emboli (Rosen 2001). As for N, while N0 indicates no nodal metastasis, N1-N3 
indicate axillary lymph node and possibly supraclavicular/infraclavicular lymph node metastasis. 
These lymph nodes run from the armpit to the collarbone (clavicle), and can drain lymph fluid 
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from the breast and surrounding areas. Because of the location of the axillary lymph node, right 
behind the breast, historically this was the first place metastases were detected (Nemoto et al. 
1980; Giuliano et al. 1994). And finally for M, M0 means there are no detectable metastases, 
while M1 indicates there is one or more detected (larger than 0.2 mm). Staging (I-IV) takes all of 
these into account, although any tumor with M1 is considered Stage IV, regardless of T or N 
status. Stage IV breast cancers have the worst prognosis, with a median survival of 26 months - 
although advances in imaging and therapy have improved this considerably from several 
decades ago (Thomas et al. 2015). 
It should be clarified that many of the above studies use endpoints like ‘disease-free 
survival’, which encompasses any local or distant evidence of disease, or any death, even if not 
attributable to cancer (Hudis et al. 2007). Progression-free survival or recurrence-free interval 
would refer to evidence of breast cancer-specific disease or death due to that cancer. Overall 
survival is probably the clearest, while another often-used term is ‘pathologic complete 
response’ or pCR. This may describe a situation in which there is no residual disease in the 
breast or nodes, or minimal non-invasive disease in the breast only (Fisher et al. 1998). pCR 
was found to be a good endpoint and statistically higher in luminal B, HER2-enriched and triple-
negative cancers (von Minckwitz et al. 2012; Cortazar et al. 2014). Usually pCR is associated 
with longer survival time, unfortunately, only a fraction of patients will attain this state.   
 
A complication in treating cancer is that tumor heterogeneity commonly occurs and adds 
difficulty in determining proper treatment regimens (see review by Bedard et al. 2013). There is 
intertumor heterogeneity, where patients with the same subtype display large genetic variation. 
Then there is intratumor heterogeneity, wherein areas of the same tumor display genetic or 
phenotypic differences. Single cell sequencing has been used to detect these differences; and 
to follow clonal evolution and oncogenic drivers in primary breast cancers (Shah et al. 2012; 
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Nik-Zainal et al. 2012). Indeed, the first report indicated there is larger intratumor and intertumor 
heterogeneity in TNBCs, suggesting these cancers should not be treated as a single entity 
(Shah et al. 2012). While clonal evolution contributes to heterogeneity, differentiation of cells 
within tumors may be another mechanism (reviewed in Meacham and Morrison 2013). 
In addition, genomic instability is frequent in cancers and is likely to contribute to 
heterogeneity (see review by Giam and Rancati 2015). This can occur at two levels: nucleotide 
or chromosome instability, where large sections of chromosomes may be gained or lost and 
rearrangements may take place. Chromosomal instability (CIN) often leads to aneuploidy, 
where total chromosome numbers are abnormal. CIN has been correlated to poor prognosis, 
but with aneuploidy, correlation with prognosis is less clear (McGranahan et al. 2012). 
Additionally, localized regions undergoing high rates of mutations were discovered in breast 
cancers (Nik-Zainal et al. 2012; Alexandrov et al. 2013). Recently, a new mutational event has 
been described, termed ‘chromothripsis’, wherein large amounts of chromosomal 
rearrangements occur in a single event (Stephens et al. 2011; Rausch et al. 2012). So far, only 
a subset of cancers have been found to undergo this process, but this might explain the greater 
aggressiveness in cancers where this is prevalent.   
Finally, therapies can provoke larger tumor heterogeneity, which may be correlated to 
poor prognosis (Robinson et al. 2013; Janiszewska et al. 2015).  This is called temporal 
heterogeneity, and it suggests that comparison to patient samples from before treatment may 
be irrelevant in some cases. This is a conundrum in cancers where it is not easy to get a biopsy 
after each treatment regime, or there is a slight risk associated with such procedures. Hence, 
there is a need for less invasive assays that can paint a clear picture of what is happening 
during tumor progression in vivo. 
Circulating tumor cells (CTCs) have been isolated from patient cancers, and these 
behaved like cancer stem cells (CSCs) in that they were able to form tumors in mice (Baccelli et 
9 
 
al. 2013). CTCs show promise for the tracking of tumor progression. For instance, they can be 
analyzed for HER2 status after treatment with Herceptin, so treatment can be adjusted if 
necessary (Munzone et al. 2010). Many assays are being developed to capture or detect CTCs, 
and to see whether biomarkers correlate to various endpoints (reviewed in Bystricky and Mego 
2015). Some groups have even developed PCR-based methods to assay circulating tumor DNA 
(ctDNA) from small cohorts of breast cancer patients undergoing treatment (S-J. Dawson et al. 
2013; Olsson et al. 2015). In these cases, levels of ctDNA predicted relapse and disease-free 
survival, suggesting that they are excellent biomarkers. In another report, similar to the work 
with HER2 tracking above, specific patient mutations was tracked via ctDNA sequencing 
(Garcia-Murillas et al. 2015).  This group demonstrated that such mutation tracking indicated 
whether treatment was effective; as mutation abundance was correlated with clinical relapse. 
Clearly, these technologies are promising and can give us more tools with which to fight cancer. 
The needle has shifted towards personalized/precision medicine, which relies on 
sequencing of patient tumors. Disease stratification by mutations will certainly provide more 
information about proper courses of treatment. However, the data is mixed as to whether 
targeted treatment leads to improved response rate (see review by Chen and Bedard 2013). In 
some trials, specific treatments add improvement in endpoints measured, while in others they 
do not (Gelmon et al. 2011; Andre et al. 2013; Bieniasz et al. 2015). So far, many of the trials 
use inhibitors of common alterations, like the ones discussed below. 
 
Mutations frequently found in breast and other cancers 
 A gene closely associated with breast cancer is BRCA1, for ‘breast cancer 1’. Mutations 
in BRCA1 and another gene BRCA2 were first identified in familial breast cancers, although 
perturbations in these also occur rarely in sporadic cases (Hall et al. 1990; Easton et al. 1993; 
Futreal et al. 1994; Rebbeck et al. 1996). These genes are tumor suppressors involved in repair 
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pathways like double-strand break and nucleotide excision, such that alterations in these lead to 
genomic instability (Sharan et al. 1997; Scully et al. 1997; Shen et al. 1998; Xu et al. 1999; 
Hartman & Ford 2002). Additionally, they modulate cell cycle progression by interacting with 
proteins like cyclin E1 (CCNE1) and p21 (CDKN1A), among many others (Hakem et al. 1996; 
Somasundaram et al. 1997; Xu et al. 1999). Interestingly, BRCA1 mutation carriers were more 
likely to present with the basal-like breast cancer subtype (Sorlie et al. 2003).  
A key receptor discussed earlier, EGFR2 forms heterodimers with other EGFR family 
members, leading to downstream signaling through the Ras pathway. A major effector 
downstream of Ras is the PI3K/Akt pathway. There are 8 mammalian PI3K enzymes, however 
four of them fall into class I PI3Ks, each of them playing a role in tumorigenesis (see review by 
Fruman and Rommel 2014). While all PI3Ks can synthesize phosphoinositides, class I alone is 
able to generate phosphatidylinositol-3,4,5-trisphosphates (PIP3) (reviewed in Jean and Kiger 
2014) . The four class I members are p110α, p110β, p110γ, and leukocyte-specific p110δ, and 
of these p110α (PIK3CA) mainly receives signaling input from Ras.  In mammals, any of the 
catalytic subunit p110s can form a complex with one of five regulatory subunit p85s (Carpenter 
et al. 1990; Holt et al. 1994). Upon stimulation, these complexes are brought to the membrane, 
where they can catalyze formation of phosphatidylinositol (4,5)-bisphosphates (PIP2) to PIP3. 
Opposite of this is the phosphatase PTEN, which converts PIP3 back to PIP2. Mutations in 
PIK3CA and PTEN are frequently found in breast cancers, especially those of the basal variety 
(Depowski, Rosenthal, and Ross 2001; Samuels et al. 2004; Wu et al. 2005; Stemke-Hale et al. 
2008; Cancer Genome Atlas 2012). The two most common hotspot mutations in PIK3CA 
include H1047R and E345K, which lead to increased Akt kinase activity and transformative 
properties in mammary cell lines (Zhao et al. 2005; Isakoff et al. 2005).  
Various PI3K inhibitors, including buparlisib (BKM120), a class I phosphoinositide-3-
kinase inhibitor, are undergoing trials in breast cancer patients, particularly those with PIK3CA 
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or PTEN mutations. However, most trials have reported only limited clinical activity of these 
inhibitors, with the exception of the p110δ inhibitor Zydelig (idelalisib) which gained approval in 
blood cancers (reviewed in Fruman and Rommel 2014). Additionally, mutations in these genes 
do not seem to predict prognosis, at least as reported in the trials so far. It is possible that using 
isoform-specific inhibitors or combination therapies will be more successful in staving off PI3K-
dependent cancers (see review by Thorpe, Yuzugullu, and Zhao 2015).  
 
The tumor suppressor p53 is often mutated in a range of cancers, including a quarter of 
breast tumors (Hollstein et al. 1994; Petitjean et al. 2007). Loss of an allele or mutation of this 
gene generally leads to tumor-promoting activity (see reviews by Ko and Prives 1996; J. Liu et 
al. 2014). Along with this, there is an increased likelihood of eliminating the remaining allele 
(called loss of heterozygosity or LOH). This likely explains why TP53 mutation status is a 
prognostic factor in breast cancer – that and the finding that mutations were frequently found in 
the most aggressive subtypes, basal-like and HER2-enriched (Bergh et al. 1995; Langerød et 
al. 2007). The recent TCGA study suggested p53 function was often lost in basal-like breast 
cancers (nonsense and frameshift mutations), whereas mutant p53 (missense mutations) might 
be more prevalent in the other subtypes (Cancer Genome Atlas 2012). The reason behind this 
is unclear, but it might be speculated that different cancers have a selective growth advantage 
in the context of mutant p53 or lacking p53 altogether. For instance, lymphomas and sarcomas 
commonly occur in mice homozygous for p53 deletion, whereas the p53mut mice display a more 
varied tumor spectrum (Donehower et al. 1992; Jacks et al. 1994). 
The main function of p53 is to act as a DNA damage sensor, minimizing damage to the 
genome (reviewed in M. R. Junttila and Evan 2009). It becomes stabilized after stresses 
including damaging drugs, nutrient deprivation, and others. These differentially influence post-
translational modification of p53, contributing to greater stability (see review by Lavin and 
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Gueven 2006). Opposite of this, the E3 ubiquitin ligase Mdm2 targets p53 for degradation, and 
the two form an autoregulatory feedback loop (Prives 1998; Wade et al. 2013). 
Germline mutations in hotspots like R248 and R273 are often found in patients with Li-
Fraumeni syndrome, a familial cancer syndrome marked by early onset of various malignancies 
(Frebourg et al. 1995; Varley et al. 1997). There are at least two major classes of p53 mutations 
– the two above are ‘contact mutants’ since they affect core domain-DNA interactions (Cho et 
al. 1994). Meanwhile R175, R249 and other hotspots are ‘conformational’ mutants leading to 
local or global structural deviations from WT-p53 (Sigal & Rotter 2000). Even within the same 
class, there are differences in transactivation abilities and properties including cooperation with 
Ras (Weisz et al. 2007; Solomon et al. 2012). Also, mutant p53 has been shown to have gain-
of-function effects, which may subvert the effects of WT-p53 (reviewed in H. Song et al. 2007; 
Muller et al. 2014). Among these are transactivation of genes involved in angiogenesis, 
inflammatory pathways and metabolism (Dittmer et al. 1993; Yeudall et al. 2012; Zhang et al. 
2013; Zhao et al. 2015). Furthermore, work from our lab identified mutant p53-specific effects 
upon the sterol biosynthesis and chromatin remodeling pathways (Freed-Pastor et al. 2012; 
Pfister et al. 2015). All of these effects could explain why this gene is frequently altered in breast 
and other cancers (Cancer Genome Atlas 2012; Kandoth et al. 2013). 
 
Finally, retinoblastoma 1 (RB1) is a tumor suppressor frequently altered in cancers, and 
especially in breast cancers of luminal B and TNBC subtype (Lee et al. 1988; T’Ang et al. 1988; 
Jiang et al. 2010). Inactivating mutations, usually deletions, led to predisposition to 
retinoblastomas, hence its name (Sparkes et al. 1980; Sparkes et al. 1983). The protein, termed 
pRb, forms complexes with E2F family members and controls aspects of the cell cycle, affecting 
tissue homeostasis, erythroid development, and many other dependent processes (reviewed in 
H. Liu et al. 2004). Deregulation of RB1 also leads to chromosomal instability, which is likely 
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caused by mitotic defects (Sage & Straight 2010; Nath et al. 2015). Interestingly, targeting of 
both RB1 and p53 has suggested a cooperative effect in tumorigenesis (Williams et al. 1994; 
Meuwissen et al. 2003). Additionally, there is crosstalk between many of the above pathways, 
which can have wide-ranging effects on tumorigenesis (Sherr & McCormick 2002; Scata & El-
Deiry 2007). 
 
An Introduction to Epithelial-to-Mesenchymal Transition (EMT)  
 The original hallmarks of cancer, as written by Hanahan and Weinberg in 2000, detailed 
six capabilities that cancers acquire over the course of tumorigenic development (Hanahan & 
Weinberg 2000). These include evading cell death and senescence, while sustaining chronic 
proliferation, which can be achieved by deregulation of growth suppressive pathways. Increased 
angiogenesis and invasive/metastatic abilities are also traits of the most aggressive cancers. 
Such qualities were well-substantiated by the time the review was written, but of course the field 
has evolved considerably since then.  
Based on work done largely during this century, an update in 2011 gave us an additional 
two ‘emerging hallmarks’ of cancer: metabolic reprogramming and evasion of immune 
surveillance (see Figure 3) (Hanahan and Weinberg 2011). Tumor masses often initiate a 
metabolic switch, relying on increased aerobic glycolysis and secreting lactate - called the 
Warburg effect (Warburg 1956; Christofk et al. 2008; Hsu & Sabatini 2008). Cancer cells 
increase glucose uptake and usage, using this to generate NADPH and a steady metabolite 
pool (DeBerardinis et al. 2007; DeBerardinis et al. 2008; Boroughs & DeBerardinis 2015). 
Additionally, there is evidence that a functional immune system has multiple mechanisms to 
keep tumors in check (reviewed in Zou 2005). Many tumors show evidence of T cell-infiltration, 
and the presence of these cells within a tumor often correlates with clinical response (L. Zhang 
et al. 2003; Mahmoud et al. 2011). However, tumors can suppress such infiltrating T cells, as 
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well as disrupt T cell homing by deregulating chemokine expression (Curiel et al. 2004; Pivarcsi 
et al. 2007; Molon et al. 2011). Along with these, there are other pathways tumors have evolved 
to bypass immune surveillance (reviewed in Gajewski et al. 2013). 
A key question is how do cancers acquire these capabilities? Some may gain increased 
invasive and proliferative abilities by undergoing a program called “epithelial-to-mesenchymal 
transition” or EMT. Cells at the invasive front (the interface between normal stroma and the 
tumor) may go through this transition, to better migrate and disseminate (see review by Brabletz 
et al. 2005). Cell-cell attachment is mediated by factors including cadherins, which are Ca2+ 
transmembrane receptors (reviewed in Stemmler 2008). When extracellular Ca2+ is available, 
cadherins can form dynamic interactions with a range of molecules including catenins (α, β, γ 
and p120), anchoring the cytoskeleton to the plasma membrane (Aberle et al. 1996; Kobielak 
and Fuchs 2004). In this manner, E-cadherin can provoke assembly of adherens junctions and 
tight junctions, promoting close cell-cell contact (Gumbiner 2005; Hartsock & Nelson 2008). The 
cells grow closely to one another and resemble a cobblestone pattern when confluent.  
The transition process is characterized by loss of the classical Type I cadherin, epithelial 
cadherin (E-cadherin, CDH1). Once this happens, neuronal cadherin is induced (N-cadherin, 
CDH2) along with other mesenchymal markers (Hennig et al. 1995; Perl et al. 1998; Thiery 
2002). This process is also known as cadherin switching. E-cadherin acts as an invasion 
suppressor, possibly through its stabilizing interaction with β-catenin (Meiners et al. 1998; J. Luo 
et al. 1999; Wong and Gumbiner 2003). Perturbation of E-cadherin generally leads to disruption 
of the junctions, so that cells are no longer tightly attached. In addition, apical-basal polarity, a 
hallmark of epithelial cells and required for the correct patterning of tissue layers, is lost 
(reviewed in R. Y. Huang et al. 2012). These activities are dependent specifically on E-cadherin.  
How does loss of E-cadherin occur? Older studies suggested it was due to mutations 
within the gene, or possibly promoter hypermethylation (Graff et al. 1995; Berx et al. 1998). 
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However, the recent TCGA study suggested that the CDH1 gene is altered in only 7% of breast 
cancers, although germline mutations are slightly more common in lobular breast cancers 
(Cancer Genome Atlas 2012; J. S. Ross et al. 2013). Currently, it is accepted that in the majority 
of cases, E-cadherin expression is silenced by a range of transcription factors. This may be 
modulated by signaling pathways like transforming growth factor β (TGF-β), fibroblast growth 
factor receptor (FGFR), Notch, and Hedgehog, among others (reviewed in the next section). 
These pathways all lead to repression of E-cadherin, and subsequently mesenchymal transition. 
 
What is the function of N-cadherin? Although it is able to bind to many of the molecules 
as E-cadherin, it acts as a weaker intracellullar adhesion system (Monier-Gavelle & Duband 
1995; Chu et al. 2006). Cells expressing N-cadherin are more motile and invasive, even if they 
also have E-cadherin (Nieman et al. 1999; Hazan et al. 2000; J-B. Kim et al. 2000). This may be 
due to increased levels of cytokines such as interleukin-6 (IL6) and matrix metalloproteinases 
(MMPs) like MMP-9 (Suyama et al. 2002; Sullivan et al. 2009). Cancer cells typically secrete 
IL6, which plays a role in the immune response as well as migration and invasive ability 
(Boxman et al. 1993; Chavey et al. 2007). High levels of MMPs have also been linked to 
invasive properties and stimulation of angiogenesis (reviewed in Folgueras et al. 2004). MMPs 
function as zinc-dependent endopeptidases that cleave ECM components, thereby participating 
in tissue remodeling and modulation of the immune response. Besides MMP-9, MMP-2 and 
MMP-14 (also called MT1-MMP) have been connected to breast cancer, although there are 
many other family members, some of which are not increased in cancers (reviewed in Brown 
and Murray 2015). Together with expression of N-cadherin, these factors allows cancer cells to 
gain greater migratory, invasive and metastatic abilities (Hazan et al. 2000; Derycke & Bracke 
2004; Brown & Murray 2015). It should be noted that N-cadherin is normally present in 
16 
 
mesodermal tissues including the brain, where it affects neurite outgrowth and synapse 
plasticity (Paradies & Grunwald 1993; Jungling et al. 2006).  
Along with upregulation of N-cadherin, other typical mesenchymal markers include 
fibronectin, vimentin, and α-smooth muscle actin (αSMA, transcribed from the gene ACTA2). 
Different combinations of these genes, along with other markers, may be induced depending on 
the setting (reviewed in Lamouille et al., 2014). Mesenchymal cell migration is aided by 
fibronectin-dependent processes, like integrin and actin binding (Ridley et al. 2003; Veevers-
Lowe et al. 2011). Vimentin is an intermediate filament protein of fibroblasts, also linked to cell-
matrix interaction and focal adhesion dynamics (Ivaska et al. 2007). Perhaps because it 
mediates these processes, a distinct morphology and increased motility are seen in the event of 
vimentin expression (Hendrix et al. 1997; Mendez et al. 2010). Meanwhile, αSMA is present in 
stress fibers of fibroblasts, mediating ECM remodeling to allow cells greater contractibility (Hinz 
et al. 2001; Kondo et al. 2004).  
It should be noted that EMT can occur normally in development, such as at the 
gastrulation stage (Nakaya & Sheng 2008). In metazoans (kingdom Animalia), this process 
gives rise to three distinct germ layers (endoderm, mesoderm and ectoderm) which will form all 
the tissues of the body. The mechanisms for this vary across animals, but the similarity is that 
the epitheliod ectoderm gives rise to a mesenchymal-like mesoderm after a morphogenetic 
reorganization of the embryo (Morali et al. 2000; Ohta et al. 2007). The reorganization step may 
involve one or several of the following: involution, invagination and ingression. These refer to 
the precise movement of the cells involved. Additionally, EMT is essential during normal organ 
formation (Tam et al. 1997; Rivera-Feliciano et al. 2006).  
There are at least three types of EMT, differing on context (reviewed in Lamouille et al. 
2014). Type 1 covers development, including embryogenesis; as described above. Type 2 
occurs in tissue homeostasis, and it includes endothelial-to-mesenchymal transition (EndMT), a 
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similar process that generates fibroblasts leading to cardiac or renal fibrosis (Zeisberg et al. 
2007a; Zeisberg et al. 2008). Type 3 takes place in cancer settings, and has been linked to 
increased migratory and invasive properties, along with self-renewal capabilities (Friedl and 
Wolf 2003; L. Wan et al. 2013; Clark and Vignjevic 2015). In Type 3 EMT, the gain of N-
cadherin and the corresponding dispersed phenotype allows cancer cells greater invasive 
abilities (Frixen et al. 1991; Vleminckx et al. 1991). A key step of the metastatic cascade is 
intravasation; the process wherein primary tumor cells migrate through the basement 
membrane into the blood vessels (see Figure 4). EMT-enhanced invasive abilities likely 
contribute to cancer cell intravasation, and possibly other steps of the metastatic cascade 
(reviewed in Kalluri and Weinberg 2009, Bravo-Cordero 2012). 
It should be noted that EMT is usually reversible. There are many reports of in vitro EMT 
being revoked by drugs targeting the MAPK pathway, ROCK, and other important kinases 
(Janda et al. 2002; Rhyu et al. 2005; Das et al. 2009). Plasticity of this process is thought to be 
required for cells to undergo the opposing process, mesenchymal-to-epithelial transition (MET) 
once within the target organ. This is a logical reason for why it is hard to track such cells in 
metastatic tumors (reviewed in Brabletz et al. 2005; Gunasinghe et al. 2012). The evidence for 
MET at metastatic sites is limited, but includes re-expression of E-cadherin, allowing renewed 
cell-cell adhesion and proliferation (Oltean et al. 2006; Y. L. Chao et al. 2010; Y. Chao et al. 
2012; Wendt et al. 2011). On the other hand, some studies suggest EMT is altogether 
dispensible for metastasis, but it mediates chemoresistance and stemness (Steinestel et al. 
2014; Fischer et al. 2015; Zheng et al. 2015).  
Cells also undergo EMT to escape immune surveillance, another hallmark of cancer 
mentioned above. HER2-driven tumors underwent immunoediting, as defined by loss of 
antigenic variants and MHC expression (Knutson et al. 2006). Targeted immunoediting using 
HER2/neu-treated dendritic cells in DCIS patients also affected their immune response 
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(Czerniecki et al. 2007). Snail-induced EMT was shown to subdue the immune system by 
inducing suppressor T (Treg) cells and TSP1, an inhibitor of dendritic cells (Kudo-Saito et al. 
2009). Gaining a mesenchymal phenotype also protected cells against lysis by cytotoxic T 
lymphocytes (Akalay et al. 2013). These results and others suggest that the EMT pathway holds 
many advantages for cancers, allowing them to proliferate free of immune regulation. 
 
Regulators of EMT 
There are several canonical transcription factors known to repress E-cadherin by binding 
to E-boxes within its promoter - including Snail, Slug, and Zeb1 (Cano et al. 2000; Comijn et al. 
2001; Hajra et al. 2002). Twist and FoxC2 are also EMT inducers, although they indirectly 
repress E-cadherin (Yang et al. 2004; Thiery et al. 2009). Interestingly, some factors like Twist 
and Snail were first discovered in Drosophila melanogaster, the common fruit fly, where they are 
required for dorsoventral patterning of the embryos (Simpson 1983).  Deletion of either of these 
genes is lethal at the embryonic stage, as gastrulation does not occur (Nüsslein-Volhard et al. 
1984). Slug (SNAI2, or escargot in D. melanogaster) belongs to the Snail family and is required 
for mesoderm formation and neural crest development in some animals (Nieto et al. 1994; R. 
Mayor et al. 1995). Interestingly, mutant p53 can activate Slug and Twist, while there seems to 
be a negative feedback loop between WT-p53 and Twist (Shiota et al. 2008; Wang et al. 2009; 
Kogan-Sakin et al. 2011). 
Some recently discovered factors include YB-1, which allows for increased translation of 
Slug, Zeb2 and other canonical TFs, thereby inducing EMT (Evdokimova et al. 2009; Khan et al. 
2014). Lbx1 can similarly induce Snail, Zeb1 and Zeb2; increasing the stem cell/progenitor 
population (Yu, Smolen, et al. 2009). And FoxC2, mentioned earlier, is a member of the 
forkhead family of transcription factors, affecting EMT through PDGFR-β transactivation and 
likely other methods (Mani et al. 2007; Hollier et al. 2013). This gene was reported to be highly 
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expressed in the claudin-low subset of basal-like breast cancers (Hollier et al. 2013). 
Meanwhile, the Six1 transcription factor strengthens TGF-β-dependent signaling, leading to 
mesenchymal transition and increased metastasis in vivo (Micalizzi et al. 2009; McCoy et al. 
2009). Additional new inducers of EMT are still being elucidated. 
 
Many microRNAs regulators have also come to light, including miR-34a and miR-200 
family members (de Craene 2013, Jolly 2015).  MiR-34a is a well-known p53 target and acts as 
a tumor suppressor to induce cellular outcomes like arrest or apoptosis (Chang 2007, Tarasov 
2007). A recent report indicated miR-34a normally represses Snail, and by compromising p53 or 
miR-34a, Snail-dependent EMT is induced (Kim 2011). This microRNA is also known to interact 
with pluripotency factors like Nanog, Sox2 and N-Myc, along with Wnt1 and β-catenin, thereby 
affecting processes like EMT (Choi 2011, Kim 2011).  As it involves these stem-like elements 
and phenotypic switching, EMT can be considered akin to transdifferentiation (Jopling 2011). 
Members of the miR-200 family, including miR-141, miR-200b, and miR-200c are well-
known EMT suppressors, acting to inhibit Zeb1 and Zeb2 (Gregory et al. 2008; Korpal et al. 
2008; Park et al. 2008). MiR-203 and miR-205 also possess these abilities (Tucci et al. 2012; 
Tran et al. 2013; Moes et al. 2012). In these cases, overexpression of one of these miRNAs was 
sufficient to repress EMT, suggesting that they are quite powerful regulators. MiR-203 even 
exists in a feedback loop with Snail, and some miR-200 family members are reciprocally 
regulated by Zeb1 (Burk et al. 2008; Wellner et al. 2009; Moes et al. 2012). Additionally, these 
miRNAs are targets of p53 (T. Kim et al. 2011; Chang et al. 2011). Furthermore, miR-192 is a 
mediator of TGF-β-mediated EMT via Zeb2 (T. Kim et al. 2011; Hong et al. 2013). MiR-145 is 
another p53 target that plays a role in the mesenchymal transition, leading to pancreatic cancer 
invasiveness (Ren et al. 2013). In summary, microRNAs are powerful regulators of EMT, and 




One of the major signaling pathways leading to EMT is the TGF-β pathway. TGF-β 
comprises a family of serine/threonine kinase receptors, and alteration of these is associated 
with developmentally induced- and cancer associated-EMT induction (reviewed in Thiery et al. 
2009). In the canonical TGF-β pathway, ligand binding to a complex of receptors allows for 
downstream phosphorylation of transcription factors Smad2 and Smad3 (reviewed in Derynck 
and Zhang 2003). These activated Smads form a complex with Smad4 and are translocated to 
the nucleus, where they can activate or repress target genes. Transfection of either receptors I, 
II or III, or downstream Smad2 or Smad3, is sufficient to elicit EMT, suggesting that these 
Smads are key mediators of this pathway (Valcourt et al. 2005). The Smad3-Smad4 complex 
may even act as a cofactor for certain EMT regulators to provoke this effect (Vincent et al. 
2009). Also, the TGF-β pathway has extensive crosstalk with PI3K and MAPK signaling, 
suggesting additional sources of regulation (Bakin et al. 2000; Derynck & Zhang 2003). 
Several other growth factor pathways, including FGFR, can induce EMT possibly 
through factors such as Slug and Notch1 (Boyer and Thiery 1993; Savagner et al. 1997; Billottet 
et al. 2008). FGFR signaling mediates cell survival and angiogenesis, among other processes 
(reviewed in Turner and Grose 2010). Some FGFR members are also altered in cancers, 
particularly of the breast (Luqmani et al. 1992; Relf et al. 1997). In fact, SNPs within FGFR2 are 
strongly associated with breast tumors, indicating that this gene contributes to oncogenesis 
(Hunter et al. 2007; Easton et al. 2007). 
Meanwhile, Notch signaling directs cell fate in metazoan development; harnessing both 
proliferative and growth-suppressive effects to achieve correct patterning of the organism 
(Artavanis-Tsakonas et al. 1999). After ligands such as Jagged-1 or Delta-like 1 bind to the 
Notch receptor, cleavage results in an active fragment, Notch intracellular domain (NICD) 
(Blaumueller et al. 1997). NICD is translocated to the nucleus, activating many downstream 
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targets such as the HEY family of transcription factors, Gata3, c-Myc, and others (reviewed in 
Borggrefe and Oswald 2009). It can also interact with Snail and Slug in mediating mesenchymal 
transition, even cooperating with TGF-β for this effect (Zavadil et al. 2004; K. G. Leong et al. 
2007; Sahlgren et al. 2008). Besides this, Notch signaling is linked to hypoxia, and some reports 
suggest hypoxia induces Notch-mediated EMT (Gustafsson et al. 2005; Sahlgren et al. 2008; 
Zheng et al. 2008; Xing et al. 2011). 
Hedgehog (HH) signaling also works to regulate cell fate and patterning, and is essential 
for normal mammary gland development (Nusslein-Volhard & Wieschaus 1980; Lewis et al. 
1999; Michno et al. 2003). This pathway is associated with proliferation control, especially in the 
context of stem/progenitor cells (Liu et al. 2006; N. Li et al. 2008; Vied & Kalderon 2009; Tanaka 
et al. 2009). Components of the pathway are often altered in breast cancers, and especially in 
TNBCs (Tao et al. 2011; Souzaki et al. 2011). As HH ligands are secreted proteins, paracrine 
interactions have been studied in many contexts, including the breast (Yu, Gipp, et al. 2009; 
Garcia-Zaragoza et al. 2012). In the latter study, a HH ligand is secreted by breast luminal cells 
and received by nearby basal progenitor cells, implicating intraepithelial signaling in the 
aforementioned processes. There may also be epithelial-stromal HH signaling, affecting tumor 
growth and metastasis (O’Toole et al. 2011). HH signaling was shown to enhance EMT and 
metastatic growth, possibly through stimulation of the PI3K/Akt pathway (Kawahira et al. 2005; 
Morton et al. 2007; Yoo et al. 2011). Other reports suggest that Gli1, a key HH effector, can 
repress E-cadherin via induction of Snail (Louro et al. 2002; X. Li et al. 2006).  
In summary, there are many pathways that can induce EMT, and some of these act in 
concert to drive cells towards the mesenchymal state. This also suggests that the reverse 
process can occur via alterations of these pathways. For more about other regulators of this 





Breast Cancer Stem Cells, Progenitor Cells, and Mammary Stem Cells 
Stem cells are a rare subset of cells capable of self-renewal and differentiation into all 
cell types in a particular tissue (see review by Reya et al. 2001). These may be found in a stem 
cell niche, which was first described several decades ago (Schofield 1978). The niche is a 
specialized microenvironment composed of cells supporting the stem cells, or a mixture of cells 
and ECM components (reviewed in Lander et al. 2012). It is also a signaling hub where stem 
cells can receive cues from other tissues, thereby influencing whether they stay dormant, self-
renew or differentiate.  
Niches for specialized stem cells have been described, such as the niche for hair follicle 
stem cells or intestinal stem cells (Oshima et al. 2001; Barker et al. 2007). The hematopoietic 
stem cell (HSC) niche, which resides in bone marrow, is by now well-characterized (Lo Celso & 
Scadden 2011). Wnt and Notch signaling seem to play a role in regulating the HSC niche, as do 
adhesion molecules and surrounding chemicals. Importantly, niches can protect stem cells from 
damaging agents and/or immune attack (Eliasson & Jönsson 2010; Fujisaki et al. 2011). 
Stem cells have been found to drive both liquid and solid tumors, giving rise to the theory 
of cancer stem cells (CSCs) (Bonnet & Dick 1997; Al-Hajj et al. 2003). There is some evidence 
that CSCs, also called cancer-initiating cells (CICs) are formed after cells undergo EMT and 
gain stem-like markers (Mani et al. 2008; Morel et al. 2008). EMT regulators like Zeb1 and 
FoxC2 can regulate factors involved in stemness, including miRNAs (Mani et al. 2007; Wellner 
et al. 2009; Hollier et al. 2013). Another report suggested cooperation between Slug and 
stemness factor Sox9 can increase the metastatic potential of breast cancer lines (Guo et al. 
2012). These two factors can also convert differentiated luminal cells into mammary stem cells 
(MaSC), highlighting the similarity between these and breast cancer stem cells (BCSC). 
Polycomb group (PcG) proteins like Bmi1 and EZH2 also regulate self-renewal and 
tumorigenesis (O’Carroll et al. 2001; Lessard & Sauvageau 2003; Boyer et al. 2006). These act 
in Polycomb repressive complexes (PRCs), epigenetic modulators that can silence or activate 
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transcription of certain genes (reviewed in Di Croce and Helin 2013). Bmi1, EZH2 and other 
PcG members are often altered in cancers and in CSCs, and have also been found to enhance 
chemoresistance (Chase & Cross 2011; Siddique & Saleem 2012; Michalak et al. 2013).  
CSCs may reside in typical stem cell niches, or they may produce niche-like proteins 
and have the support of nearby factors (reviewed in Oskarsson et al. 2014). Cancer-associated 
fibroblasts (CAFs) are recruited to these sites or generated through mesenchymal transition, 
aiding in ECM remodeling and tumorigenic processes (Zeisberg, Potenta, et al. 2007; Erez et al. 
2010; Dumont et al. 2013). Stromal factors like periostin (Postn) and osteopontin (Spp1) are 
essential for metastatic niche colonization, regulating stromal-niche interactions (Malanchi et al. 
2012; Sangaletti et al. 2014; Squadrito & De Palma 2015). Macrophages are often recruited, 
likely to co-opt the native immune response and to assist in tumor invasion (Condeelis & Pollard 
2006; Wyckoff et al. 2007). The EMT program is also associated with niche activation, and vice 
versa (Sleeman 2012; Del Pozo Martin et al. 2015). This could be due to niche proteins like 
tenascin C, MMPs and the S100 family members aiding metastatic formation (Calvo et al. 2008; 
Oskarsson et al. 2011; Lukanidin & Sleeman 2012). In particular, S100A4 is secreted from 
tumor cells, upregulating MMPs and angiogenic factors (Bjørnland et al. 1999; Schmidt-Hansen 
et al. 2004). Other family members S100A8 and S100A9 prepare the niche by inducing 
inflammatory cytokines, attracting myeloid cells (see review by Lukanidin and Sleeman 2012). 
As mentioned before, infiltration of tumors with these cells is associated with increased 
vasculature and poor prognosis (reviewed in Murdoch et al. 2008). 
At the same time, niches are often hypoxic environments, so that stem cells can be kept 
dormant and protected from damage (reviewed in Cabarcas et al. 2011). Hypoxia-inducible 
factor 1, α subunit (HIF-1α) and its targets, such as Oct4 and Notch, are induced, and maintain 
the stem cell pool. ECM remodeling may take place, including upregulation of CXCR4, a 
chemokine receptor and CSC homing molecule (Burger & Kipps 2005; Ishikawa et al. 2009). 
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The hypoxic environment allows for increased Vascular Endothelial Growth Factor A (VEGF-A) 
and Lysyl Oxidase (LOX) production, driving further vascularization (Erler et al. 2009; Wong et 
al. 2011). It was noticed quite early on that CSCs are known to reside near blood vessels or 
areas with extensive vascularization, perhaps because of these effects (Bao et al. 2006; 
Calabrese et al. 2007). All of this can ensure that the CSCs are in a nutrient-rich environment, 
where they may be sheltered from harm. 
 
But, how are BCSCs, in particular, distinguishable from other CSCs? Like other CSCs, 
they are generally refractory to treatment (M. Diehn et al. 2009; Smalley et al. 2013). Some 
reports indicate BCSCs are CD44-positive and CD24-negative, with high aldehyde 
dehydrogenase (ALDH1) activity (Al-Hajj et al. 2003; Ginestier et al. 2007; Honeth et al. 2008). 
CD44 and CD24 are not only stem cell surface markers, they regulate cell-matrix interactions, 
often facilitating metastases (reviewed in Jaggupilli and Elkord 2012). There is some evidence 
that ALDH1, a detoxification enzyme, could play a role in BSCS resistance to chemotherapy 
(Sakakibara et al. 2012; Alamgeer et al. 2014). Another possibility is that altered levels of ATP-
binding cassette (ABC) transporters increase drug efflux; however targeting these factors 
remains problematic due to their expression in normal tissues as well as cancerous ones 
(reviewed in Dean 2009; Choi and Yu 2014). Additionally, various chemokines such as CXCR4, 
CXCL7 and IL6 are important regulators/markers of BCSCs (Sansone et al. 2007; Hwang-
Verslues et al. 2009; Liu et al. 2011). 
Despite the BCSC model, the cell-of-origin leading to breast cancers is still controversial 
(see review by Petersen and Polyak 2010). This may be due to the various strategies/assays 
used to isolate and investigate such cells, as well the likelihood that breast cancer subtypes 
differ in their originating cells. It is also important to note that the cell-of-origin may or may not 
resemble the BCSC, or even the MaSC (Visvader 2011). Most studies endeavoring to isolate 
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such cells use flow cytometry, based on the markers above. Other surface markers that may be 
associated with these cells include CD326 (EpCAM), the epithelial cell adhesion molecule, and 
CD133 (also known as prominin-1) (O’Brien et al. 2007; Wright et al. 2008; Sarrio et al. 2012). 
Additionally there is CD29 (Integrin-β1), which is highly expressed in cap cells of the terminal 
end buds, where stem cells reside (Kenney et al. 2001; Shackleton et al. 2006). Finally, Mucin-1 
(MUC1) is a glycoprotein prominently expressed in breast cancers and is a marker of BCSCs 
(McGuckin et al. 1995; Christgen et al. 2007; Engelmann et al. 2008). Not only can MUC1 
enhance ALDH1 activity; it may also heighten Zeb1-dependent EMT (Alam et al. 2013; Rajabi et 
al. 2014).  
 
Once a subset of cells have been isolated, it is common to test whether they can 
recapitulate mammary architecture in vivo. If the mammary gland is surgically removed from the 
fat pads of mice of 3 weeks age, full mammary development will not occur and the fat pads are 
considered cleared (Brill et al. 2008; Dunphy et al. 2010). In a pioneering study, transplantation 
of mammary tissue into cleared fat pads showed mammary fragments or dissociated cells could 
regenerate the full mammary gland (DeOme et al. 1959). This important assay can also be used 
to confirm the potential of MaSCs or progenitor cells in an orthotopic model. Seminal studies 
have indicated that a small amount of such cells could reconstitute a functional mammary gland 
(Kordon & Smith 1998; Shackleton et al. 2006). The latter study found that CD29-high CD24-
positive cells were capable of self-renewal and could form both ductal and lobular tissue in the 
fat pad (Shackleton et al. 2006). A very similar study had earlier found that CD44-positive 
CD24-negative cells formed tumors when injected into mammary fat pads of mice, and these 
cells could be expanded by serial passaging (Al-Hajj et al. 2003). These results and others 
would suggest a single lineage of stem cells gives rise to basal and luminal cells, suggesting a 
hierarchy in development. This is consistent with reports indicating the bipotent progenitor is 
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positive for Keratin 14 and Keratin 19 (Villadsen et al. 2007; LaBarge et al. 2009). A review 
proposed that bipotent progenitors are EPCAM-positive CD133-negtive and CD49f-positive 
whilst the luminal and basal progenitors express other markers (Stingl et al. 2005). These 
bipotent progenitors may also express the Wnt targets Lgr5 and Notch1, the latter receptor often 
being highly expressed in breast cancers (Rios et al. 2014; Rodilla et al. 2015; Yuan et al. 
2015).  
As for the luminal and basal/myoepithelial progenitors, these are described in other 
studies (Smith 1996; Stingl et al. 2005; Van Keymeulen et al. 2011). Consideration of these 
various progenitors might explain why there are somewhat conflicting results in this field. Adding 
to that, there is also evidence that luminal or basal progenitors can be reprogrammed to the 
other type (LaBarge et al. 2009; Van Keymeulen et al. 2015). This might happen as a result of 
oncogenic stimulus or microenvironmental changes. Interestingly, studies indicate BRCA1-
associated basal cancers have expanded luminal progenitor cell populations, and that gene 
expression profiles of luminal progenitors and basal cancers are quite similar (Lim et al. 2009; 
Shehata et al. 2012). This evidence suggests BRCA1-mutated basal cancers actually derive 
from luminal progenitor cells (Molyneux et al. 2010), although this may not be the case for other 
basal-like breast cancers.  
While the mammary fat pad assay is extremely useful, it is not exactly similar to the 
human breast. This is evidenced by the fact that some human mammary epithelial cells do not 
grow well in cleared fat pads, likely due to stromal interactions (reviewed in Hovey et al. 1999). 
Several groups have humanized the mouse fat pad by adding fibroblasts or immune cells like 
macrophages, resulting in greater progenitor self-renewal or enhanced tumor outgrowths 
(Kuperwasser et al. 2004; Proia & Kuperwasser 2006; Ginestier et al. 2007; Fleming et al. 
2012). One group describes another in vivo method where single epithelial cells and fibroblasts 
are embedded together in collagen gels, and after some time these were injected under the 
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kidney capsule of hormone-supplemented immunodeficient mice (Eirew et al. 2008). This 
causes bilayered ducts to form that resemble the human breast in distribution of proteins and 
regenerative potential. MaSCs can also be isolated, suggesting that epithelial-stromal 
interactions are key for progenitor cell development (Parmar 2002, Eirew 2008). 
 
Mammospheres can also be grown in gels made of collagen or Matrigel™, a 
reconstituted basement membrane secreted by Engelbreth-Holm-Swarm (EHS) sarcomas. This 
is an in vitro assay that can enrich for MaSCs (Dontu et al. 2003; Eirew et al. 2008). It is also 
feasible to qualitatively tell the differences in lineage of the cells tested (Eirew et al. 2008; Smart 
et al. 2013). Moreover, normal mammary cells or breast cancer cells are typically tested in 
Matrigel, as they usually grow well in this environment (O. W. Petersen et al. 1992; Janke et al. 
2000). Fascinatingly, they are several different morphologies seen in this 3D setting, including 
disorganized (grape-like) from the luminal lines and round colonies from most of the basal lines 
tested (Kenny et al. 2007).  
Additionally, spheroid assays in these 3D environments have yielded different toxicity 
data from 2D drug screens. It is commonly thought that 3D assays can better simulate the 
normal/tumor microenviroment and in vivo growth (Cioce et al. 2010; Oak et al. 2012). High-
throughput methods have been developed to screen large libraries of compounds, and cell line 
growth in 3D can be assessed to optimize treatments (Ranga et al. 2014; Li et al. 2015). It is 
noted that the cells become more heterogenous in 3D cultures with varying gene expression 
changes, and this, together with the microenvironment, mimics the situation in the human body 
(Celli et al. 2010; Smith et al. 2012; Tew & Fisher 2014). The hope is that such screens will 
allow for better synchronization with patient response, so that we will have more therapies 




Model cell lines for cancer research 
Mammalian cell lines and humanized mice are commonly used in cancer research. As 
there are a number of human-derived lines, both normal and tumorigenic, it is typical to use 
several of these for any study looking at a purported oncogenic or tumor suppressive effect. For 
our work in Chapter 2, well-characterized mammary epithelial lines were utilized. MCF-10A and 
MCF-12A are derived from spontaneously immortalized reduction mammoplasty samples from 
two separate women (Soule et al. 1990; Paine et al. 1992). These lines are non-tumorigenic and 
triple receptor-negative. Because of these attributes, experimental evidence with these lines 
may give us insight into patient TNBCs. However, they cannot be considered ‘normal’ cell lines 
due to the women having fibrocystic disease, which leads to benign lumps in the breasts 
(though this disease is not cancer-associated) (Guinebretière et al. 2005). The MCF-10A line 
strongly expresses myoepithelial/basal characteristics, including associated keratins and p63. 
The MCF-12A line is reported to represent either a basal population or a mixed basal/luminal 
population, depending on the paper (Paine et al. 1992; Subik et al. 2010). Transcriptional 
profiling of these cell lines suggests that they most resemble the basal-like subset of cancers, 
suggesting that both arise from basal progenitors (Neve et al. 2006; Kao et al. 2009).  
Neither the MCF-10A nor the MCF-12A cells form tumors when xenografted into nude 
mice, which are engineered to have a defective immune system response. They also do not 
form colonies in soft agar. However, several groups have described the characteristics of MCF-
10A cells transformed with H-RasV12, also known as MCF-10AT cells (Miller et al. 1993; Pauley 
et al. 1993; Dawson et al. 1996; Santner et al. 2001). When these cells are xenografted into the 
nude mice, a subset of the mice present with carcinomas; therefore the MCF10AT line is 
thought to closely resemble DCIS, a pre-neoplastic state. Additionally, they exhibit anchorage-
independent growth in soft agar and disorganized stuctures in Matrigel. Similarly, MCF-10A cell 
lines expressing hotspot mutations in PIK3CA undergo transformation, exhibiting enhanced 
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proliferation and colony forming ability (Isakoff et al. 2005). A separate derivative cell line 
MCF10CA1a had both the H-RasV12 and hotspot PIK3CA mutation, along with other cancer-
associated mutations (Santner et al. 2001; Kadota et al. 2010). This line was much more 
oncogenic than the parental MCF-10A cells, forming undifferentiated tumors in nude mice 100% 
of the time. Finally, another mutagenic study showed p53 mutations in MCF-10A lines were 
associated with anchorage-independent growth and tumor forming ability in vivo (Zientek-
Targosz et al. 2008).  
 
For our work in Chapter 3, NCI-H1299 lung carcinoma cells were used (from here, 
H1299). This line was derived from the lymph node metastasis of a patient with large cell 
carcinoma (Maneckjee & Minna 1990; Giaccone et al. 1992). It is positive for vimentin and has a 
homozygous deletion in p53, so that it lacks full-length p53 protein (Bodner et al. 1992). This 
must be an important growth requirement for these cells, as re-expressing p53 here leads to 
growth arrest, or inhibition of colony formation (Zakut & Givol 1995; Wang et al. 1998). So, in 
order to avoid senescence or arrest in these cells, we chose to use the tetracycline-inducible 
system to transiently express p53 in this background. These systems allow for the tight control 
of a protein of interest, by regulating the levels of tetracycline antibiotic in the media (Gossen & 
Bujard 1992; Gossen et al. 1995).  
 
 
An introduction to the p53 family, and p53 target genes 
The p63 gene was the most recently discovered among its family members, p53 and 
p73, although an ancient gene resembling p63/p73 actually predates the appearance of a p53-
like gene (reviewed in A. Yang et al. 2002; Belyi et al. 2010). The ancestral p63/p73 gene 
seems to be important for germline integrity; and gene duplication into the separate genes is not 
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seen until cartilaginous fish appear. However, the p53-like gene does not appear until the 
advent of bony fish like zebrafish, and continuing through vertebrates, some of the family 
members take on novel functions (Belyi et al. 2010, Yang et al. 1999, Mills et al. 1999, Yang et 
al. 2000). In this vein, analysis of the DNA-binding domains of these proteins demonstrates p53 
has changed considerably throughout its evolution in vertebrates, whereas p63 evolved the 
least and p73, an intermediate amount. 
There are general processes that each family member regulates, such as cell death, 
senescence and proliferation (Osada et al. 1998; M Dohn et al. 2001). This is not surprising as 
they share a similar modular architecture, with an N-terminus consisting of a transactivation 
domain (TAD), DNA-binding domain (DBD), and proline-enriched region. The C-terminal domain 
(CTD) also contains an oligomerization domain (OD), required for stabilization of the proteins 
(Sturzbecher et al. 1992; Iwabuchi et al. 1993). The p63 and p73 genes additionally contain a 
sterile α-motif (SAM) domain and the transcription inhibition domain (TID) at the C-terminal end.   
P53 and its family members regulate genes by binding to response elements usually 
within the promoters of genes, although there are some exceptions (Riley et al. 2008). This 
significant review also describes how p53 can acts as transcriptional activator, by recruiting 
histone acetyltransferases (HATs) to the promoter, or as a repressor, through various 
mechanisms.  For instance, p53 can inhibit transcription factors like Sp1 and CAAT enhancer-
binding protein α (CEBPA) and β (CEBPB), repressing genes they control like albumin and 
cyclin B1 (Kubicka et al. 1999; Innocente & Lee 2005). Binding of p53 can also result in 
recruitment of histone deacetylases (HDACs), leading to the repression of genes like 
microtubule-associated protein 4 (MAP4) and stathmin (STMN1) (Murphy et al. 1999).  
Usually, the p53 binding site is composed of two half-sites with the sequence 5'-
PuPuPuC(A/T)(T/A)GPyPyPy-3' separated by a variable spacer, although some genes contain 
many half-sites within close proximity (termed ‘cluster sites’) (Riley et al. 2008). Near-perfect 
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sites exist within the promoter of the p21 (CDKN1A) gene, a canonical p53 target also regulated 
by BRCA proteins (el-Deiry et al. 1993). The protein p21 can bind to various cyclin-dependent 
kinases (CDKs) and inhibit phosphorylation of Rb, thus limiting cell cycle progression (Harper et 
al. 1993). Interestingly, later work identified the necessity of p21 in facilitating p53’s repression 
of certain target genes like survivin (BIRC5) (Löhr et al. 2003). Another G1/S transition regulator 
is B-cell translocation gene 2 (BTG2), a member of the BTG/Tob family (Rouault et al. 1996). 
This family acts through various transcription factor complexes, altogether having an 
antiproliferative effect (Bogdan et al. 1998; Prevot et al. 2000). However GADD45A (growth 
arrest and DNA damage-inducible protein 45, alpha) leads to G2/M arrest, partly through 
inhibition of the Cdc2/Cyclin B1 complex (Kastan et al. 1992; Wang et al. 1999; Zhan et al. 
1999). The microRNA mentioned in an earlier section, miR-34a, is also a p53 target and can 
trigger apoptosis, arrest, and other outcomes (reviewed in Misso et al. 2014).  
In addition, there are pro-apoptotic p53 targets such as Puma, Noxa, and Bid, all 
members of the Bcl-2 family (Oda et al. 2000; Nakano & Vousden 2001; Sax et al. 2002). 
Usually, a combination of these are induced, leading to mitochondrial outer membrane 
permeabilization and caspase activation (reviewed in Vaseva and Moll 2009). Some evidence 
points to these factors being key to p53’s tumor suppressive abilities, as their deficiency was 
found to accelerate Myc-driven lymphomas (Garrison et al. 2008; Michalak et al. 2009). 
However, there is also data suggesting p53 has anti-tumorigenic effects outside of those 
mediated by p21, Puma and Noxa (Jiang et al. 2011; Valente et al. 2013).  
 
Certain p53 targets can affect the redox state of the cell. The aptly named TP53-
induced Glycolysis and Apoptosis Regulator (TIGAR) can reduce ROS levels, thus modulating 
the apoptotic response (Bensaad et al. 2006). Other p53 direct targets like Sestrin1 (SESN1) 
and Sestrin 2 (SESN2) also can protect cells from high ROS and chemotherapies (Velasco-
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Miguel et al. 1999; Budanov et al. 2002). The mitochondrial glutaminase 2 (GLS2) not only 
controls ROS levels, it also alters energy metabolism by increasing ATP generation (Hu et al. 
2010; Suzuki et al. 2010). These diverse properties of p53 have been shown to defend against 
in vivo tumorigenesis (Sablina et al. 2005; J. Liu, Zhang, Lin, et al. 2014; Bartesaghi et al. 
2015). 
The control of autophagy, a self-digestive form of cell death and organismal survival 
mechanism, may also be taken into consideration. DRAM (damage-regulated autophagy 
modulator) was found to be required for p53-induced autophagy (Crighton et al. 2006). Control 
of SESN2 and kinases Ulk1 and Ulk2 also contribute to regulation of this process (Maiuri et al. 
2009; Gao et al. 2011). Opposite of this, cytoplasmic p53 actually inhibits autophagy, possibly 
via interaction with RB1CC1 (RB1-inducible coiled-coil protein 1) or other autophagy proteins 
like Atg5 or Atg10 (Tasdemir et al. 2008; Morselli et al. 2011). In summary, p53 is an influential 
transcription factor, and its myriad impacts on cellular processes and outcomes are still being 
illuminated.   
 
The p53 protein undergoes many post-translational modifications 
As written earlier, p53 becomes stabilized after various stress stimuli, aided by post-
translational modifications (PTMs). These increase tetramerization and the stability of tetrameric 
p53, allowing it to act as a nuclear transcription factor and activate expression of a wide variety 
of genes.  Among the factors acting upon p53 are ATM (ataxia telangiectasia -mutated) kinase, 
which phosphorylates several N-terminal serines of p53 after radiation treatment (Banin et al. 
1998; Saito et al. 2002). Some of these serines are also phosphorylated by p38 kinase, 
especially after radiation (Bulavin et al. 1999). Various damaging agents lead to Jun NH2-
terminal kinase (JNK) phosphorylation of Thr-81 (Buschmann et al. 2001). Homeodomain-
interacting protein kinase-2 (HIPK2) can phosphorylate Ser46, affecting the stability of p53 
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(D’Orazi et al. 2002; Stefano et al. 2004). As these sites are within the transactivation domain of 
p53, transcriptional activity is altered in these cases. 
The p53 CTD is also subjected to various modifications that can affect transcriptional 
activity, and sometimes stability of the protein itself. Early work showed that p53 forms a 
complex with the acetyltransferases p300 and CREB-binding protein (CBP), and these can 
acetylate lysines within p53 (Gu et al. 1997; Avantaggiati et al. 1997). Another acetyltransferase 
is p300/CBP-associated factor (PCAF/KAT2B), which associates with p300 to modify residues 
upon p53 activation (Liu et al. 1999). Fascinatingly, Mdm2 can regulate these factors, 
suppressing p53 acetylation (Jin et al. 2002; Legube et al. 2002). Still, various signaling 
pathways are affected by activated p53, including Wnt/β-catenin (reviewed in Harris and Levine 
2005). This review also describes how several feedback loops from p53 to other pathways 
require the presence of Mdm2. 
 
 
Specific studies that delve into the consequences of CTD-mutant p53 will now be 
discussed. Many of these involve mutation of specific lysines to arginine, which preserves their 
positive charge but is not generally modified. Mutation to alanine similarly blocks modification, 
but neutralizes the positive charge. However, lysine mutation to glutamine, a negative amino 
acid, neutralizes the charge and is theorized to mimic acetylated lysine (Megee et al. 1990; 
Zhang et al. 1998). Of course, these residue switches may or may not affect the structure or 
stability of the mutant protein (reviewed in Barnes and Gray 2003). 
In the extreme C-terminal domain, past the ODi, changing 6 lysines to arginines (K6R) in 
mouse p53 led to impaired transactivation ability, but it did not affect protein stability (Feng et al. 
2005). Work from our lab also indicated that human 6KR p53 (analogous mutations to mouse 
                                                          
i OD = oligomerization domain 
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p53) bound significantly less targets than WT-p53, and 6KQ an even smaller subset (Laptenko 
et al. 2015). On the other hand, a mouse with similar mutations in 7 lysines (7KR) was viable 
and appeared phenotypically normal, with this mutant p53 acting equivalently to WT-p53 
(Krummel et al. 2005). Similarly, mutation of 4 lysines to alanine, neutralizing their positive 
charge, did not affect binding to target genes, although it affected Mdm2-dependent 
ubiquitination (Nakamura et al. 2000).  Other studies found that upon altering PTM sites of p53, 
interaction with coactivators was affected  (Barlev et al. 2001; Knights et al. 2006; A. G. Li et al. 
2007; Kurash et al. 2008). Some of these find a linkage between acetylation, phosphorylation, 
and/or methylation, suggesting such modifications might occur in directed cascades to alter 
function (Sakaguchi et al. 1998; Ivanov et al. 2007; Knights et al. 2006; Kurash et al. 2008). In 
this manner, even modification of one residue in p53, which may or may not cause modification 
of other residues, can be sufficient to alter target gene specificity (Chuikov et al. 2004; Chao et 
al. 2006; Tang et al. 2006).  
Furthermore, deletion of the last 30 residues of WT-p53 (termed ‘∆30 p53’) altered target 
gene binding (Espinosa & Emerson 2001; McKinney et al. 2004; Laptenko et al. 2015). Mice 
engineered with a synonymous deletion, ∆24 p53, exhibit severe developmental defects, dying 
soon after birth (Hamard et al. 2013). The heart, kidney and other organs are abnormal, 
ostensibly due to altered induction of target genes like p21, Puma and others (Hamard et al. 
2012; Hamard et al. 2013). Interestingly, a mouse expressing a ∆31 p53 actually displays 
greater p53 stabilization, along with increased repression of targets involved in telomere 
metabolism (Simeonova et al. 2013). In sum, PTMs in the CTD, as well as the CTD itself, are 
greatly important for the function of p53 protein and its control of cellular outcomes. 
 
The motivation to study specific residues K351 and K357 within the OD came from 
studies showing that these were modified in various settings (Kruse & Gu 2009; Joubel et al. 
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2009; W. Kim et al. 2011; DeHart et al. 2014). One of these reports found that MSL2, the human 
equivalent of D. melanogaster male-specific lethal-2, acts as an E3 ligase to ubiquitinate these 
lysines (Kruse and Gu 2009). This increases the levels of cytoplasmic p53 suggesting export is 
affected; although surprisingly this p53 is not targeted for proteasomal degradation. A 
proteomics study found that lysines 351 and 357 may also be methylated and acetylated, 
although the consequences of this have not been studied (DeHart et al. 2014). Mining of TCGA 
data also showed there are various human cancers containing mutations at these sites, 
suggesting they are relevant to disease. Therefore, we also mutated these residues to arginine 
or glutamine, and set out to characterize the effect this would have on gene transactivation and 
general processes (see Chapter 3). 
 
All in the family: how p63 differs from p53 
While p63 can bind many of the same target genes as p53, its story is complicated by 
the fact that it is uniquely a regulator of the epithelial state. First, there is evidence from various 
studies where the p63 gene is knocked out in mice. In the first, exons 6-8 encoding the DBD 
were targeted and replaced with a neomycin-resistance cassette (Yang et al. 1999). In these 
mice, squamous epithelia of the esophagus, mammary gland and other tissues are absent; and 
limb/craniofacial development is abnormal. Clumps of differentiated keratinocytes are found 
instead of a normal epidermis, and the mice die soon after birth, likely due to dehydration. In 
another study, mouse models called Brdm1 and Brdm2 were constructed by targeting exons 6 
or 10, resulting in a loss of functional p63 protein (Mills et al. 1999).  These mice were born with 
“shiny, transparent skin” that again showed lack of epithelial stratification and died of 
dehydration soon after birth. Here, the teeth, hair follicles and mammary glands are absent, with 
the forelimbs being truncated. It is clear that p63 is important for proper formation of these 
diverse features. One report hypothesized that p63 was necessary for the self-renewal of 
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progenitor/stem cells, which was verified by later work in various tissues (Yang et al. 1999; 
Senoo et al. 2007; Fletcher et al. 2011; Chakrabarti et al. 2014). 
Of course, the distinctive architecture of the p63 and p73 genes was realized quite early, 
along with the mixture of isoforms that could be generated (Kaghad et al. 1997; Yang et al. 
1998). We shall discuss the major isoforms of these genes as they have been studied for some 
time, although several novel isoforms have been revealed (Engelmann & Pützer 2014). For 
reference, this review also discusses p53 isoforms, and the biological context in which they may 
function. 
 
Meanwhile, for p63 and p73, there are the major classes TA and ΔN which are 
transcribed from alternative promoters (Osada et al. 1998; Yang et al. 1998). The ∆N isoforms 
lack the classical N-terminal transactivation domain and it was thought that they mainly regulate 
genes by interacting with TAp63 or p53 (Yang et al. 1998; Celli et al. 1999; Lee & Kimelman 
2002). However, it was soon determined that these proteins have a unique N-terminal 
transactivation domain, rendering them capable of target gene activation in their own right (M 
Dohn et al. 2001; Ghioni et al. 2002). Alternative splicing also occurs at the 3’ end, generating 
isoforms such as α, β, and γ, with slightly different targeting specificities.  
Most studies concentrate on the major classes and α/β isoforms, while the γ isoforms 
are comparatively less-studied. They alone lack the transactivation-inhibitory domain (TID) at 
the C-terminal end, which might explain the high apoptotic target gene induction in cells 
expressing this isoform (A. Yang et al. 1998). There is evidence p63γ induces target genes 
more strongly than the related proteins (A. Yang et al. 1998, Ghioni et al. 2002). Also, there is 
evidence that TAp63γ regulates expression of ∆Np63 in a p53-independent manner (N. Li et al. 
2006). TAp63γ may even signal to maspin (SERPINB5), in the absence of p53 (Spiesbach et al. 
2005). Both TAp63α and γ can induce Bcl-2, which is also a p53 target gene that controls the 
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intrinsic apoptotic pathway (Miyashita et al. 1994; Lantner et al. 2007). On the other hand, some 
studies suggest that the ΔNp63α/β isoforms have much stronger transactivation activity than the 
γ isoform (Helton et al. 2006; Marcel et al. 2012). 
Perhaps this is not surprising because in some studies, ∆Np63α was found to be the 
most stable isoform. Tracking of the six major isoforms after ectopic expression revealed each 
had a half-life of about 1 hour, except for ∆Np63α at around 8 hours (Petitjean et al. 2008). The 
half-life of endogenous ∆Np63α seems to be similarly long (Galli et al. 2010). ΔNp63 is also the 
predominant isoform expressed in epithelial cells (Yang et al. 1998; Nylander et al. 2002). 
Furthermore, it was also determined to be responsible for the characteristics of p63-knockout 
mice, as was clarified by isoform-specific knockdowns and genetic complementation (Koster et 
al. 2004; Candi et al. 2006; R-A. Romano et al. 2012). In these studies, expression of ∆Np63 
alone was required for normal epithelial stratification. In developed tissue, though, it is only 
expressed in the basal/proliferative layer of epithelial tissue, and its expression decreases at the 
suprabasal/luminal level (Parsa et al. 1999; Hall et al. 2000).  
In these suprabasal cells, TAp63 levels increase, suggesting the balance between the 
isoforms is important for epidermal differentiation (Candi et al. 2006, Su et al. 2009). The exact 
role of TAp63 in epithelial cells is controversial, as the mouse models have conflicting 
phenotypes. A general knockout model showed normal epithelia, but the oocytes displayed a 
deficient apoptotic response after various damages (Suh et al. 2006). However, germline 
deletion of TAp63 led to skin ulcers, blisters, and a compromised wound healing response (Su 
et al. 2009). These mice also displayed signs of accelerating aging like kyphosis (hunchback), 
and significantly reduced survival. Surprisingly, deletion of TAp63 in K14-positive cells did not 
phenocopy the above mice, suggesting they might be expressed in other populations. 
Consistent with this, one recent study found TAp63 transcripts were not expressed in epithelial 
cell lines, but TAp63α was expressed in some Burkitt’s lymphoma cell lines (Sethi et al. 2015). 
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This finding clarifies many earlier IHC studies that found p63 expression, based on an antibody 
that could not discriminate between isoforms, in a variety of lymphoma lines (Di Como et al. 
2002; Park & Oh 2005). Even if TAp63 is not normally present in epithelial tissues, it still has a 
role in the induction of neuronal cell death and protecting germline tissues from chemotherapy 
(Jacobs et al. 2005; Suh et al. 2006; Gonfloni et al. 2009). As such, p63 can be considered a 
“guardian of human reproduction”, although it is true that p53 and p73 contribute to this process 
as well (reviewed in Levine et al. 2011; Amelio et al. 2012).  
As for p73, targeted disruption of the gene in mice had a very different phenotype. The 
p73-/- mice died soon after birth, but in this case it was due to gastrointestinal hemorrhages or 
intracranial bleeding (Yang et al. 2000). They displayed a defect in the localization of neurons 
responsible for cerebrum development, along with hydrocephalus; likely explanations for the 
bleeding. Later work confirmed that p73 is required for the maintenance of CNS neurons, and 
that the ∆Np73 isoform is particularly vital for the survival of mature neurons (Pozniak et al. 
2002; Talos et al. 2010). 
 
As p63 and p73 belong to the p53 family, their contribution to tumorigenesis was 
examined. One study suggested lacking a copy of either gene leads to lesion formation, and 
LOH, explaining why the mice have a significantly shorter lifespan (Flores et al. 2005). The 
double heterozygote (p63+/-; p73+/-) mice have even higher tumor burden than p53+/- mice, 
display an aged phenotype and a greater variety of tumors (mammary and lung 
adenocarcinomas, sarcomas) (Flores et al. 2005). However, another p63+/- mouse model (using 
the Brdm alleles described previously) displayed less tumor burden than their WT littermates, 
suggesting a protective effect for p63 (Mills et al. 1999; Keyes et al. 2006). Of the cancers that 
did develop in these mice, there was also a larger spectrum, and these mice displayed some 
epithelial hyperplasia and inflammation. How are these two very different phenotypes 
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explicable? It may be due to the different targeting strategies these groups used; also one study 
used mouse strains C57BL/6J and 129S5, while the other used strains C57BL/6 and 129SvJae. 
Both the 129 and C57BL/6 lines are genetically distinct (Simpson et al. 1997; Mekada et al. 
2009). In any case, p63 clearly has an impact on tumorigenesis. 
Interestingly, one group found that the Brdm2 mouse described previously (Mills et al. 
1999), with the insertional mutagenesis at exon 10, may not be a complete knockout as 
previously thought (Wolff et al. 2009). These mice actually expressed truncated TA and ∆N 
isoforms resembling p63γ, along with incomplete epidermal/limb development. This would 
suggest that the α and/or β isoforms are responsible for progression of these areas. However, 
this work must be taken with a grain of salt, since spontaneous reversion events are known to 
occur frequently in heterozygote mice (Zheng et al. 1999; Mikkola et al. 2010).  
 
Mutations in p63 lead to several disorders in humans; most of which are characterized 
by abnormal epithelial and craniofacial development, and possibly limb defects (reviewed in T. 
Rinne et al. 2007). Essentially, these are the same phenotype seen in the p63-/- mice described 
earlier (Mills et al. 1999, Yang et al. 1999). The human syndromes all show autosomal dominant 
inheritance, so many were first described in families. Additionally, many of the symptoms 
overlap, so separate disorders have now been classified within the same spectrum. For 
instance, EEC/AEC (ectrodactylyii or ankyloblepharoniii, ectodermal dysplasia, and cleft 
lip/palate) seems to be fundamentally the same as Rapp-Hodgkin syndrome (Rapp & Hodgkin 
1968; Rodini & Richieri-Costa 1990; Cambiaghi et al. 1994). EEC also encompasses Hay-Wells 
syndrome, named for its discoverers (Hay & Wells 1976). The ectodermal component covers 
symptoms like reduced ability to sweat (hydrosis), sparse or absent eyebrows and hair, and 
                                                          
ii Ectrodactyly is split hand/foot, with a deficiency of one or more central digits of the hand or central toes 
iii Ankyloblepharon filiforme adnatum, or adhesion of the eyelids to one another 
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tooth agenesis/hypodontiaiv, among others. These syndromes, and the ones described below, 
are typically caused by mutations within the DNA-binding domain of p63, although there are a 
few exceptions (reviewed by T. Rinne et al. 2007). 
Other p63-associated disorders include limb mammary syndrome (LMS), wherein hand 
and/or foot malformations and mammary hypoplasia/aplasiav are present (van Bokhoven et al. 
2001). These patients do not have any ectodermal abnormalities, however, those are observed 
in patients with acro-dermato-ungual-lacrimal-tooth (ADULT) syndrome (Propping et al. 2000; 
Amiel et al. 2001). ADULT syndrome not only manifests with hand/foot/mammary abnormalities, 
it also variably presents with nail dysplasia, obstruction of tooth development and the lacrimal 
duct, hair loss and freckling. Finally, about a tenth of patients with split-hand/split-foot 
malformation (SHFM) have p63 mutations (Ianakiev et al. 2000; van Bokhoven et al. 2001). 
Interestingly, none of these disorders is known to be associated with increased cancer risk. 
Of course, ectodermal abnormalities may be caused by alterations in many other genes, 
such as interferon regulatory factor 6 (IRF6). Mutations in this gene are associated with several 
human syndromes that present with cleft lip and/or palate (Kondo et al. 2002). Interestingly, the 
IRF6-/- mouse phenocopies the p63-/- mouse, with a lack of stratified epidermis, along with 
craniofacial and skeletal defects (Ingraham et al. 2006). These two genes also display a similar 
pattern of expression in tissues. As it turns out, p63 directly binds to and induces IRF6 
transcription, and this is required for normal palate and ectoderm development (Moretti et al. 
2010; Thomason et al. 2010). Also, members of the Dlx homeobox family are required for palate 
development, and can lead to cleft lip/palate when mutated in humans (Sabóia et al. 2015; Wu 
et al. 2015). A member of this family will be discussed further below, as it is a p53 target. Along 
with this, we will discuss how alteration of p63 contributes to epithelial phenotypes, and affects 
tumorigenesis. 
                                                          
iv One or more teeth are missing, due to abnormal development 




Post-translational modifications and target genes 
Early on, it was noted that genotoxic stresses, including UV radiation, generally resulted 
in p63 protein loss (Liefer et al. 2000; Hall et al. 2000; Westfall et al. 2005). There are some 
exceptions, especially when it comes to TAp63, which is stabilized after damage much like p53 
(Okada et al. 2002; Petitjean et al. 2005). However, the E3 ubiquitin ligases discussed below 
were usually shown to bind both classes of p63, translocating them to the cytoplasm where they 
are ubiquitinated for proteasomal degradation. For example, Mdm2 not only translocates p53, it 
also exports p63 to the cytoplasm, allowing Fbw7 (FBXW7) ligase to target it for destruction 
(Kadakia et al. 2001; Galli et al. 2010). The ligases Itch and Pirh2 regulate steady-state levels of 
p63 in epithelial cells (Rossi et al. 2006; Jung et al. 2013). However, the peptidyl-prolyl 
isomerase Pin1 stabilizes p63 levels by disrupting its interaction with the WWP1 ubiquitin ligase 
(Y Li et al. 2008; C. Li et al. 2013). Interestingly, Pin1 levels are high in many cancers, and it is 
known to cooperate with both mutant p53 and Ras signaling (reviewed in Lu and Hunter 2014). 
At least two mechanisms were described for p63 disintegration by the scaffold protein 
Rack1. After cisplatin usage, Stratifin (SFN) targets phosphorylated ΔNp63α to the cytoplasm, 
where Rack1 initiates its degradation (Fomenkov et al. 2004). Our lab showed another scaffold 
protein, Stxbp4, suppresses Rack1 except in stressed conditions, allowing for Rack1-mediated 
p63 degradation (Y. Li et al. 2009). ΔNp63α may also undergo sumoylation by Ubc9, except in 
the case of disease-causing mutations, leading to altered transcriptional regulation (Y-P. Huang 
et al. 2004; Bakkers et al. 2005). Finally, both IKKα and IKKβ can stabilize p63, and p63 is 
reciprocally able to sustain IKKα expression (Koster et al. 2007; MacPartlin et al. 2008). 
 
Similar to p53, p63 is regulated by a plethora of post-translational modifications. This 
often facilitates its degradation by the factors listed above. The kinases ATM, CDK2 and 
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p70S6K (RPS6KB1) phosphorylate specific sites of ΔNp63α, and degradation is dependent on 
these phosphorylated sites (Huang et al. 2008). Cisplatin’s induction of TAp63 is mediated by c-
Abl kinase phosphorylating specific tyrosine residues, and this is essential for the apoptotic 
response (Gonfloni et al. 2009). The interaction between c-Abl and p63 may also be essential 
for its acetylation by p300 (Restelli et al. 2015). Another important factor is Dlx3, a homeobox 
gene and p63 target that plays a key role in epidermal differentiation (Morasso et al. 1996; 
Radoja et al. 2007). Raf1 kinase can phosphorylate certain C-terminal residues of ΔNp63α, 
leading to degradation by Dlx3 (Di Costanzo et al. 2009). Interestingly, Dlx3 was recently 
identified as a potential cofactor for p63, as they regulate a similar network of genes (Sethi et al. 
2015). Last but not least, ISG15 is an interferon-induced ubiquitin-like factor that modulates the 
immune response (Jeon et al. 2010). ΔNp63α is ISGylated in the TID following chemotherapy, 
leading to degradation by caspase-2, whereas surprisingly, TAp63 transactivation is increased 
by the same modifications (Jeon et al. 2012). For more on regulators of the p63 protein, see the 
excellent review by C. Li and Xiao, 2014. 
It is clear that p63 can be altered in a number of ways, which might explain why it is so 
frequently misregulated in cancers. In many squamous carcinomas, p63 (especially ∆Np63) is 
amplified or overexpressed, suggesting an oncogenic role (Yamaguchi et al. 2000; Wang et al. 
2001). In these cases, ∆Np63 overexpression leads to properties such as anchorage-
independent growth or increased tumor size in nude mice (Hibi et al. 2000; Kumar Ram et al. 
2014). The antibody p40, specific for this isoform, is a valuable diagnostic marker for squamous 
cell carcinomas (SCC) of the lung, as well as for basal cells of the prostate and breast (Bishop 
et al. 2012; Nobre et al. 2013; Sailer et al. 2013; Sailer et al. 2015). Other than those of 
squamous origin, however, p63 is rarely mutated in cancerous lines (Hagiwara et al. 1999; 
Barretina et al. 2012). In fact, as written earlier, many groups, including ours, found that p63 
RNA levels are low in breast cancers. However, p63 levels may be high in specific rare 
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mammary neoplasms, such as phyllodes tumors and adenoid cystic carcinomas (Emanuel et al. 
2004; Cimino-Mathews et al. 2014). Taking this into account, it is reasonable to conclude that 
this gene is a common target of upstream signaling in various tumors.  
 
Some ChIP-seq and RNA-seq analyses suggest that p63 regulates a large subset of 
genes, perhaps even more than p53 (Yang et al. 2006; Viganò et al. 2006; Barton et al. 2010; 
Kouwenhoven et al. 2010; McDade et al. 2012). This may be due to its role as a regulator of 
epithelial tissues. In this vein, targets such as the apoptosis effector Perp, Keratin-5, Keratin-14, 
and Claudin-1, all play roles in epithelial development (Ihrie et al. 2005; Lopardo et al. 2008; 
Romano et al. 2009). Mutations in Keratin-5 and Keratin-14 cause a disorder leading to fragile 
skin and blistering, especially after trauma (Lane & McLean 2004). Interleukin-1-α (IL1A) and 
Transcription Factor 7-Like 1 (TCF7L1), a Wnt family member, are also p63 target genes that 
regulate epidermal homeostasis (Barton et al. 2010). On top of these targets, both p63 and p73 
can regulate Jagged1 and Jagged2, the Notch ligands (Sasaki et al. 2002; Fontemaggi et al. 
2002). Interestingly, Jagged1 has been associated with breast cancers, especially the basal-like 
subtype (Dickson et al. 2007; Reedijk et al. 2008).  
Importantly, one of the above ChiP-seq studies found that the p63 binding site 
resembles that of p53, only more degenerate, and these sites have enhancer-like histone 
profiles (McDade et al. 2012). This paper also identified transcription factor AP-2α (TFAP2A) 
and another family member TFAP2C as coregulators of various targets with p63, the former 
being the causative mutation for Branchiooculofacial Syndrome (Milunsky et al. 2008; McDade 
et al. 2012). Both TFAP2A and p63 can bind to a long-range enhancer element, which 
modulates p63 expression in epithelial cells (Antonini et al. 2006; Antonini et al. 2015). 
Surprisingly, BRCA1 is recruited to this enhancer and controls p63 expression, suggesting 
ΔNp63 is a downstream effector of BRCA1 signaling (Buckley et al. 2011). Another report 
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suggested that sites bound by both p63 and H3K27ac were indicative of active transcription 
(Kouwenhoven et al. 2015). About half of the p63-bound sites were also occupied by H3K27ac, 
which correlated with gene expression. From this analysis, conducted over the course of 
epidermal differentiation, they determined that p63 is poised at these sites to allow transcription 
at specific time points. 
Additionally, as can be seen from one of the TAp63 mouse models, p63 alteration is 
linked to aging, possibly due to its regulation of proliferation (Su et al. 2009). In these mice, the 
dermal and epidermal precursors become senescent, likely due to lowered p57Kip2 levels, a 
known cell cycle regulator. An earlier paper noted that in the absence of p63, PML and p16INK4A 
are induced, encouraging a senescent response (Keyes et al. 2005; de Jesus & Blasco 2012). 
Strangely, a follow-up paper suggested TAp63-dependent senescence might occur through p21 
and Rb (Guo et al. 2009). Meanwhile, ∆Np63 can control sirtuin-1 (SIRT1) and a lymphoid-
specific helicase (HELLS, also known as LSH), which are regulators of cell survival and 
senescence (Sommer et al. 2006; Keyes et al. 2011). HELLS is a member of the SNF2 family of 
helicases, and was shown to repress p16INK4A via histone deacetylases (HDACs) (Zhou et al. 
2009). Of course, modulation of p53 sometimes leads to premature aging in mouse models, so 
the balance between the family members may be important in mediating the cell cycle (Tyner et 
al. 2002; Maier et al. 2004). 
Both p53 and p63 can regulate CD44, the transmembrane cell surface marker discussed 
above that also delineates stem cells (Carroll, Carroll, Leong, Cheng, Brown, A. A. Mills, et al. 
2006; Boldrup et al. 2007; Godar et al. 2008). This protein not only associates with growth factor 
receptors like HER2, it also plays a role in tumor initiation and growth (Ponta et al. 2003; Godar 
et al. 2008; Louderbough and Schroeder 2011). Interestingly, another surface/stemness marker, 
CD24, was found to be associated with inactivating p53 mutations in various cancers (Wang et 
al. 2015). TRAF4 is another p53/p63 target that is overexpressed in breast carcinomas (Régnier 
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et al. 1995; Sax & El-Deiry 2003; Gu et al. 2007). It can activate the NF-κB pathway, and it also 
destabilizes tight junctions, leading to cell migration (reviewed in Chung et al. 2002; Rousseau 
et al. 2013). Furthermore, ∆Np63 can induce NF-κB targets like IL-8 and CSF2: inflammatory 
cytokines that may be responsible for its malignancy in SCC lines (Yang et al. 2011; Du et al. 
2014). ∆Np63 can also positively affect β-catenin nuclear accumulation, and therefore 
downstream signaling (Patturajan et al. 2002; Lee et al. 2014). Of course, the Wnt/β-catenin 
pathway includes tumor suppressors like Axin1, as well as famed oncogenes like Myc, which is 
high in certain types of breast cancers (Katoh and Katoh 2007; Cancer Genome Atlas 2012). 
 
Perhaps because it can regulate all of these targets, p63 has been shown to have both 
oncogenic and tumor suppressive effects in carcinomas (see Figure 5, Graziano and De 
Laurenzi 2011). Broadly, there is evidence to support an oncogenic role for ∆Np63 in various 
tumor types. For instance, p63 regulation of a Hedgehog pathway factor and STAT3 could be 
responsible for its transformative properties in osteosarcomas (Bid et al. 2014; Kumar Ram et 
al. 2014). FGFR2-mediated induction of p63 might be responsible for the survival of SCCs, 
explaining why these cancers often have high p63 levels (Ramsey et al. 2013). In melanomas, 
both major isoforms of p63 were correlated to poor survival, possibly via deregulation of p53 
stabilization and/or apoptotic signaling (Matin et al. 2013). And strangely, p63 has been 
associated with opposing effects in bladder cancers, depending on whether it has invaded the 
detrusor muscle. In muscle-invasive cases, p63 expression is associated with poor survival, 
while in non-muscle invasive disease, it is a positive prognostic factor (Karni-Schmidt et al. 
2011; Choi et al. 2012). It is clear that cellular context can affect p63 signaling, and in some 




In an earlier section, mutant p53 was discussed, as it is a common alteration in cancers 
including those originating from mammary tissue. This factor has been shown to limit the effects 
of p63 via several mechanisms; suggesting p63 could inhibit tumorigenesis. First, mutant p53 
can bind to and sequester p63 to assist TGF-β in driving cell invasion/metastasis (Adorno et al. 
2009). Fascinatingly, it worked in concert with oncogenic Ras, whereas p63 (specifically ∆Np63) 
was necessary to oppose this migratory/invasive phenotype. Other evidence pointed to a TGF-
β-independent role for mutant p53 in suppressing p63 (Muller et al. 2009). In this context, 
integrin recycling/EGFR signaling is enhanced, promoting 3D invasion. As alluded to above, 
Pin1 and mutant p53 are inversely correlated to survival in breast cancers, and these factors 
also inhibit p63 (Girardini et al. 2011). Interestingly, Mdm2 was recently shown to decrease the 
mutant p53-p63 interaction by binding to the mutant p53, and not p63 (Stindt et al. 2015). It is 
not known whether this signaling takes place in human cancers with mutant p53, although this 
could be a potential mechanism to combat this oncogenic alteration.   
For other factors that are known to regulate p63, see our review (Appendix). Many p63 
targets feed back into regulation of p63, so those reciprocal loops are discussed. Note that our 
research paper in Chapter 2 delineates a novel role for Ras/PI3K pathways in directing p63 
expression, previously unknown. As for how p63 acts against carcinogenesis, along with the 
targets listed above, it also regulates a number of tumor-suppressive microRNAs. 
 
microRNA processing and p63 
MicroRNAs are short noncoding RNAs that have the ability to silence a wide variety of 
genes by binding to and targeting the 3’ UTR of mRNAs for destruction. There have been more 
than 1,000 of these validated and several thousand more candidates are in evaluation; many 
playing roles in cellular processes and tumorigenesis (Friedlander et al. 2014). Most are 
transcribed by RNA Polymerase II and undergo capping and polyadenylation, just like mRNAs, 
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only these are called primary miRNAs (pri-miRNAs). These transcripts may comprise a single 
miRNA or several, if they are transcribed from the same locus. In any case, these are cleaved 
into individual stem-loop transcripts (pre-miRNAs) by the Microprocessor complex, which 
includes the RNase III enzyme Drosha and a cofactor, the double-stranded RNA (dsRNA)-
binding protein DiGeorge syndrome critical region 8 (DGCR8) (Gregory et al. 2004; Han et al. 
2004). There are other factors involved in this complex, but these are the two essential 
elements.  
The pre-miRNAs can then be translocated into the cytoplasm by exportin 5 (XPO5), 
where they undergo further processing by a ribonuclease type III enzyme, DICER1 (Bernstein et 
al. 2001). This enzyme cleaves the stem-loop structure so that a mature miRNA duplex is 
formed, complete with overhanging ends. These ends are particularly important for binding to 
Argonaute proteins (AGO1-AGO4 in humans), which are major components of the miRNA-
induced silencing complex (miRISC) (Ma et al. 2004; J.-B. Ma et al. 2005). The miRNA then 
acts as a guide for RISC to identify complementary RNA to cleave (reviewed in Pratt and 
MacRae 2009).  
Interestingly, there are multiple links between p63 and miRNA processing factors. 
∆Np63 was found to induce DGCR8, and this axis was responsible for suppressing stemness 
factors like Sox2 and Nanog (Chakravarti et al. 2014). This paper delineated at least seven 
miRNAs, including miR-141 and miR-205, which are strongly regulated by that axis. Another 
finding is that TAp63 binds to and induces DICER1 transcription, and in the absence of TAp63, 
DICER1 is low and there is defective processing of several microRNAs (Su et al. 2010). As 
modulation of DICER1 levels in TAp63-/- cells affected invasion, it seems that miRNAs strongly 
contribute to TAp63’s anti-metastatic effects. Of course, DGCR8, DICER1 and other processing 
components are altered in tumors and likely have multiple ways to affect oncogenesis (reviewed 
in Lin and Gregory 2015). 
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A recent report used computational analysis to identify 39 microRNAs putatively 
regulated by p63 (see Figure 5, C. Lin et al. 2015).  Some were previously examined, including 
miR-200a/b and miR-429 (Knouf et al. 2012). As stated in an earlier section, these are members 
of the miR-200 family that are known to suppress EMT, suggesting an anti-tumorigenic role for 
p63. Interestingly, cisplatin-induced phosphorylation of ∆Np63 can influence several miRNAs 
like miR-181a in SCC cells (Huang et al. 2013). Another paper identified ∆Np63’s direct 
repression of miR-34a and miR-34c, which exert significant control over the cell cycle (Antonini 
et al. 2010). On the other hand, TAp63 can induce miR-34a, along with miR-130b, contributing 
to an anti-invasive phenotype (Su et al. 2010; Dong et al. 2013). Meanwhile, ∆Np63 can inhibit 
expression of miR-30b, 138, -181a, and -181b, which protects keratinocytes from senescence 
(Rivetti di Val Cervo et al. 2012). In these cases, it seems that TAp63 and ∆Np63 have 
opposing effects. Most importantly, ∆Np63 was required for miR-205 expression, but loss of 
either of these led to increased invasion in prostate and bladder cancer cells (Tucci et al. 2012; 
Tran et al. 2013). The EMT regulator Zeb1 was induced by the depletion of ∆Np63 or miR-205, 
suggesting one mechanism by which p63 controls EMT. 
There are several connections suggesting that p63 is an important regulatory factor of 
mesenchymal transition. For example, ΔNp63 is downregulated during Snail-mediated and/or 
Slug-mediated EMT in SCC cells, allowing TAp63 stabilization (Higashikawa et al. 2007; Herfs 
et al. 2010). The loss of ΔNp63 also occurs in prostate cells that undergo EMT or cancers from 
this tissue, and re-expression of it leads to gain of epithelial characteristics (Tucci et al. 2012; 
Olsen et al. 2013). As mentioned previously, negative feedback loops occur between the p63-
controlled miR-200 family and EMT. There is also the p63 target Grainyhead-like-2 (GRHL2), a 
transcription factor that normally keeps Zeb1 expression in check (Werner et al. 2013; Cieply et 
al. 2013; Mehrazarin et al. 2015). A perplexing result is that knockdown of ∆Np63α and -β led to 
EMT in mammary cells, mediated by Twist and/or Slug, while expression of the γ isoform 
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supports TGF-β-mediated EMT (Lindsay et al. 2011). If this is the case, then it seems these 
isoforms have entirely contradictory roles in mediating tumorigenesis. Similar to the ∆Np63γ 
evidence, another paper found that overexpression of ΔNp63α enhances TGF-β signaling to 
drive mesenchymal transition in human keratinocytes (Oh et al. 2011).  
In conclusion, ΔNp63 can control almost all of the major regulators of EMT, along with 
various other cancer-related genes (refer to Figure 5). Although TAp63 is somewhat less 
studied, because it has the same architecture it is possible that it also regulates many of these 
same targets. A number of tumor suppressive targets may play a role in cell cycle control (p21, 
HELLS, miR-34f, p57), whereas some are microRNAs that inhibit EMT (see Figure 5). There are 
also oncogenic targets that lie in a variety of signaling pathways (CD44, FGFR2, VDR, SOX2). 
The presence of associated factors and balance between isoforms also complicates p63 
signaling. As it is still unknown how this important factor is downregulated in some cancers, we 





An introduction to the Ras signaling pathway 
 Alterations in the tumor suppressor APC (Adenomatous Polyposis Coli) and oncogene 
K-Ras (V-Ki-Ras2 or Kirsten Rat Sarcoma 2 Viral Oncogene Homolog) were suggested to be 
early mutations in one model for multistep colorectal tumorigenesis (see Figure 6) (Vogelstein et 
al. 1988). The 1988 paper found these genes were frequently perturbed in carcinomas but 
infrequently in adenomas. Furthermore, a smaller subset of carcinomas had p53 mutations, 
suggesting alterations in this gene occurs late in tumorigenesis. However, some studies found 
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that only rare colorectal tumors harbor modifications in all of these genes; yet the fact is these 
are important genes involved in carcinogenesis (Smith et al. 2002; Conlin et al. 2005). 
 Although K-Ras is a transforming protein from a rat sarcoma virus, H-Ras, another 
transforming protein from a similar rodent virus was actually the first family member described 
(Harvey 1964; Kirsten & Mayer 1967; Anderson & Robbins 1976). The other classical family 
member is N-Ras, so named because it was discovered in a neuroblastoma; although it is 
expressed in multiple tissues  (Shimizu et al. 1983; Hall et al. 1983). Furthermore there are 
related family proteins like M-Ras, E-Ras and R-Ras, which are also known to utilize some of 
the canonical Ras effector pathways (see review by Rajalingam et al. 2007).  
The Ras family members are membrane-bound guanosine triphosphate 
(GTP)/guanosine diphosphate (GDP)-binding proteins, also called GTPases. They transduce 
signals from receptor tyrosine kinases (RTKs) like EGFR to the nucleus (Satoh et al. 1990a; 
Satoh et al. 1990b). Upon ligand binding, RTKs become phosphorylated, initiating formation of a 
complex with adaptor proteins like Grb2 and SOS1 (a guanine nucleotide exchange factor or 
GEF) (Buday & Downward 1993; Li et al. 1993). The RTK-Grb2-SOS1 complex promotes Ras 
nucleotide exchange, so that Ras-GDP (“Inactive”) becomes Ras-GTP (“Active”). The opposite 
step, hydrolysis of the GTP to GDP, is controlled by GAPs (GTPase activating proteins) like 
p120GAP. Yet, hotspot mutations in Ras disturb the ability of GAPs to hydrolyze GTP, thus 
ensuring constitutively active GTP-Ras (Scheffzek et al. 1997). Such mutations are found in a 
variety of tumors, with K-Ras the most common alteration at around 20% and H-Ras/N-Ras 
under 10% (Bos 1989; Prior et al. 2012). The three common hotspots are G12, G13 and Q61, 
with G12 alterations most prevalent in H-Ras and K-Ras (reviewed in Cox and Der 2010). Since 
Ras signaling affects processes like proliferation, migration and differentiation, alterations can 




One of the main branches downstream of Ras is PI3K/Akt signaling, which was 
discussed earlier (refer to Figure 2). Beyond PTEN, the PI3Ks and downstream Akt kinases; a 
major downstream player is mammalian target of rapamycin (mTOR), a serine/threonine kinase. 
Interestingly, mTOR is a member of at least two complexes that generally regulate different 
processes, called mTORC1 and mTORC2 (reviewed in Laplante and Sabatini 2009). For 
instance, mTORC1 activates SREBP-1 (sterol regulatory element binding protein 1) and PGC1-
α (PPARγ coactivator 1), affecting lipid synthesis and energy metabolism (Cunningham et al. 
2007; Porstmann et al. 2008). mTORC1 also modulates mRNA biogenesis through 
phosphorylation of 4E-BP1 and S6 Kinase (S6K), leading to initiation of translation (reviewed in 
X. M. Ma and Blenis 2009). On other hand, mTORC2 loops back to fully activate Akt kinase, as 
well as a similar kinase SGK1 (serum- and glucocorticoid-induced protein kinase 1), a key gene 
in cellular homeostasis (Sarbassov et al. 2005; García-Martínez & Alessi 2008; Yan et al. 2008). 
Furthermore, both complexes can affect the actin cytoskeleton either through interactions with 
small G proteins like RhoA and Rac1, or by phosphorylating targets like PKC-α (protein kinase 
C-α) (Jacinto et al. 2004; Sarbassov et al. 2004; Liu et al. 2010). 
Another layer of complexity lies with the TSC1-TSC2 complex, named for the disease 
caused when either gene is mutated - tuberous sclerosis complex. In this disease, benign 
tumors form in various organs and developmental problems are prevalent (European Tuberous 
Sclerosis Consortium 1993; Slegtenhorst et al. 1997). Fascinatingly, the TSC1-TSC2 complex 
can inhibit mTORC1, while increasing the activity of mTORC2 (Huang & Manning 2009). The 
inhibition of mTORC1 functions through reduced GTP loading of Rheb (Ras homolog enriched 
in brain), with TSC2 acting as a GAP for this small G protein (Tee et al. 2003; Y. Zhang et al. 
2003). Moreover, TSC1-TSC2 receives input from kinases such as Akt, AMP-activated protein 
kinase (AMPK) and ERK1 (extracellular-signal-regulated kinase 1) (Inoki et al. 2002; Inoki et al. 




 This brings us to another branch of Ras signaling, the Raf/MAPK pathway where ERK1 
and family members lie. These two kinases are known as conventional mitogen-activated 
protein kinases (MAPKs), along with some c-Jun amino (N)-terminal kinases (JNKs) and p38 
isoforms (reviewed in Cargnello & Roux 2011). They are serine/threonine kinases containing a 
Thr–X–Tyr motif, where phosphorylation of these residues is required for activation (Johnson et 
al. 1996). Atypical MAPKs seem to contain a different phospho-acceptor motif, which may 
explain their altered substrate specificity and properties (see review by Coulombe & Meloche 
2007).  
 Also, conventional MAPKs are composed of a cascade of three kinases (see figure 7). In 
the canonical activation of ERK1, the activating signal is Ras-GTP. It binds to one of the Raf 
proteins (A-Raf, B-Raf or C-Raf/Raf1) which can act as a MAPKKK (MAP kinase kinase kinase) 
to phosphorylate MEK1. Then, MEK1 functions as a MAPKK to phosphorylate ERK1, the last 
MAPK in the cascade. Activated ERK1 can phosphorylate various targets like p90RSK, Elk1, c-
Fos and p53 (reviewed in Shaul & Seger 2007). This can result in the transcription of immediate 
early genes, or factors involved in the cellular stress response (Buchwalter et al. 2004; Anjum & 
Blenis 2008). Similar cascades also exist for JNKs and p38 isoforms, even involving some of 
the same activators and/or target substrates (refer to Raman et al. 2007). 
 
 Another branch of GTPases affected by Ras includes the Rho family, which 
encompasses RhoA, Rac1 and Cdc42 (some of these reinforce canonical MAPK cascades). 
Like Ras, most of these are responsive to GAPs and GEFs that regulate their activation state, 
although there are some exceptions. This class of GTPases is also bound by GDIs (guanine-
nucleotide-dissociation inhibitors); sequestering them in the inactive state (-GDP) and 
preventing conversion to the active (-GTP) conformation (reviewed in DerMardirossian & 
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Bokoch 2005). Various kinases can phosphorylate the GDI or GTPase, either enhancing 
complex formation or releasing the GTPase from inhibition. Thus, the control of these Rho 
GTPases is quite complex, ensuring activation only after various stimuli have been assimilated. 
 The classical studies on RhoA and Rac1 established that they are necessary for the 
formation of actin stress fibers and membrane ruffles (or lamellipodia) (Ridley & Hall 1992; 
Ridley et al. 1992). Meanwhile, Cdc42 was found to regulate actin-rich projections called 
filopodia, which together with lamellipodia, are involved in cell migration (Nobes & Hall 1995). Of 
course, these descriptions are simplistic - not only are there multiple members of each group 
(Rho-like, Rac-like, etc), there is also crosstalk among the family members (reviewed in 
Burridge & Wennerberg 2004). For example, a combination of the three GTPases is needed in 
order for focal adhesion complexes to form (Hotchin & Hall 1995; Allen et al. 1997). These 
complexes are integrin-rich structures at the cellular periphery that serve as mechano-sensors, 
influencing cell behavior. Similarly, the three G proteins are required for apicobasal polarity and 
the integrity of adherens junctions (reviewed in Mack & Georgiou 2014). In particular, RhoA and 
Rac1 regulate factors involved in vascular permeability, such as VE-cadherin (Vascular 
Epithelium) (Hordijk et al. 1999; Wojciak-Stothard et al. 2001; Garcia-Ponce et al. 2015).  
The Rho-like family includes not only RhoA, but also RhoB and RhoC, which can affect 
cancer cell invasion and progression (reviewed in Ridley 2013). The preponderance of evidence 
suggests RhoA and RhoC are oncogenic, whereas RhoB may act as a tumor suppressor 
through its induction of apoptosis. Among the three, the most is known about RhoA, including its 
effectors ROCK1 (Rho kinase 1) and ROCK2. These are serine/threonine kinases that interact 
with regulators of actomyosin contractibility, including the LIM kinase family (Maekawa et al. 
1999). Another effector, mDia1, links Rho to profilin, which promotes actin filament assembly 
(Watanabe et al. 1997). Interestingly, activated Rho promotes phosphorylation of myosin light 
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chain, increasing actomyosin contractibility; whereas Rac opposes this via its effector PAK1 
(p21-activated kinase 1) (Sanders et al. 1999). 
PAK1 and its family member PAK2 are actually effector kinases for both Rac1 and 
Cdc42 (Manser et al. 1994). When activated PAK1 was microinjected into cells, both filopodia 
and lamellipodia formed (Sells et al. 1997). Similarly, Rac and Cdc42 bind to various members 
of the WASP (Wiskott–Aldrich syndrome protein) and WAVE (WASP-family verprolin-
homologous) family (reviewed in Takenawa & Suetsugu 2007). Binding to these factors 
activates the ARP2/3 complex, inducing actin polymerization (Miki et al. 1998; Machesky et al. 
1999). ADP-ribosylation factor (ARF) family members like ARF6 are regulated by Rac1, 
increasing membrane trafficking leading to cytoskeletal rearrangements (Radhakrishna et al. 
1999). However, these effects are just the tip of the iceberg when it comes to the Rho family of 
GTPases. To be precise, they can mediate many processes beyond migration and polarity, as 
summarized in many excellent reviews (Hanna & El-Sibai 2013; Wilson et al. 2013).  
 
Many of the Ras family members are subject to various post-translational modifications 
which determine their activation and localization (reviewed in Ahearn 2012). The GTPases have 
a CAAX motif, which is required for attachment to polyisoprenoids, intermediates from the 
mevalonate pathway, as well as to GDIs (Casey 1989, Seabra 1991). Depending on the Ras 
protein in question, they may be regulated by one or both prenyltransferases: 
farnesyltransferase (FTase) or geranylgeranyltransferase type I (GGTase I). As indicated by 
their names, they are responsible for attaching either a farnesyl pyrophosphate (FPP) or 
geranylgeranyl pyrophosphate (GGPP) to the cysteine of the CAAX sequence. Farnesylation 
targets the protein to the endoplasmic reticulum (ER), where further processing cleaves the 
AAX off and carboxymethylates the farnesyl cysteine (Kim et al. 1999; Bergo et al. 2000). This 
imparts the C-terminus with hydrophobicity, which (along with palmitoylation for some family 
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members) allows Ras to efficiently localize to the plasma membrane (Shahinian & Silvius 1995; 
Choy et al. 1999). Alternatively, geranylgeranylation can be undergone by K-Ras and N-Ras 
(but not H-Ras), after which the same processing steps and localization occur.  
As these modifications have been shown to affect the activation of these oncogenes, a 
key objective has been to target these pathways. Statins limit the availability of the isoprenoid 
moieties, decreasing Ras prenylation, although not at the therapeutic dose (Demierre et al. 
2005; Cho et al. 2011). FTase and GGTase inhibitors are of limited clinical efficacy as single 
agents, due to the presence of the other prenylation pathway (reviewed in Cox et al. 2015). Dual 
inhibition has not been successful so far, but it is possible inhibitors of post-prenylation 
processing enzymes may be efficacious (reviewed in Tamanoi & Lu 2013).  
 
Although A-Raf and C-Raf/Raf1 mutations are not common in cancers, B-Raf mutations 
are frequent, especially in melanomas (Davies et al. 2002; Anon 2015). Most of these B-Raf 
mutations take place within the kinase domain (often V600), and result in a conformational 
change to the active state, irrespective of outside signaling (Davies et al. 2002; Wan et al. 
2004). Thus, there is constitutive activation of downstream targets like ERK1/2. Whereas Ras 
inhibitors have had limited success, there are two specific inhibitors of B-Raf V600E approved 
for metastatic melanoma patients (Chapman et al. 2011; Hauschild et al. 2012). Additionally, 
another drug Nexavar (sorafenib) that targets Raf and other kinases, is used to treat renal cell 
carcinomas and several other cancers (Wilhelm et al. 2008). Moreover, the MEK1/2 inhibitor 
Mekinist (trametinib) was approved for melanoma patients with the same mutation, and 
combination therapy with both B-Raf and MEK inhibition improves survival more than MEK1/2 
inhibition alone (Flaherty et al. 2012; Long et al. 2015). Interestingly, there have been many 
MEK and ERK inhibitors tested for clinical efficacy, but only Mekinist has received FDA approval 
for cancer (Frémin & Meloche 2010; Samatar & Poulikakos 2014). Some tumors with Raf 
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mutations are more sensitive to MEK inhibition, suggesting the need for more combinatorial 
targeted therapy. In conclusion, although Ras has proven difficult to inhibit, there have been 
successes when it comes to targeting its effectors.  
 
 Ras has been shown to influence various processes that increase metastasis (reviewed 
in Pylayeva-Gupta et al. 2011). Among these are alterations in the levels of EMT regulators. For 
example, Snail and Slug are induced by activated Ras, possibly through the MAPK and/or 
PI3K/Akt pathway (Conacci-Sorrell et al. 2003; Z. Wang et al. 2006; Saegusa et al. 2009; Wang 
et al. 2010). Recently a feedback loop was described between Ras, Rb and Zeb1, leading to 
either oncogene-induced senescence or tumor initiation (Y. Liu et al. 2014). It is possible that 
Ras-dependent regulation of Zeb1 and Zeb2 takes place through the ERK1/2 target, Fra1 (Shin 
et al. 2010; Bakiri et al. 2015). Glycogen synthase kinase 3 beta (GSK3β), which is inhibited by 
MAPK and PI3K signaling, phosphorylates Snail leading to its export from the nucleus and 
degradation by the proteasome (Cohen & Frame 2001; Zhou et al. 2004). Therefore when 
GSK3β is suppressed, Snail protein can accumulate in the nucleus and act upon its targets. 
Interestingly, ERK1/2 may also phosphorylate Slug, enhancing upregulation of vimentin and 
cellular invasion (Virtakoivu et al. 2015). 
 Previously, I described how TGF-β signaling can drive EMT. In some cases, activated 
Ras in conjunction with TGF-β treatment was required to produce invasive transformation (Oft et 
al. 1996; Oft et al. 2002; Janda et al. 2002). There is some evidence that Raf/MAPK signaling is 
particularly important in enhancing TGF-β signaling, perhaps by increasing secretion of the 
ligand (Lehmann et al. 2000; Janda et al. 2002). It is also possible that the MAPK pathway 
increases accumulation of Smads, key transcription factors that transactivate TGF-β targets 
(Saha et al. 2001; Oft et al. 2002; Davies et al. 2005). Ras-upregulated BLT2 (leukotriene B4 
receptor-2) was found to cooperates with TGF-β via NF-κB and ROS induction (Yoo et al. 2004; 
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Kim et al. 2014).  Furthermore, various MAPKs are stimulated by TGF-β treatment, and may 
increase TGF-β-dependent upregulation of targets like MMP-2 (Xu et al. 2006; Burch et al. 
2010; Li et al. 2010). Ras also promotes complex formation between p53 and TGF-β family 
members, to various effects (Cordenonsi et al. 2007; Adorno et al. 2009).   
 
Herein, a role for Ras in regulating p63 is described, but there are some prior studies 
linking the two factors. Fascinatingly, TAp63 was found to be required for Ras-induced 
senescence (Guo et al. 2009). In mouse embryonic fibroblasts, overexpression of TAp63 and H-
RasV12 led to a strong senescence response. The aforementioned group found that genetic 
ablation of endogenous TAp63 in the context of oncogenic H-Ras led to increased proliferation 
and larger tumors after subcutaneous injection in mice. On the other hand, another report in 
primary mouse keratinocytes indicated ∆Np63 loss with H-Ras leads to oncogene-induced 
senescence (Keyes et al. 2011). In this case, ∆Np63 actually cooperates with H-Ras to promote 
self-renewal and tumor formation. This is consistent with other work indicating ∆Np63 
expression with H-Ras leads to more malignant skin tumor formation in nude mice than with H-
Ras alone (Ha et al. 2011). There was evidence that this was due to p63 suppression of 
p16INK4A and p19ARF; two key cell cycle regulators. 
Furthermore, Ras signaling can regulate p53 and/or its targets through various 
mechanisms. Activated Ras promotes upregulation of the tumor suppressor PML (associated 
with acute promyelocytic leukaemia) (Ferbeyre et al. 2000; Pearson et al. 2000). This results in 
the formation of complexes with p53, PML and CBP that promote the induction of senescence. 
Ras also affects p21CDKN1A, p16INK4A, p27KIP1 and other CDK inhibitors (reviewed in McMahon & 
Woods 2001). Similarly, there is evidence of crosstalk between Ras GTPases and the Bcl-2 
family (reviewed in Kang & Pervaiz 2012). It is puzzling that activated Ras both increases Mdm2 
transcription and induces p19ARF accumulation, which negatively regulates Mdm2 (Palmero et 
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al. 1998; Ries et al. 2000). The accrual of p19 (also known as p14ARF in humans) may be due to 
Ras upregulation of the transcription factor Dmp1 (Sreeramaneni et al. 2005). The net effect is 
that when p19 is not present, Mdm2 levels are increased and it can degrade p53; but if p19 is 
expressed, Mdm2 is sequestered to the nucleolus.  
There is also evidence that p53 can regulate some Ras targets - which is not surprising 
given perturbations in p53 can cooperate with mutant Ras to further metastasis (Hingorani et al. 
2005; Y. Wang et al. 2006; Tsumura et al. 2006). Several studies have identified factors that 
may be responsible for this synergistic effect (McMurray et al. 2008; Buganim et al. 2010; 
Solomon et al. 2012). For instance, BTG2 is not only a p53 target gene, it also suppresses GTP 
loading of Ras (Boiko et al. 2006; Buganim et al. 2010). Other p53 target genes include the 
phosphatases Pac1/Dusp2, Dusp5 and Mkp1, which can activate conventional MAPK signaling 
cascades (reviewed in Wu 2004). The powerful tumor suppressor also influences RhoA and 
ROCK, affecting the cytoskeleton and cellular movement (Mizuarai et al. 2006; Gadea et al. 
2007; Xia & Land 2007; Lefort et al. 2007). Additionally, a feedback loop occurs between p53 
and the phosphatase PTEN (Stambolic et al. 2001; Tang & Eng 2006). Finally, p53 can directly 
bind to H-Ras, activating gene transcription (Zhang et al. 1995). One study found that after 
treatment with a DNA topoisomerase I inhibitor, camptothecin, p53 is stabilized and a particular 
H-Ras splice variant is induced (Barbier et al. 2007). However, the splice variant is targeted by 
the nonsense-mediated decay pathway, and total H-Ras protein levels do not change, so the 
purpose of this conduit is unknown. 
It is not surprising there are multiple links between these genes, as they each regulate a 
large number of targets. Our work adds to the literature involving the regulation of p63 and p53. 
Since these genes are important to human development and disease, this work can have an 
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Human breast diagram. Duct inset is shown to the right. TDLU = Terminal ductal lobular units. 
The human mammary gland usually consists of 15-20 lobes per breast, not depicted here. 




















The HER2 signaling pathway. Ligand binding induces dimerization, leading to activation of the 
intracellular tyrosine kinase. On auto- and cross-phosporylation of the receptor complex, key 
downstream effectors are recruited. This figure illustrates a HER2-HER3 heterodimer, but HER2 
can also form homodimers or heterodimerize with other members of the HER2 family. FKHR, 
forkhead in rhabdomyosarcoma; Grb2, growth factor receptor-bound protein 2; GSK-3, glycogen 
kinase synthase-3; MAPK, mitogen-activated protein kinase; mTOR, molecular target of 
rapamycin; PI3K, phospatidyl-inositol 3-kinase; PTEN, phosphatase and tensin homologue 
deleted on chromosome 10; SOS, son-of-sevenless guanine nucleotide exchange factor  (© Lin 









The original six hallmarks of cancers, plus two new emerging hallmarks (in black font) are 
shown (adapted from Hanahan and Weinberg, 2000; 2011). Not all cancers display these 






















In the metastatic cascade, a primary tumor undergoes these steps to seed a tumor in a distant 
organ. Tumor cells must become motile, invade the basement membrane to reach the blood 
vessels (intravasation), translocate through the blood system and extravasate into the target 





















Selected p63 targets play a role in cell cycle control (arrest, proliferation, senescence), with 
some coordinately regulating antitumorigenic mechanisms including the repression of EMT 
factors. For some microRNAs, ‘f’ is used to denote their family members. Meanwhile, some p63 
forms alter the levels of known oncogenes or stemness factors like SOX2, which is upregulated 



















Multistep model of colorectal cancer: Certain genetic alterations are seen early or late in 
tumor development. Alterations in the oncogene K-Ras are generally not seen in polyps 
(dysplatic tissue), however they are found in a high percentage of adenomas and carcinomas (© 





















Simplistic model of MAPK cascades. At left, the categories including Activator, MAPK-MAP3K 
and Targets. There are many targets for each MAPK and often several upstream activators for 
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    The p53-related transcription factor p63 is required for maintenance of epithelial cell 
differentiation. We found that activated forms of the H-RAS and PIK3CA oncogenes strongly 
repress expression of ∆Np63α, the predominant p63 isoform in mammary epithelial cells. This 
regulation occurred at the transcriptional level and a short promoter sequence is sufficient for 
altered expression induced by H-RasV12. The suppression of ∆Np63α expression by these 
oncogenes concomitantly leads to an epithelial-to-mesenchymal transition (EMT). In addition, 
the depletion of ∆Np63α alone is sufficient to induce EMT. Both H-RasV12 expression and 
∆Np63α depletion induce individual cell invasion in a 3D collagen gel system, thereby 
demonstrating how Ras can drive the mammary epithelial cell state towards greater invasive 
ability. Together these results suggest a pathway by which RAS and PIK3CA oncogenes induce 
EMT through regulation of ∆Np63α. 
 
 
Significance     
The H-RAS and PIK3CA oncogenes are well-known for altering cell growth and 
morphology. We show here that they are also able to modify the differentiation state of 
mammary epithelial cells by inducing an epithelial-to-mesenchymal transition (EMT). This 
transition leads to greater invasiveness, a hallmark of the progression of tumors towards 
metastasis. Expression of p63, a gene required for the development of mammary epithelial 
cells, is strongly repressed by these oncogenes. In turn, loss of p63, which occurs at the 
transcriptional level, causes a shift in microRNAs and transcription factors that control EMT. 







   H-Ras, a member of the Ras family of GTPases, was originally identified as the 
transforming protein encoded by the Harvey rat sarcoma retrovirus (DeFeo et al. 1981). 
Activating mutations in H-Ras and its family members, K-Ras and N-Ras, were identified in a 
variety of cancers, and nearly 30% of all cancers have mutations in one of the Ras genes 
(Forbes et al. 2011; Prior et al. 2012). The EGFR2 receptor, also known as HER2/neu, is a main 
signal transducer to Ras and is amplified in about 20-30% of breast cancers (Slamon et al. 
1987; Varley et al. 1987). While many HER2+ cancers are sensitive to the drug Herceptin 
(trastuzumab), resistance usually develops (Narayan et al. 2009; Gajria & Chandarlapaty 2011). 
Therefore, it is of great importance to understand signaling pathways that are downstream of 
EGFR2 and Ras in order to develop new therapeutics. 
    A major effector downstream of Ras is the phosphatidylinositol 3-kinase (PI3K) pathway. 
The catalytic subunit of PI3K, PIK3CA, is frequently found mutated in cancers, especially those 
originating in the breast (Samuels et al. 2004; Cancer Genome Atlas 2012). Like mutant Ras, 
expression of mutant PIK3CA can cause non-tumorigenic cells to undergo transformation and 
gain invasive abilities (Zhao et al. 2005; Kang et al. 2005). Cancerous cells may gain increased 
invasive abilities by undergoing an epithelial-to-mesenchymal transition (EMT), where adherens 
junctions mediated by E-cadherin are disrupted (Perl et al. 1998; Krakhmal et al. 2015). 
Canonical transcription factors that repress E-cadherin include Twist, Snail, Slug, and Zeb1, 
although this network has grown more complex in recent years (Craene & Berx 2013; Comijn et 
al. 2001).   
The transcription factor p63 not only induces transcription of canonical p53 targets, but is 
a master regulator of epithelial cells (Koster et al. 2004; Barbieri & Pietenpol 2006). Mice losing 
both alleles of p63 display complications due to the loss of epithelial stratification, including 
absence of mammary glands (Yang et al. 1999; Mills et al. 1999). They also have significant 
161 
 
craniofacial and limb abnormalities, indicating that p63 plays a key role in embryonic 
development. There are many isoforms of p63, including the major types TAp63 and ΔNp63, 
which are transcribed from alternative start sites (Yang et al. 1998). There is also alternative 
splicing at the 3’ end, resulting in the isoforms α, β, and γ (Yang et al. 1998). ΔNp63 was 
determined to be responsible for the aforementioned characteristics in mice, as isoform-specific 
knockdown led to similar epidermal defects (Koster et al. 2007; Romano et al. 2012).  
Interestingly, p63 has a controversial role in cancer, possibly due to the different 
activities of its various isoforms and/or tissue specificity. In head and neck squamous cell 
carcinomas (HNSCC), the p63 locus is often amplified, suggesting an oncogenic role (Hibi et al. 
2000). However in other types of tumors, basal epithelial markers like p63 and Keratin 14 are 
lost (Urist et al. 2002; Dairkee et al. 1985; Nylander et al. 2002) and ∆Np63 has been found to 
suppress EMT in prostate and bladder cancer cells (Tucci et al. 2012; Tran et al. 2013). 
Surprisingly, in one report, ∆Np63 and  were found to inhibit, while ∆Np63 promoted EMT in 
MCF10A mammary epithelial cells (Lindsay et al. 2011). These conflicting results make it 
important to determine the effects of p63 on cell growth, differentiation and invasiveness in 
different cell types. 
    We endeavored to study gene and network changes downstream of Ras signaling 
pathways in mammary epithelial cells. Our analysis of these changes indicates that Ras and 
PIK3CA oncogenes can induce EMT via repression of p63. 
 
Results 
   We were originally interested in how the H-Ras and p53 pathways might interact to 
regulate gene expression. For this purpose we utilized a pair of isogenic MCF10A cell lines, one 
with wild-type (WT) p53 and another with a deletion of p53’s second exon, leading to loss of p53 
protein (termed ‘p53-del’ here; clone 1A from (Weiss et al. 2010)). MCF10A is a non-
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transformed mammary epithelial cell line that was spontaneously immortalized after derivation 
from a healthy woman who underwent reduction mammoplasty (Soule et al. 1990). This line is 
thought to derive from myoepithelial cells as they express p63, keratin 5 and keratin 14 
(Barbareschi et al. 2001). Activated H-RasV12 or the empty Vector (pBabepuro) were 
introduced into MCF10A cells by retroviral transduction. Expression of H-Ras was confirmed by 
immunoblots and quantitative RT-PCR (qPCR) (Figures 1A and S1A). The morphology of the H-
Ras cells was altered, as previously seen for the comparable cell line MCF10AT (Figure S1B) 
(Miller et al. 1993). While the Vector lines were cobblestone-like when confluent, characteristic 
of epithelial cells, the two lines with overexpressed H-Ras displayed an elongated shape with 
loss of cell-cell attachments (Figure S1B). We also found that the H-Ras, but not the Vector cell 
lines, formed large colonies in soft agar, demonstrating anchorage-independent growth (Figure 
S1B), indicating their transformed properties. 
  In order to assess gene expression changes and identify novel targets downstream of H-
Ras and p53, we performed RNA-Seq for the four cell lines. A Venn diagram of genes 
significantly regulated by H-RasV12 (fold change > 2 and p < 0.05) is shown for the p53-del and 
WT cell lines (Figure 1B). Interestingly, the total number of significantly changed targets was 
smaller in the WT-p53 set of cell lines than in the p53-del set of cell lines, suggesting that the 
presence of p53 has a dampening effect on H-Ras signaling pathways.   
   There was an overlap of 821 genes up- or down-regulated by H-Ras in both the p53-del 
and WT cell lines, listed in Table S1A. Genes uniquely regulated by H-Ras in the p53-del and 
WT cell lines are listed in Tables S1B and C. In addition to H-Ras, which was high due to its 
introduction into these cell lines, a number of mesenchymal genes, including Zeb1, Zeb2, 
Vimentin (VIM), N-cadherin (CDH2) and Fibronectin (FN1), were within the top 100 significantly 
upregulated targets (Figure S1C, Supplemental Table 1A). This suggests that the cells have 
undergone EMT. Correspondingly, genes associated with the epithelial state were significantly 
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downregulated, including E-cadherin (CDH1), miR-205 host gene (MIR205HG), keratin 5 
(KRT5), grainyhead-like transcription factor 2 (GRHL2), and epithelial splicing regulatory protein 
1 (ESRP1) (Figure 1C, Table S1A). Interestingly, TP63, a transcription factor associated with 
the epithelial state, was the 2nd and 6th most significantly downregulated target in the WT-p53 
and p53-del cells, respectively.  
We performed a gene ontology (GO) cluster analysis and found that mutant H-Ras-
downregulated genes were strongly associated with epidermis and ectoderm development, as 
well as epithelial cell differentiation, further suggesting that H-Ras causes changes in epithelial 
differentiation (Figure 1B). There was weaker, but significant association of Ras-upregulated 
genes with ‘response to wounding’ and vasculature development (Figure S1D). Due to this 
regulation of epithelial-related genes in both the p53-del and WT-p53 lines, we chose to focus 
on this p53-independent aspect of H-Ras signaling. (For future reference, Tables S1B and C 
provide lists of genes regulated by H-Ras uniquely in either the WT-p53 or p53-del 
backgrounds.) 
   We validated by qPCR that p63, specifically the ΔNp63α isoform, is strongly reduced in 
the H-Ras cells and found that the ΔNp63α isoform is the predominant p63 isoform expressed 
in MCF10A cells, as has been described previously (Figure 1D and Table S1D) (Carroll, Carroll, 
Leong, Cheng, Brown, A. a Mills, et al. 2006). Furthermore, using intronic primers in order to 
measure pre-mRNA in the nucleus we showed that p63 pre-mRNA was similarly repressed by 
H-RasV12 indicating that ΔNp63α expression is regulated at the transcriptional level (Figure 
1E).  
To investigate how ΔNp63α expression is repressed by H-RasV12, we constructed 
promoter reporter genes with various lengths of upstream p63 genomic sequence, starting with 
a construct containing -3043 to +139 of the ΔNp63α promoter (Lanza et al. 2006). These 
reporters were transfected into the MCF10A cells (WT-p53) expressing Vector or H-Ras. We 
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found that there was 2-3 fold higher expression of the promoter constructs in Vector vs. H-Ras 
cells, after normalizing to the internal control of an SV40 promoter-Renilla luciferase plasmid 
(pRLSV40) (Figure 2A). Progressive deletion from the 5’ end resulted in reduced expression; 
however each construct down to -100 showed similar differential expression between Vector 
and H-Ras cells. As controls, we found that the promoter activity of a p53 response element 
(p53 RE) plasmid was not altered, while a minimal E-cadherin promoter was significantly 
lowered in Ras cells as expected given the lower E-cadherin expression in these cells 
discussed below (Figure 2C). 
    In order to separate the effects of the upstream promoter from that of the sequence 
surrounding the transcriptional start site, we tested the -100 to -30 region (just upstream of a 
TATA box) using a reporter with a minimal c-fos promoter. This sequence was similarly 
preferentially expressed in Vector cells (Figure S2A). We also tested a trimer of the -100 to -30 
region and found even stronger Vector-specific activity (Figure S2B). The -83 to -30 region was 
also sufficient for this regulation, however deletion of either the 5’ or 3’ parts of this sequence 
caused a loss of promoter activity, suggesting that multiple sequences within this region are 
required for expression (Figure S2A).  
   We were able to further narrow the region required for differential expression to -83 to -
44 (Figure 2B). Examination of the sequence of this region showed a CCAAT box and potential 
SP1 site. When we made specific mutations along the -83 to -44 sequence (Figure 2B, left), 
altering CCAAT Box and Sp1 sites, promoter activity was completely abolished, while mutations 
in the other sites had only partial effects on expression (Figure 2B, right). We also tested the 
CCAAT Box and Sp1 mutations in the context of a longer promoter sequence, -500 to +139, 
and these also displayed strongly decreased promoter activity (Figure S2C). Collectively, these 
results suggest the importance of the entire -83 to -44 region for regulation, and point to the 
CCAAT box and SP1 sites as being particularly critical.  
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    Given the strong effects of the CCAAT box and SP1 site mutations, we tested whether 
the main factors associated with these sites bind to them in MCF10A cells using chromatin 
immunoprecipitation followed by qPCR. For the CCAAT box, a trimer of NF-YA/B/C is the 
primary binding factor (Dorn et al. 1987; Sinha et al. 1995), while SP1 binds to GC-rich boxes 
(Dynan & Tjian 1983). While there were no differences in the expression levels of NF-YA or SP1 
from immunoblotting, we were able to detect their binding by chromatin immunoprecipitation to a 
sequence near the transcriptional start site (TSS) of a known target, Thymidine Kinase 1 (Figure 
2D, right). However, no binding was detected at the TSS of the ΔNp63α promoter above that of 
a non-specific IgG control (Figure 2D, left). These results argue against an involvement of these 
factors in ΔNp63α regulation. It is possible that factors other than Sp1 and NF-YA bind to the 
above-mentioned sequences in the ΔNp63 promoter, in contrast to the case in mouse 
keratinocytes. Importantly, when we measured binding of activated RNA polymerase II at the 
ΔNp63α TSS using antibodies to phospho-serine 5 of the C-terminal domain, there was a strong 
signal in Vector cells, but greatly decreased binding in H-Ras cells that was close to the 
background of the IgG control (Figure 2D). These results further confirm that ΔNp63α is 
regulated by H-RasV12 at the transcriptional level, affecting RNA polymerase II activity and 
leading to repression of ΔNp63α expression.  
Given the changes in epithelial-specific genes seen by RNA- The hallmark epithelial 
marker E-cadherin was suppressed, while the mesenchymal marker N-cadherin was activated 
by H-Ras at both levels (Figure 3A, S1E). Similar to the mRNA levels, ∆Np63α protein levels 
were suppressed, while mesenchymal proteins Fibronectin and Vimentin were increased in H-
Ras cells (Figures 1D, 3A), demonstrating that these cells have undergone EMT.  
As many reports have suggested that the transcription factors Twist, Snail and Slug are 
regulators of the cadherin switch, it is likely they are not EMT inducers in this model due to the 
lack of RNA regulation (although we cannot rule out post-transcriptional regulation). Other 
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known inducers of EMT and E-cadherin repression are the ZEB1 and ZEB2 transcription factors 
(Comijn et al. 2001; Guaita et al. 2002; Vandewalle et al. 2005). In contrast to the other 
regulators, these factors were strongly upregulated in the H-Ras cells, suggesting that they are 
the likely regulators of EMT in these cells (Figure 3B, C). 
A well-known mechanism of suppression of the ZEB factors is by miR-205 and members 
of the miR-200 family (including miR-200a, miR-200b, miR-200c, miR-141 and miR-429; from 
here on, miR-200f) (Gregory et al. 2008; Korpal et al. 2008). These microRNAs have also been 
reported to be regulated by p63 (Knouf et al. 2012; Tucci et al. 2012; Tran et al. 2013), 
suggesting a pathway for ∆Np63α regulation of ZEB1/2. We validated that expression of miR-
200b, miR-200c and miR-205 was suppressed by H-Ras in the four cell lines, while there was 
no change in expression of a control miRNA, miR-375 (Figure 3D). These results are consistent 
with p63 regulation of ZEB1/2 through these miRNAs, though additional mechanisms are 
possible. 
To test whether the effect of H-RasV12 was specific to the cell line used, we expressed 
H-RasV12 in an independent mammary epithelial cell line, MCF12A. This is an immortalized, 
non-tumorigenic breast epithelial cell line from a different patient than MCF10A, who also 
underwent reduction mammoplasty. The MCF12A H-RasV12 line similarly underwent EMT, 
displaying the same loss of E-cadherin and ∆Np63α, along with induction of N-cadherin, 
Fibronectin, Zeb1 and Zeb2 (Figures S3A, B, and data not shown). Therefore, the downstream 
effects of H-Ras activation may be generalizable to multiple mammary epithelial cell lines. 
While mutant H-Ras is significantly overexpressed in the MCF10A cells, it is also 
possible that endogenous H-Ras is expressed at low levels in MCF10A cells. We therefore 
compared the levels of total Ras proteins using a pan-Ras antibody. In this case, the 
overexpression of Ras in our MCF10A cells is only 3-4 fold (Figure S3C). We also found that the 
levels of mutant Ras expressed in our engineered cell lines were only 2.5-7 fold higher than the 
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level in a breast adenocarcinoma line Hs578T containing mutant H-Ras. It was also only 1-4.4x 
higher than the level in a colorectal carcinoma line HT-29 containing wild-type Ras (Figure 
S3C). These results suggest that the expression of mutant H-Ras in the MCF10A lines are 
within a range of physiological expression and that the observed effects cannot be attributed to 
grossly overexpressed Ras oncoprotein.   
In order to understand more about the kinetics of Ras’ effects, we engineered a stable 
cell line with doxycycline-inducible H-RasV12, termed ‘TR-Hras’. We found that it took about 5 
days of H-Ras induction by doxycycline to cause ∆Np63 and E-cadherin repression, and to 
induce mesenchymal markers N-cadherin, Fibronectin and Zeb1 (Figure S4A, B). These results 
further confirm the coordinate regulation of p63 and EMT by H-Ras. Also, these are not 
immediate effects of H-RasV12 activity, but rather necessitate several days, as is common for 
induction of mesenchymal transition (Grunert et al. 2003).  
Since activation of PI3K and loss of the phosphoinositide phosphatase PTEN (which 
leads to hyperactive PI3K) are more common in breast cancers than Ras mutations, we 
expressed mutant H1047R of PIK3CA in MCF10A cells by retroviral transduction, establishing 
two clonal cell lines, P1 and P2 (Figure 4A). Hotspot mutations in the PI3K catalytic subunit 
PIK3CA, like H1047R, are found in nearly a quarter of breast cancers, and H1047R in particular 
was shown to lead to strong activation of the Akt kinase, driving mammary tumorigenesis 
(Bachman et al. 2004; Zhao et al. 2005; Samuels et al. 2004).  Clones P1 and P2 showed 
induced phosphorylation of Akt1, demonstrating their activation downstream of PIK3CA (Figure 
4A). They also displayed fibroblast-like morphology, along with repression of ∆Np63α and E-
cadherin, similar to the H-Ras cell lines (Figure 4A, B, data not shown). Mesenchymal genes 
were again upregulated in these clones (Figure 4B). These results show that PIK3CA, a 
common breast cancer oncogene, can induce EMT and ΔNp63α repression and suggest that H-
Ras’ effects may be due to its activation of PI3K/Akt signaling. 
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In order to determine whether repression of ΔNp63α is sufficient to induce EMT, we 
made stable cell lines with shRNA to inhibit ΔNp63α expression. We established two clonal cell 
lines with independent shRNAs targeting the unique N-terminus of ΔNp63. These clones 
displayed near total inhibition of ∆Np63 mRNA and protein levels (Figure 5A). Concordantly, 
they exhibited characteristics of EMT, including loss of E-cadherin and gain of N-cadherin, 
Vimentin, Fibronectin and Zeb1 expression (Figures 5A and S5A). In addition, epithelial-
associated miRNAs showed strongly reduced expression (Figure 5B) and the cells displayed a 
loss of epithelial morphology (data not shown).  
 We also performed RNA-seq on the control (LMP vector) and sh-ΔNp63 lines and 
identified 2,255 genes that were significantly altered by both shRNAs (Table S2A). GO analysis 
found that many of the same epithelial gene signatures as in H-Ras cells were prominently 
altered, along with cell migration and adhesion (Figure S5B). Upon comparison with the mutant 
Ras-regulated genes, 380 overlapping targets were identified (Figure 5C, Table S2B), indicating 
that p63 regulates an appreciable subset of the genes that H-Ras controls. We performed GO 
analysis on the genes downregulated by both perturbations and again found many processes 
related to an epithelial phenotype (Figure 5C). Epithelial-specific genes such as MIR205HG, 
KRT5, CDH1, ESRP1, GRHL2 were significantly downregulated following both alterations. The 
loss of these genes further demonstrated that the induction of EMT in these cells is due to 
circuits controlled by Ras and p63. 
When we analyzed several transcription factors among genes uniquely regulated by H-
Ras (Table S2C), from preliminary data, we did not identify any one factor as being sufficient to 
control p63 or induce EMT. It is possible that several factors coordinately regulate this pathway, 
or it is feasible that other targets are regulated post-transcriptionally to control EMT. 
   Collagen is a major component of extracellular matrix (ECM) in human breast tissue and 
known to support growth of MCF10A mammospheres (Krause et al. 2008). As H-Ras controlled 
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EMT has been associated with metastasis (Thiery et al. 2009; Zheng & Kang 2014), we 
examined 3D cell invasiveness in 3D collagen I gels. For these assays, we embedded 
spheroids consisting of 5000 cells into collagen I matrices and then monitored any outward 
cellular invasion into the fibrillar matrix at 24 hours. Under these conditions proliferation is 
minimal. We found that Vector cells only spread from the spheroid in a sheet-like manner, 
exhibiting a closed front characteristic of epithelial growth (Figure 6A). In contrast, H-RasV12 
and sh-ΔNp63α cells demonstrated extensive individual invasion of cells into the ECM (Figure 
6A). We quantified the change in invasive behavior by counting the number of single cells that 
left the spheroid. While few cells invaded beyond the spheroid core with the Vector cells, a 
significant number left the core of H-RasV12 and sh-ΔNp63α spheroids (Figure 6B). This 
invasive behavior is consistent with a shift to a mesenchymal phenotype.  
Adhesion to and force generation on ECM via integrin receptors is a prerequisite for 
mesenchymal locomotion in 3D environments such as the collagen I matrices used here (Friedl 
& Wolf 2010). Radial alignment of collagen fibers at the spheroid surface is a robust indicator of 
integrin-dependent interaction with the ECM (Schiro et al. 1991; Friedl et al. 1997). To exclude 
the possibility that invasion differences were caused by variances in the cells’ abilities to 
establish contacts with the collagen matrix, we imaged them soon after embedment (T = 2h) 
with confocal reflectance microscopy, which allows for the visualization of collagen fibers. In 
each case we observed collagen fibers radially aligned to the spheroid surface, indicating 
comparable cell-matrix attachments (Figure S6).   
    In order to determine whether p63 levels in tumors might be similarly regulated as in 
Ras-transformed MCF10A cells, we looked at expression of the p53 family in paired 
normal/tumor samples from the TCGA Breast Cancer dataset (Cancer Genome Atlas 2012).  In 
fact, p63 expression was significantly lower in tumor samples as compared to their normal 
tissue counterparts, while there was little change in p53 and p73 expression (Figure 7A). This 
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suggests that, although p63 is not frequently mutated in cancers, its expression is commonly 
lowered by tumorigenic mechanisms.  
It was also possible that since p63 is expressed in basal but not luminal epithelial cells 
(Yang et al. 1998), the low p63 expression is simply due to a predominance of non-basal 
tumors. However after stratifying a larger breast cancer dataset of tumors by molecular subtype 
according to the PAM50 gene set (Parker et al. 2009), p63 expression in basal-like breast 
cancers is still close to zero and significantly lower than that in normal tissue (Figure 7B). In fact, 
expression of p63 in basal tumors was comparable to that in luminal-type tumors, which would 
not be expected to express p63. Finally, we examined a tissue microarray (TMA) of triple-
negative breast cancer (TNBC) tissues for p63 protein expression. Various studies have shown 
that the majority of basal-like breast cancers fall within the TNBC subtype, and these express 
basal keratins (Bertucci et al. 2008; Cheang et al. 2008). However, in 94% of these patient 
samples, p63 was expressed in ≤5% of tumor nuclei (Table S3). Together, these results show 
that p63 expression is greatly reduced in a preponderance of breast cancers and support our 
model that oncogene downregulation of this gene is important for tumor progression. We cannot 
rule out, however, that basal tumors originate in luminal progenitors as has been reported for 
basal tumors from BRCA1 carriers (Lim et al. 2009; Molyneux et al. 2010). 
 
Discussion 
We found that ectopic expression of mutant H-Ras and PIK3CA in MCF10A cells leads 
to downregulation of ∆Np63 and differentiation to a mesenchymal phenotype. This was 
accompanied by a distinct change in invasive behavior, suggesting that the transdifferentiation 
process leads to greater metastatic potential. Depletion of ∆Np63 with shRNA also caused 
EMT, demonstrating that this depletion is sufficient to induce the transition. Along with other 
evidence that ∆Np63 is required for epithelial stratification (Yang et al. 1999; Koster et al. 2004), 
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these results confirm that ∆Np63 is a master regulator of the epithelial state. ∆Np63 activates 
expression of epithelial-specific miRNAs that are repressors of the mesenchymal-inducing 
transcription factors Zeb1 and Zeb2. These factors directly repress E-cadherin expression, 
suggesting a pathway for induction of EMT from Ras to ∆Np63 to E-cadherin (Figure 7C).  
There are many afferent pathways that can induce EMT (Kalluri & Weinberg 2009). 
While TGF-β was one of the first characterized inducers of this transition, signaling from Ras 
and TGF-β can synergistically drive cells towards the mesenchymal state (Oft et al. 1996; Janda 
et al. 2002). We have not observed activation of the TGF-β pathway in our MCF10A-Ras cells, 
suggesting that they are driven to EMT independent of TGF-β. As we found that mutant PIK3CA 
phenocopied the H-Ras cells, we postulate that a factor(s) within the PI3K/Akt signaling 
pathway are responsible for direct repression of the ΔNp63 promoter and induction of EMT, 
independent of the TGF-β pathway. 
We were concerned that the MCF10A cell lines we generated markedly overexpress mutant H-
Ras when compared to the endogenous H-Ras in the control cell lines and that this 
overexpression might cause non-physiological effects. However, the levels of total Ras proteins 
(H-, K- and N-Ras) were more modestly overexpressed and there was 1-7 fold higher 
expression than endogenous Ras compared to two human cancer cell lines that were tested 
(Figure S3C).  While we cannot rule out spurious effects of high levels of ectopic mutant H-Ras 
in MCF10A cells, the PIK3CA cell lines we generated expressed p110α protein at levels similar 
to the endogenous protein. As PIK3CA mutations are common in breast cancer, our results 
suggest that physiological levels of mutant PIK3CA can have effects on EMT during breast 
cancer progression and that the similar effects of H-Ras overexpression in our cell lines on EMT 
are physiological. Further work will be required in mammary tumor models to test the 
importance of oncogene repression of p63 and activation of EMT.  
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We mapped a short region of the ∆Np63 promoter required for differential expression in 
Ras transformed cells. While the entire region of -83 to -44 is required, the CCAAT box and SP1 
sites were particularly critical. A similar requirement for these sites for ∆Np63 expression was 
also found in mouse keratinocytes (Romano et al. 2006). However, while Romano et al. 
detected binding of NF-Y and Sp1 to the ∆Np63 promoter in these cells, we did not detect 
binding by chromatin immunoprecipitation in MCF10A mammary epithelial cells, suggesting that 
other factors are required. A number of transcription factors have been reported to regulate 
∆Np63 expression (reviewed in 58). More work will be required to determine which transcription 
factors directly regulate the ∆Np63 promoter in mammary cells, and how Ras and PI3K 
signaling modulate their activity. 
Among all of the canonical EMT regulators, Zeb1 and Zeb2 expression was induced in 
both H-Ras and sh-∆Np63 cells. One mechanism for ∆Np63 regulation of Zeb1/2 is through 
miR-200f and miR-205 (Gregory et al. 2008; Korpal et al. 2008; Tucci et al. 2012; Tran et al. 
2013) (Fig. 7C). We found that these miRNAs are strongly repressed by H-Ras and ∆Np63 
depletion in MCF10A cells, consistent with this model. Intriguingly, we also found that Zeb1/2 
pre-mRNA levels were increased by H-Ras, suggesting that there may also be regulation at the 
transcriptional level (data not shown).  
    Consistent with our data linking repression of ∆Np63 with occurrence of EMT, there is a 
precipitous loss of ∆Np63 expression in the TCGA breast cancer dataset, suggesting that this 
repression is a common occurrence in breast cancer progression. In particular, separate 
analyses revealed that basal-like cancers and TNBCs have low ∆Np63 expression. The 
importance of these results is that triple negative breast cancers are the most resistant to 
therapy (Hudis & Gianni 2011). There have been many other reports of low p63 expression in 
breast cancers (Barbareschi et al. 2001; D Stefanou et al. 2004; Hanker et al. 2010), however 
there are also cases where higher expression is seen (C.-O. Leong et al. 2007; H. Li et al. 2007; 
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Sailer et al. 2015). The latter examples may be similar to the situation in squamous carcinomas; 
indicating either the different cellular origin of breast carcinomas with elevated p63, or a 
separate pathway for oncogenesis (Hu et al. 2002; Reis-Filho et al. 2003; King et al. 2013).   
 The cell-of-origin of basal–like breast cancers from BRCA1 mutation carriers may 
actually be a luminal progenitor cell; such cells have similar gene expression patterns to patient 
basal-like tumors (Lim et al. 2009; Molyneux et al. 2010). It is currently unknown as to whether 
all basal-like breast cancers derive from luminal progenitors, not just those with BRCA1 
alterations. Indeed, there may be several differentiation pathways for mammary cancers since 
multipotent and unipotent progenitors have been characterized (Fu et al. 2014). Some basal 
myoepithelial cells even have mammary stem cell properties in that they are able to repopulate 
a mammary gland in vivo (Prater et al. 2014), raising the possibility that these stem cells could 
be targeted for transformation resulting in basal-like tumors. It is possible that oncogenes such 
as H-Ras and PIK3CA could participate in this transformation to a basal-like cancer state, which 
might result in the gain of mesenchymal properties.  
There is considerable evidence that EMT contributes to cancer progression and 
metastasis as well as inducing stem cell properties (Wan et al. 2013). EMT is also known to 
induce individual cell migration, which is a property we observed after Ras pathway activation 
and ∆Np63 depletion (Krakhmal et al. 2015; Wan et al. 2013; Friedl & Alexander 2011). 
However, two recent papers have concluded rather provocatively that EMT is not required for 
metastasis, although it increases chemoresistance (Fischer et al. 2015; Zheng et al. 2015). It is 
unclear if these conclusions hold true for human breast cancer; so further manipulation of EMT 
will be required to determine its role in different cancer types.  
In conclusion, the strong repression of ∆Np63 by H-Ras and PIK3CA and induction of 
EMT suggest that this process is critical for mammary tumorigenesis. Future studies must 
determine how important this pathway is to human breast cancer progression and how p63 
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regulation influences pathogenesis. A more detailed understanding of this pathway may lead to 
an alternate approach to block this extremely prevalent disease.  
 
Materials and Methods 
See supplementary information for a complete description of materials and methods. 
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Figures for Chapter 2 
 
 
Figure 1: Differential expression in H-Ras transformed MCF10A cells.  
A) Western blot of MCF10A cells with WT-p53 or p53-del background, with H-RasV12 (R) or 
Vector (V). B) A Venn diagram is shown for differentially expressed genes (DEG) identified by 
RNA-seq in H-RasV12 compared to Vector cells in either background. Top gene ontology (GO) 
categories are shown for genes downregulated in H-Ras cells in both WT and p53-del settings. 
C) The top 10 downregulated genes from the overlap seen in B (values from WT-p53 set); p 
values shown are always adjusted for multiple testing using the Benjamini–Hochberg procedure. 
D) Validation of ΔNp63 mRNA levels by qPCR. Error bars are the standard deviation from three 


















Figure 2. Analysis of the ∆Np63 promoter.  
A) Luciferase reporter assays were performed in the Vector (V) and H-Ras (R) cell lines (WT-
p53 background) with ∆Np63 promoter constructs with the indicated sequence upstream of the 
transcriptional start site. B) Left, sequence of the -83 to -44 ∆Np63 promoter region with the 
indicated transcription factor binding sites and mutations. Right, reporter assays of -83 to -44 
region on a Fos minimal promoter and indicated mutants. C) Luciferase reporter assays of 
control E-cadherin and p53 Response Element reporters. These are the means of at least three 
experiments with the standard deviation. D) Chromatin immunoprecipitation of the ∆Np63 and 
TK1 promoters. The indicated antibodies were used to detect transcription factor or RNA 
polymerase II phospho-S5 binding to the ∆Np63 TSS (left) or control Thymidine Kinase 1 (TK1) 
TSS (right) in Vector of H-RasV12 cells. Non-specific IgG was used as a control antibody. The 
error bars indicate the standard deviation of three experiments. X-axis is Arbitrary Units 














Figure 3. Regulation of EMT factors in H-Ras cells.  
A) Protein levels of p63 and EMT markers. Western blots were performed with the indicated 
antibodies. The results are representative of at least three experiments. B) Zeb1 and Zeb2 
mRNA levels were measured by qPCR. C) Western blots of Vector and Ras cells were 
performed with the indicated antibodies. D) Expression of the indicated miRNA levels were 










Figure 4. Activation of the PI3K pathway causes EMT.  
A) Phase contrast (left) and Western blots with the indicated antibodies (right) of MCF10A cells 
infected with Vector (V) or PI3KCA mutant H1047R (P1 and P2). The endogenous and 3X Flag-
tagged p110α can be seen separately in the P1 and P2 cells. B) Western blots and qPCR of 
p63 and EMT markers. For qPCR, the results are normalized to 1.0 in Vector cells for E-
cadherin and ∆Np63 and in P1 cells for N-cadherin, Zeb1 and Zeb2; error bars show the 



















Figure 5. Depletion of ∆Np63 induces an EMT phenotype.  
A) MCF 10A cells stably expressing shRNA (#1, #2) to ∆Np63 or a control shRNA (V) were 
immunoblotted with the indicated antibodies (left) or analyzed for mRNA expression by qPCR 
(right). B) Levels of the indicated miRNAs in the control and sh-∆Np63 cell lines were 
determined by qPCR. C) A Venn diagram is shown for genes identified by RNA-seq that are 
differentially expressed in H-RasV12 and ∆Np63 shRNA cell lines compared to control cells. 










Figure 6. Invasiveness of H-RasV12 and p63-depleted cells.  
A) Multicellular spheroid invasion was measured in 3D collagen I gels. After cells invaded for 24 
hours, spheroids were fixed and stained with fluorescently-labeled phalloidin (scale bar = 200 
µM). B) Individual cell invasion was quantified by counting single cells beyond the spheroid core 
(at least 20 spheroids were measured from 2 independent experiments; *** indicates p < 0.0001 












Figure 7. p63 expression in human breast cancers.  
A) p53 family expression in breast tumors. TP53, TP63 and TP73 gene expression in paired 
normal and tumor samples (n = 110) from the TCGA Breast Cancer dataset are shown as 
normalized counts from RSEM. The p value for the difference in TP63 expression between 
Normal and Tumor cells is shown. B) Breast tumors (n = 795) were stratified by molecular 
subtype using the PAM50 gene set and compared to normal samples, from above (n = 110). 
‘HER2-Enr’ stands for HER2-Enriched tumors. The normalized expression for ΔNp63α is shown 
(*** = p < 0.0001 using Welch’s t-Test for basal compared to normal). C) Model of signaling from 





















Figure S1: Characterization of MCF10A lines with and without H-RasV12.  
A) H-Ras mRNA levels were measured in transduced Vector (V) or H-RasV12 (R) MCF10A 
cells by qPCR. B) Top, differential interference contrast images of Vector and H-Ras cells (scale 
bar = 100 µM). Bottom, colony growth of WT-p53 cells in soft agar after 11 days (scale bar = 
200 µM); representative of three independent experiments. C) Top 10 H-RasV12 upregulated 
genes from the overlapping gene set of p53-del and WT-p53 cells, sorted by adjusted p value. 
D) Top GO biological pathways associated with genes upregulated after H-RasV12 expression. 
E) Levels of E-cadherin and N-cadherin mRNA measured by qPCR. 





Figure S2: Luciferase reporter assays.  
A) The indicated regions of the ΔNp63 promoter were cloned upstream of the c-fos minimal 
promoter and assayed for luciferase activity in Vector (V) or H-RasV12 (R) MCF10A cells. B) 
The 3x(-100 to -30) sequence was cloned upstream of the c-fos minimal promoter and assayed 
for luciferase activity as in A (A, B are the average of 3 experiments). C) The indicated mutants 
were constructed in the -500 to +139 background, replicating the results in Figure 2B (average 









Figure S3: Induction of EMT after H-RasV12 was transduced into MCF12A cells.  
A) Western blot with the indicated antibodies. B) ΔNp63 and E-cadherin mRNA levels were 


















Figure S4: EMT is induced in a “Tet-on” cell line, TR-Hras.  
A) Left, TR-Hras cells with and without doxycycline treatment for the indicated days were lysed 
and immunoblotted with the indicated antibodies.  Right, qPCR analysis for the indicated genes 
after four days of doxycycline treatment. B) The indicated mesenchymal gene expression was 















Figure S5: Characterization of the ΔNp63 shRNA cell lines.  
A) The indicated mesenchymal genes were measured by qPCR. B) The expression of genes in 
the ΔNp63 shRNA and control cell lines was determined by RNA-seq. Selected GO categories 


















Figure S6: Collagen attachment of spheroids. 
Confocal reflectance microscopy (CRM) was used to assess cell-ECM contact and visualize 
collagen fibers in MCF10A-derived cell lines two hours after the spheroids were embedded in 
the matrix. Collagen fibers radially aligned to the spheroid surface (arrows) indicate integrin-
mediated cell-matrix adhesion (scale bar = 50 µm). The bright spot in the images is an optical 












Supplemental Materials and Methods 
 
Plasmids, cell culture and generation of stable cell lines 
pBabe puro HA PIK3CA H1047R was a gift from Dr. Jean Zhou (Addgene plasmid 
#12524) (1). The MSCV LTRmiR30-PIG (LMP) vector, pBabepuro, pBabepuro-H-RasV12 
(Addgene plasmid #18744) and Phoenix-Ampho cell line were generous gifts from Dr. Scott 
Lowe. The -3000 ∆Np63 promoter construct was a gift from Dr. Antonio Costanzo and contains -
3043 to +139 of the human ∆Np63 gene in the pGL3-basic luciferase plasmid (2). The -1500, -
500, -165 and -100 constructs were made by PCR from these bases to +139 and cloning the 
fragments between the KpnI and HindIII sites of pGL3-basic. The Cdh1 (E-cadherin) reporter 
contains -178 to +91 of the E-cadherin promoter and was a gift from Dr. Kumiko Ui-Tei (3). The 
c-fos minimal promoter, pOF-GL3, was previously described (4). The fragments of the ∆Np63 
promoter were made by PCR and cloned upstream of the c-fos minimal promoter into pOF-GL3 
containing -54 to +49 of the human c-fos promoter using KpnI and HindIII sites. The 3x (-100 to 
-30) construct was made by synthesizing the 3x fragment (Genewiz) before cloning into pOF-
FL3. The -83 to -44 fragment and mutations were made by synthesizing oligonucleotides 
(Integrated DNA Technologies) that were annealed before cloning into pOF-GL3. The p53 RE 
promoter plasmid contains the p53 response element from the p21 promoter (-2.3 kB) cloned in 
front of the c-fos minimal promoter of pOF-GL3 (Dr. Kristine McKinney, unpublished). 
MCF10A and MCF10A clone 1A (p53 -/-) were a kind gift from Dr. David Weber (5). We 
received the MCF12A cells from Dr. Jose Silva. These breast cell lines and their derivatives 
were grown in DME/F-12 media (Thermo Fisher #11765) with 5% horse serum (Thermo Fisher 
#16050122), 0.5 μg/mL hydrocortisone (Sigma-Aldrich #H0888), 10 μg/mL insulin (Sigma-
Aldrich #91077C), and 20 ng/mL EGF (Peprotech #AF-100-15) in a 37°C incubator with 5% 
CO2. For stable expression lines, the Phoenix-Ampho packaging cell line was grown in DME 
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with 10% FBS (Gemini #900108H). To package virus, they were transfected with 10 μg of 
plasmid with Lipofectamine 2000 (Thermo Fisher). After three days, retroviral supernatant was 
filtered (0.45 microns) and added to MCF10A or MCF12A cells with 5 μg/mL polybrene (Sigma-
Aldrich #107689). After two days, cell lines were selected with 2 μg/mL puromycin (InvivoGen) 
and individual clones were picked (for PIK3CA) or surviving cells were pooled (for H-RasV12). 
After selection was completed (about 7 days), all cells were kept in 1 μg/mL puromycin for 
maintenance.   
MCF10A-TR cells (containing the tetracycline repressor TetR) were from Dr. Rosalie 
Sears (6) and pLenti CMV/TO-RasV12-Puro vector was from Dr. Eric Campeau (Addgene 
plasmid #22262). For the TR-Hras cell line, the pLenti CMV/TO-RasV12-Puro vector was 
transfected into 293 cells with the lentiviral packaging plasmids (p∆8.9 and pVSVG) and the 
viral supernatant was then used to infect MCF10A-TR cells. The infected cells were selected 
with 5 µg/mL blasticidin (Thermo Fisher).  
For the OEΔN line, the FLAG-∆Np63α sequence was taken from pCMV7.1-∆Np63 
previously described (7) and inserted in pBabebleo at the BamHI site to make the pBabebleo-
Flag-∆Np63α vector. pBabebleo was a gift from Drs. Hartmut Land, Jay Morgenstern, and Bob 
Weinberg (Addgene plasmid #1766) (8). The same transduction procedure was used as above 
for pBabepuro-H-RasV12, except that these cells were selected with 5 μg/mL phleomycin 
(Invivogen) and maintained in 2 μg/mL. 
For the shRNA cell lines, short hairpin sequences to ∆Np63 (unique to the N-terminal 
coding region) were designed as previously described (9) (Table S4). These were subcloned 
into the LMP vector. As above, Phoenix packaging cells were transfected using Lipofectamine 
2000 with the vector of interest. Retroviruses were harvested 48-60 hours post-transfection, and 
the viral supernatant was filtered before it was added to plates of MCF10A cells, in the presence 
of 8 μg/mL polybrene (Sigma-Aldrich). Cells were grown for 1 day before selection was begun 
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using 1 μg/ml puromycin (Sigma-Aldrich). Antibiotic selection was complete 24 hours after the 
last cell on the untransduced plate was eliminated, and cells were grown without any further 
antibiotic usage. 
 
Protein extraction and Western blotting 
Cells grown on 10 cm plates to 80-90% confluency were washed twice with cold PBS 
and scraped into cold TEGN buffer (10 mM Tris at pH 7.9, 1 mM EDTA, 10% glycerol, 40 mM 
NaCl, 0.5% NP-40 and 100 μM DTT with protease inhibitors (10 μM benzamidine, 70 nM 
leupeptin, 10 μg/mL α2-macroglobulin, 0.7 μM bacitracin, 0.5 μM PMSF)). The lysates were kept 
on ice for 30 minutes with vortexing every 10 minutes. These were centrifuged at 13000 RPM 
for 10 minutes after which the supernatant was isolated. Finally, the protein concentrations of 
the lysates were quantitated using Bradford assays (Bio-Rad). These whole-cell lysates (40 µg) 
were run on 7-15% polyacrylamide gels (depending on the proteins to be detected), and 
transferred to nitrocellulose filters followed by blocking for one hour at RT (5% nonfat dry milk in 
phosphate-buffered saline (PBS) with 0.05% Tween-20).  Antibodies used include anti-ΔNp63 
(polyclonal rabbit serum raised from peptide sequence MLYLENNAQTQFSEP, by Covance), 
anti-N-cadherin (BD Biosciences 561553), anti-Flag (Sigma-Aldrich F1804), anti-Fibronectin 
(Sigma-Aldrich F3648) and anti-β-actin (Sigma-Aldrich A5316). The following antibodies were 
from Santa Cruz Biotechnology: p63α (H-129), Zeb1 (H-102), Vimentin (C-20), E-cadherin (H-
108), H-Ras (F235), pS473-Akt1 (11E6), Akt1 (5C10), p110α (H-201), NF-YA (H-209 X), and 








For quantitative RT-PCR (qPCR) RNA was extracted from cell pellets using TRIzol 
reagent according to the manufacturer’s protocol (Thermo Fisher) and quantitated by ultraviolet 
spectrophotometry.  cDNA was created from 1 µg of total RNA using the ImProm-II Reverse 
Transcription System (Promega), following the protocol for random hexamer priming. PCR was 
then performed using a dNTP mix (Roche) and Sybr Green Master Mix (Life Technologies) on 
an Applied Biosystems Step One Plus. Conditions for linear amplification were established 
through template and cycle curves. The cycling conditions were as follows: a denaturation step 
at 95°C for 10 min followed by 40 cycles: 95°C for 15 seconds, 60°C for 1 minute and 72°C for 
30 sec, with a final extension of 72°C for 7 min. The cDNA quantity was normalized to GAPDH 
or 18s rRNA levels. Primer sets are listed in Supplementary Table 4. The following miScript 
Primer Assays were used to quantitate miRNA levels following the Qiagen protocol: Hs_miR-
205_1, Hs_miR-200b_3 and Hs_miR-200c_1, all of which were normalized to RNU6B using 
Hs_RNU6-2_11.  
 
Luciferase reporter assays 
Cells were plated in 24-well plates in triplicate for each point, and transfected at 50% 
confluency with 400 ng promoter plasmid and 200 ng pRLSV40 following the protocol for 
Lipofectamine LTX with Plus reagent in 50% optimem/media (Thermo Fisher). After one day, 
cells were washed in PBS, then gently swirled with 1x PLB (Promega) for 30 minutes at RT. 
Firefly and Renilla luciferease activites were measured following the protocol for Dual-
Luciferase Reporter Assays (Promega) using a Turner 20/20 Luminometer (TD-20/20). 
Background readings for Firefly and Renilla luciferase in the untransfected control cells were 
subtracted from experimental readings; then ratios were quantitated and averaged for at least 




Invasion and soft agar assays 
For the invasion assay, cells were grown to 80-90% confluency, Accutase (MP 
Biomedicals) was used to detach cells from the plates, and spheroids were formed for 24h at 
37oC and 5% CO2 using a previously described centrifugation method (10) that results in 
multicellular spheroids surrounded by a shell of basement membrane. Spheroids were 
immersed in Cell Recovery Solution (Corning) to remove the basement membrane shell. Single 
spheroids were collected and each was added to collagen solution prepared from pepsin-
treated (PT) bovine collagen I (Advanced BioMatrix). This solution (1.0 mg/ml collagen) was 
prepared by diluting the stock solution with DMEM (Sigma-Aldrich), 2.5% HEPES buffer 
(Invitrogen), 2.5% sodium bicarbonate (Sigma-Aldrich) and double distilled (dd) H2O. Just 
before addition of the spheroid, the collagen solution was neutralized with NaOH to adjust the 
pH to 7.4. The samples were then transferred to an incubator at 37°C and 5% CO2. After 1 hour 
that allowed for complete collagen gelation, the gels were overlaid with 50 µl growth medium. 
For immunocytochemical staining, cells were fixed in neutrally buffered 4% formaline solution 
(Fisher Scientific) for 20 min at 24°C and washed extensively with PBS. For staining of the actin 
cytoskeleton, cells were permeabilized with 0.5% Triton-X, washed with PBS, and then 
fluorescently-labelled phalloidin (Invitrogen) was added to the samples for 16 h at 4°C. Then this 
solution was removed and spheroids were rinsed several times with PBS. For assessment of 
cell invasion, live cell imaging was performed using a custom-built microscope incubation 
chamber and objective heater to keep cells at 37°C and 5% CO2. A 10x air objective (NA = 0.4) 
was used during this imaging. At least 20 spheroids were imaged for each condition from two 
independent experiments. Only cells completely distinct from the spheroid core at t = 24h were 
counted. For more detailed characterization of cell morphology and collagen structure, a 60x oil 
objective (NA = 1.42) was used. For all imaging, an inverted confocal laser-scanning 
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microscope (Olympus Fluoview 300) was used in transmitted light or confocal 
fluorescence/reflectance modes. For fluorescence imaging of cells, a 543 nm HeNe laser was 
used for excitation and detection was performed through a longpass 570 nm filter. Black-and-
white inverted images are shown for maximum clarity. Collagen was imaged via confocal 
reflectance microscopy (CRM) with the 488 nm laser at t = 2 hours after spheroid embedding. 
 For soft agar plates, 4% agarose (Invitrogen) was diluted to 1.2% and mixed with 2x 
DME/F-12 to make a solution of 0.6% agarose DME/F-12 media. To each 35 mm plate, 1 mL of 
this solution was added and allowed to harden for at least 30 minutes at 4°C. Cells (500) were 
plated in a final concentration of 0.3% agarose in DME/F-12 media (1 mL). Complete (1 mL) 
media was added, and this media was changed every 3 days. Differential interference contrast 
(DIC) micrographs were taken 11 days after seeding on a Nikon Diaphot 300 microscope. 
Morphology pictures of passaging cells were taken in DIC or phase contrast mode. 
 
Bioinformatics/RNA-Seq  
The Cancer Genome Atlas (TCGA) datasets were downloaded directly from the TCGA 
data portal (http://cancergenome.nih.gov/). We used the Breast Invasive Carcinoma (BRCA) 
(12) TCGA Provisional dataset for analysis (February 2014). Data analysis was performed using 
Matlab (13). The RNA-sequence V2 (RNA-SeqV2) dataset was downloaded and analyzed to 
determine the expression levels of genes of interest. In the TCGA portal, the RNA-SeqV2 
dataset includes the normalized gene expression of all genes and isoforms as estimated by 
upper quartile normalization procedure using the RSEM software package (14). The median 
gene expression was calculated for each of the genes of interest following sample stratification 
based on metadata (normal tissue or tumor sample) and plotted using the box plot function. The 
statistical significance of the findings was determined by Welch’s t-test (15), which is a 
modification in which the two samples may have unequal variances (heteroscedastic). The 
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results were corrected for multiple testing by using the false discovery rate procedure (FDR) of 
Benjamini and Hochberg to obtain the adjusted p-values (16, 17). The box plots (18, 19) in the 
figures were plotted in Matlab and are standard box plots with the notch to show the confidence 
intervals of the median of gene expression. In the plots, asterisks (***) are used to denote 
statistical significance (p-value <0.0001). The accuracy of the analytical procedure was verified 
by corroborating several key genes to the results obtained from the cBioPortal website (20). 
Then, the samples were further stratified on the basis of the PAM50 classifier of 50 genes (21, 
22) based on the datasets downloaded from the UCSC Cancer Genome Browser (23, 24). The 
calculation of the median of gene expression and statistical significance of the findings was 
determined as described for the previous analysis. Some of the computationally intensive 
analyses were carried out using the high performance computing systems of the XSEDE 
network (25). 
For RNA-seq, mRNA was isolated from total RNA using oligo-dT beads (Thermo Fisher). 
Construction of the RNA-seq library was carried out based on the Illumina HiSeq2000 protocols 
in order to generate 101 pair-end RNA-seq reads. RNA-Seq was carried out by C&K Genomics 
(Vector and H-Ras cells) and Macrogen (LMP and sh-∆Np63 cells). The raw data quality was 
checked using FastQC, and adapter sequences were trimmed using Trimmomatic before further 
analysis. All quality-filtered reads were aligned to the human reference genome (GRCh37) from 
the Ensembl database using Tophat. Aligned reads were sorted using Samtools, and the 
number of reads for each gene were counted using HTseq. Differentially expressed genes 
(DEG) were filtered using the criteria of fold change > 2.0 and p value (adjusted using the 
Benjamini-Hochberg procedure) < 0.05. Only genes above a threshold for expression in the 
positive cell lines were included. These genes were categorized for gene ontology with the 
DAVID v6.7 program restricting to categories of biological processes (https://david.ncifcrf.gov) 
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Cell lines were grown to 80-90% confluence in 10 cm plates, washed twice with PBS 
and crosslinked with 1% formaldehyde in PBS for 15 minutes at room temperature (RT). Glycine 
was added to 0.125 M for 5 minutes to quench the crosslinker; then cells were washed twice 
with PBS. Cells were scraped into PBS with protease inhibitors (same as above) and 
centrifuged at 8000 x g for 5 minutes at 4°C. Cells were then resuspended in lysis buffer (50 
mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% NP-40 with the same protease inhibitors as above). 
Batches of cell lysates (2 mL) were sonicated for 4 minutes each, consisting of 20 second 
pulses at 24 Watts with a Misonix Sonicator 3000. Debris was removed by centrifugation for 10 
minutes at 4°C at 3000 RPM. Supernatant was isolated, and protein levels were quantitated 
using Bradford reagent and normalized to 1.5 mg/mL aliquots. An aliquot (500 μL) was saved as 
input for each cell line and was frozen with liquid nitrogen and stored at -80oC. Aliquots for ChIP 
were precleared with 1 μg/mL BSA and salmon sperm DNA (Invitrogen) for two hours. 
Previously, Protein A-protein G beads (Thermo Fisher, GE Healthcare) were washed three 
times and resuspended in the same lysis buffer as above, and rotated overnight at 4°C with 
control IgG or specific antibodies, as described above for western blots and with anti-RNA 
polymerase II p-Ser5 CTD (Abcam, ab5408). For the ChIP, 100 μL antibody-bound beads (1 μg 
antibody) were added to precleared aliquots of sonicated lysates and rotated overnight at 4°C. 
The following day, beads were washed five times with RIPA buffer (150 mM sodium chloride, 
1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, and 50 mM Tris at pH 8.0)  and then once 
with TE (10 mM Tris-Cl, at pH 7.5, 1 mM EDTA), with 5 minutes rotation in between each wash. 
Beads were resuspended in 100 μL TE and 200 μL 1.5x Talianidis Elution Buffer (105 mM Tris-
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Cl at pH 8.0, 1.5 mM EDTA pH 8.0, 2.25% SDS) was added, along with 1 μg/mL RNase A 
(Qiagen). Beads were left to elute at RT for one hour, then for 10 minutes at 65°C. At this point, 
NaCl was added to 0.2 M to both inputs and samples, and they were incubated at 65°C for two 
hours to reverse crosslinking. Proteinase K (20 μg/mL) was added for the last hour. Finally, 
samples and inputs were subjected to ethanol precipitation and resuspended in 300 μL ddH2O. 
Eluates (8 μL) were analyzed by qPCR as above (see primer sets in Table S4). Normalization 
was set to 2.5 ng of input DNA for each sample. 
 
Tissue microarrays 
Three triple-negative breast cancer tissue microarrays were constructed under Columbia 
University Medical Center (CUMC) IRB protocol AAAB2667 (Research with Human Surgical 
Specimens). Cases were selected for inclusion from the clinical records at CUMC matching the 
following criteria: invasive breast cases negative for estrogen and progesterone receptor 
expression (<10% nuclear staining) by immunohistochemistry (IHC) and Her2-negative for 
overexpression by IHC (HercepTest score 0, 1 or 2 with the latter also FISH- or SISH-negative 
for Her2 amplification). Three cores of invasive breast carcinoma (1 mm in diameter), and, in 
many cases, three cores of adjacent normal (non-neoplastic) breast tissue were represented 
per case in the array. Regarding staining, a 10 mM citrate buffer (pH = 6.0) was used for heat-
induced antigen retrieval adapted from (29). The ΔNp63 antibody from Santa Cruz 
Biotechnology (sc-71825) was utilized at 1:100 for 90 minutes at RT. The secondary antibody 
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 Functional in a tetrameric state, the protein product of the p53 tumor suppressor gene 
confers its tumor-suppressive activity by transactivating genes which promote cell-cycle arrest, 
senescence, or programmed cell death.  How p53 distinguishes between these divergent 
outcomes is still a matter of considerable interest. Here we discuss the impact of two mutations 
in the tetramerization domain that confer unique properties onto p53.  By changing lysines 351 
and 357 to arginine, thereby blocking all post-translational modifications of these residues, DNA 
binding and transcriptional regulation by p53 remain virtually unchanged. On the other hand, by 
changing these lysines to glutamine (2KQ-p53), thereby neutralizing their positive charge and 
potentially mimicking acetylation, p53 is impaired in the induction of cell cycle arrest.  
Surprisingly, when 2KQ-p53 is expressed at high levels in H1299 cells, it can bind to and 
transactivate numerous p53 target genes including p21, but not others such as miR-34a and 
cyclin G1 - and yet it still cannot arrest cells in the G1 phase of the cell cycle. Our findings show 
that strong induction of p21 is not sufficient to block H1299 cells in G1, and imply that 
modification of one or both of the lysines within the tetramerization domain may serve as a 




 p53 is a DNA-binding transcription factor that carries out its tumor suppressive function 
by playing roles in cell cycle arrest, apoptosis, genomic stability and DNA repair, as well as 
other pathways (see refs. 1-5). The p53 protein consists of 393 amino acid residues with a 
number of functional domains and isoforms of various lengths.6  The full-length wild-type (WT) 
protein contains a bipartite transactivation domain within the N-terminal region (residues 20-40 
and 40-60), a proline-rich domain with a pro-apoptotic role (residues 60-90), a sequence-
specific DNA binding domain (DBD) where most of the tumor-derived mutations reside (residues 
100-300), an oligomerization domain which confers the tetrameric structure necessary for p53 
function (residues 320-357), and a highly basic C-terminal domain (CTD) (residues 363-393) 
which possesses the ability to interact with DNA in a sequence non-specific manner.7, 8  
Well-studied as a sequence-specific DNA-binding transcription factor, p53 is most active 
in that regard in its tetrameric state. Maintenance of its proper conformation is controlled by the 
tetramerization domain.9, 10 Although not nearly as frequently mutated in cancer as the DBD, the 
tetramerization domain of p53 has sustained certain tumor-derived mutations including L344 
and R337. These are found mutated predominantly in Li-Fraumeni patients, affecting 
oligomerization and transactivation abilities.11 In particular, an inherited mutation in p53 
(R337H) was found to be associated strongly with familial pediatric adrenocortical carcinoma.12 
Most relevantly, it was shown that an ovarian carcinoma mutation, K351N, attenuates p53 
function via a similar mechanism.13 This same mutation was shown to compromise p53 
ubiquitination and subsequent mitochondrial localization, affecting the apoptotic response.14 
 The tetramerization domain contains a nuclear export signal (NES) (residues 340 to 
351), which is masked upon tetramerization of p53, allowing it to accumulate in the nucleus.15 
Two residues in the NES (L348 and L350) appear to be critical both for nuclear export and 
efficient tetramerization, suggesting an interplay between these two processes and optimal p53 
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function. Biochemical studies suggested phosphorylation of S392 could increase tetramer 
formation, while phosphorylation of S315 (within the linker region) might counteract this effect.16 
Additionally, two reports conflictingly implicate CTD acetylation in either the promotion of 
tetramerization and maintenance of high acetyl-p53 levels by PTEN, or the disruption of 
oligomerization, followed by nuclear export.17-18 
Following a wide range of cellular stresses, p53 becomes extensively modified at both 
the N-termini and C-termini by a number of phosphorylating, acetylating, ubiquitinating, 
sumoylating, methylating and neddylating enzymes.19-21 Acetylation and ubiquitination occur 
predominantly within the CTD of p53 and there is an important balance between ubiquitination 
and acetylation since acetylated lysines cannot simultaneously be ubiquitinated by Mdm2.22 
Few modifications have been reported in the tetramerization domain of p53. One report 
implicated PRMT5-mediated arginine methylation of three residues, R333, R335 and R337 as 
being required for full induction of the GADD45, p21 and APAF1 genes.23 Another paper 
identified K357 by mass spectrometry as undergoing acetylation in COS-1 cells,24 although no 
biological consequence of the modification was reported.  Lysine residues 351 and 357 have 
been reported to be ubiquitinated by MSL2, a novel E3 ligase for p53 that promotes the 
cytoplasmic localization of the protein, but not its degradation.25 A large screen to identify 
ubiquitin-modified proteins confirmed the modification of lysine 357, but not lysine 351.26  
However, mass spectrometry analysis of COS-1 p53 or etoposide-induced p53 from human 
foreskin fibroblasts indicates acetylation and methylation take place at lysines 351 and 357. 27 
From mining the TCGA database, we found various human cancers with alterations in 
K351, including one kidney carcinoma with a K351N mutation and a lung carcinoma with a 
mutation in 351 leading to a nonsense codon, as well as a malignant melanoma and an adrenal 
cortical carcinoma with K351E mutations (see Table I). 
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Additionally, the modification of other residues within p53 requires an intact quaternary 
structure. For example, in a p53 protein where the tetramerization domain has been deleted, 
Chk1 can no longer phosphorylate p53.28 One study reported that oligomerization of p53 is 
essential for the acetylation of the protein’s CTD lysines.29 
Since the functional consequences of modifications at K351 and K357 are still being 
elucidated, and they are clearly of physiological interest, we generated cell lines expressing 
mutations to either glutamine or arginine for both residues. Our results indicate that these 
lysines are involved in differential regulation of p53 target genes and ensuing cellular outcomes, 





Mutation of tetramerization domain lysines does not affect p53 localization or 
oligomerization. 
 Since conflicting data have come from studies in which p53 was overexpressed 
ectopically by transient transfection, which in some cases masked true in vivo function,30 we 
analyzed the effects of lysine mutations at residues 351 and 357 in the more physiological 
setting of inducible cell lines.  Expression of p53 protein was regulated (by reducing or omitting 
tetracycline) to levels comparable with endogenous expression.31, 32 When we undertook clonal 
selection of cells expressing lysine residues 351/357 mutations to arginine (2KR-p53) or 
glutamine (2KQ-p53), we obtained far fewer clones that expressed 2KR-p53 than their 2KQ-p53 
counterparts.  In fact, only two of the 2KR-p53 clones survived expansion and these expressed 
significant amounts of p53 protein (Table II). This result suggests that, even though protein 
expression should be completely silent in the presence of tetracycline,33, 34 there may be slight 
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leakiness from the inducible promoter that expressed a hyperactive p53 that can block cell 
survival and clonal isolation. This phenomenon was previously observed when we attempted to 
clonally isolate an apoptotically hyperactive mutant of p53 (Table II, ref. 30). We proceeded to 
characterize the p53 proteins with mutated tetramerization domain lysines (2KQ-p53 and 2KR-
p53). 
A diagram of p53 organization with the location of the two lysines in the tetramerization 
domain (denoted by asterisks) is shown in Figure 1A. As deduced from the solution structure of 
the tetramerization domain,34, 35 both of these residues are solvent-accessible, and thus 
potentially amenable to modification (Figure S1A). Since mutations at other residues in the 
tetramerization region have previously been shown to disrupt p53 quaternary structure and 
expose a nuclear export signal,11, 15 we first wanted to investigate the subcellular localization of 
our mutants.  Immunofluorescence experiments with two clones each of 2KR-p53 and 2KQ-p53 
expressing cells showed strong nuclear staining that was virtually identical to WT-p53 (Figure 
1B). The mutants further behaved like WT-p53 by showing nucleolar exclusion36 as evidenced 
both by DIC imaging and a lack of colocalization with nucleolin (data not shown).   
In general, misfolded proteins may be quickly degraded by multiple degradation 
pathways via quality control mechanisms (as reviewed in ref. 37). We performed half-life 
experiments to confirm that the tetramerization domain mutations were not causing hyperactive 
degradation of p53. Figure S1B shows that when transfected into H1299 cells, WT-p53, 2KQ-
p53, and 2KR-p53 proteins each have a similar half-life (~9 hours) as determined by 
cycloheximide chase. Although endogenous p53 has a half-life of about 20-30 minutes, 
ectopically p53 is generally known to be much more stable for as yet unknown reasons 38. 
Further, information about the tetramerization region of the wild-type and mutant protein 
was derived from NMR analysis. 1H-15N TROSY-HSQC experiments were performed with WT-
p53, 2KR-p53 or 2KQ-p53 tetramerization domain proteins (310-362) to assess whether double 
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mutations of the K351 and K357 residues perturbed the local structure of the protein. For both 
the 2KQ-p53 and 2KR-p53 mutants (310-362), the overall appearance of the HSQC spectra 
was similar to WT-p53 (Figure 1D and E), indicating the mutations did not cause global 
unfolding and/or gross aggregation of the protein. The assignments of the 1H-15N TROSY-
HSQC resonances of the mutants were straightforward because of close similarity of the 
chemical shifts to those of WT-p53 protein, except for a couple of resonances. Specifically, the 
2KR-p53 spectrum, in contrast to the 2KQ-p53 spectrum, did not show a peak for the Leu350 
resonance at the chemical shifts similar to the WT-p53 resonance (8.24, 123.8ppm). However, 
one new unassigned peak (8.51, 123.1ppm) was detected in the vicinity of the spectral region, 
allowing us to tentatively assign this peak as the L350 resonance. In summary, 1H-15N amide 
backbone resonances for all but five N-terminal residues (310-315) were assigned. 
In Figure S1C, chemical shift differences between WT-p53 and the 2KR-p53 or 2KQ-p53 
mutants are plotted versus residue number. The largest differences observed were spatially 
close to the mutated residues. The residues with great (>0.10 ppm) chemical shift deviations 
from WT-p53 were F341, A347, L350 and A355. However, the differences between 2KR and 
2KQ at these residues are minor (≤0.05 ppm), with the exception of L350. Due to their similar 
spectra, and overall deviation from WT-p53 being minimal, we conclude that the quaternary 
structure of p53 is not significantly affected by these mutations. 
To determine whether these mutations affected tetramerization of p53, we performed 
gluteraldehyde crosslinking gel electrophoresis comparing WT-p53, 2KR-p53 and 2KQ-p53 
expressed in transfected H1299 cells and showed that variants formed equivalent populations of 
tetramers and dimers under denaturing conditions (Figure 1C). Additionally, analytical size 
exclusion column chromatography analysis on Thioredoxin-fusion p53 (tetramerization domain 
only) showed that WT, 2KR and 2KQ have similar quaternary states at 150 – 500 mM NaCl 
(data not shown).  
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Together these results demonstrate that mutation of the lysines within p53’s 
tetramerization domain to either arginine or glutamine may cause minor localized alterations, 
however these do not seem to affect the tetramerization status, localization or degradation of 
the protein itself.  
 
2KQ-p53 is deficient in binding to and transactivation of p53 target genes. 
 We examined the abilities of tetramerization domain lysine p53 mutants to function as 
transcription factors.  By regulating the concentration of tetracycline in the medium, p53 protein 
expression was normalized for each cell line so that equivalent protein levels could be 
compared (Figure 2A).  Immediately a difference in activities between 2KR-p53 and 2KQ-p53 
could be seen: 2KR-p53 was able to induce similar levels of p21 protein as WT-p53 while p21 
resulting from 2KQ-p53 induction was barely increased above background basal levels. When 
looking at a direct readout of transcriptional activity by analyzing mRNA production via RT-PCR 
experiments, we saw similar results. Two clones of 2KR-p53 (2KR-13 and 2KR-17) induced 
equivalent amounts of p21, PIG3 and Mdm2 mRNA as WT-p53, yet two clones of 2KQ-p53 
(2KQ-5 and 2KQ-12) were significantly impaired in this respect (Figure 2B and C).  
We next evaluated DNA binding by these p53 variants in vivo in a ChIP assay.  Again, 
immunoblot analysis of the lysates indicated similar levels of p53 expressed for each line along 
with weaker induction of p21 protein by 2KQ-p53 (Figure 2D).  In fact, binding by the 2KR and 
2KQ mutants to three different p53 target gene promoters (p21-5’, PIG3 and Mdm2) in ChIP 
assays correlated well with the downstream induction of mRNA and protein; 2KR-p53 
reproducibly bound as well as WT-p53, and 2KQ-p53 had decreased affinity for these sites 
(Figure 2E and F).  
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Overall, our findings indicate that blocking lysine modification within the tetramerization 
domain does not impact DNA binding, whereas neutralizing charge at these residues decreases 
p53’s overall affinity for DNA in vivo.   
 
2KQ-p53 cannot arrest cells in G1 despite high levels of p21.  
We investigated the ability of the p53 variants to affect two well studied downstream 
events in the p53 pathway, namely cell cycle arrest and apoptosis. As before, cells were 
induced to express equivalent amounts of p53 protein prior to determining their cell-cycle profile 
analyzed by FACS.  A typical effect of WT-p53 expression in these cells is evidenced by a drop 
in S-phase and an increase in either G1 or the G2 population (Figure 3A, top row).  A mild 
increase in sub-G1 content was also seen, as reflected by the amount of fragmented DNA from 
apoptotic cells.39 
Results with the tetramerization domain mutants were quite striking.  Similar to cells 
expressing WT-p53, expression of 2KR-p53 caused a drop in S-phase and a strong arrest 
(Figure 3A).  2KQ-p53, on the other hand, showed the opposite phenotype.  Upon expression of 
this mutant, there was no discernable cell cycle arrest. Notably, the 2KQ-p53 mutant was able 
to induce apoptosis, both alone (weakly) and, more strongly in response to 5-FU (Figure 3B) to 
a comparable degree as did WT-p53, indicating a selective deficiency in the ability of 2KQ-p53 
to function within the cell cycle arrest pathway. We wondered if this phenotype was due to 
abnormal localization of the key cell cycle regulator, p21. However, immunofluorescence of this 
protein in the three cell lines in tetracycline-free conditions indicated that it is still localized in the 
nucleus (Figure 3C). 
It is interesting that 2KQ-p53, when regulated to express a similar amount of protein as 
WT-p53 was able to cause apoptosis despite its deficiency in inducing apoptotic target genes 
such as PIG3 (Figure 2) as well as Bax,, Puma, Noxa, and PIDD (Figure S2). The ability of 
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2KQ-p53 to transactivate these genes was not significantly increased after treatment with either 
daunorubicin or 5-FU (data not shown). Under these conditions, then, either one or more 
unidentified key pro-apoptotic targets of p53 can be well induced by 2KQ-p53 or this mutant is 
competent in regulating a p53-mediated transcription-independent apoptotic pathway.  
The inability of 2KQ-p53 to arrest cells was an intriguing finding that called for further 
investigation.  Since p21 is thought to be the major effector of p53-mediated cell-cycle arrest, 40-
42 it is possible that 2KQ-p53 was unable to cause a G1 arrest simply because it did not induce 
sufficient p21 mRNA and protein. To address this question we adjusted the amounts of 
tetracycline in the culture media of WT-p53- and 2KQ-p53-expressing cells to obtain points 
where the mutant induced markedly more p21 protein than did the WT-p53 cells (Figure 3D).  
While WT-p53 was still capable of causing a robust arrest, surprisingly, 2KQ-p53 was 
completely inert in this regard even when expressed at higher levels than the wild-type protein 
(Figure 3E).  This effect was not unique to this clone of cells, as we observed this phenotype 
with three additional 2KQ-p53-expressing clones (Figure 3F). In line with the FACS analysis, 
turning on WT-p53 caused a decrease in the levels of phospho-Rb, consistent with a G1 arrest, 
while overexpressing 2KQ-p53 did not lead to such a decrease (Figure 3D). Furthermore, when 
WT-p53 was expressed in the background of p21 downregulation by siRNA (Figure S3), cells 
were nonetheless able to arrest in G1 to a similar extent to those cells with control siRNA. Thus, 
in this system, expression of p21 alone is not sufficient (and may not be necessary) to induce a 
G1 arrest.  
 
Even when overexpressed in vivo, 2KQ-p53 is deficient in binding and inducing miR-34a 
and CCNG1.  
Since levels of p21 were clearly not the sole determinant of G1 arrest in this system, we 
next wanted to investigate how 2KQ-p53 regulates other p53 target genes when expressed at 
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high levels. As before, cells were plated and conditions were set to express more 2KQ-p53 
protein than WT-p53 protein, and the induction of a panel of p53 targets was assessed by qRT-
PCR (Figure 4A). We found that when overexpressed, 2KQ-p53 was as competent as WT p53 
in inducing several targets, with the notable exceptions of CCNG1 and miR-34a. Intriguingly, 
both of these targets have been implicated in the G1 arrest pathway.43-45 We saw similar if not 
more dramatic results with another clone of 2KQ-p53 (Figure S4A). 
 p53 DNA binding can directly correlate with mRNA induction32 and so we next asked 
whether the marked deficiency of 2KQ-p53 in inducing CCNG1 and miR-34a mRNA was due to 
an impaired ability to bind the p53 canonical response elements  at these loci.  This question 
was especially important because many alterations to the C-terminus of p53 have been shown 
to impact binding by the core domain in vitro (reviewed in ref. 46).  As before, cells were plated 
and induced with tetracycline for 24 hours to express more 2KQ-p53 protein than WT-p53 
protein, and a ChIP assay was performed to assay for p53 binding to its distal p21, miR34-a, 
and CCNG1 response elements. Nicely mimicking our RNA data, when 2KQ-p53 was 
overexpressed, it was capable of binding the p21 distal response element to a comparable 
degree as WT-p53. However, even when it was expressed at these high levels, 2KQ-p53 was 
still markedly deficient in binding the miR-34a and CCNG1 response elements in a ChIP assay 
(Figure 4B). Similar results were observed in a transient transfection/ChIP assay (Figure 
S4B,C).  
We examined whether the 2KQ-p53 binding deficiency observed in vivo was due to 
impaired direct binding to DNA by performing an electrophoretic mobility shift assay (EMSA) 
with purified WT-p53 and 2KQ-p53 proteins. WT-p53 was capable of strong binding to a probe 
derived from the p21 5’ response element, as well as a probe derived from the miR-34a 
response element, as evidenced by a shift of IRDye-labelled DNA (Figure 4C). Excess short 
oligonucleotide was used as a carrier to compete away any nonspecific interactions in these 
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reactions since long carrier can engage the p53 C-terminus and has led to confusing 
interpretations of EMSA data in the past. 47, 48 Surprisingly, given our ChIP data, at high 
concentrations, 2KQ-p53 protein bound probes derived from p21 and miR-34a response 
elements somewhat better than WT-p53 (Figure 4C). That WT-p53 and 2KQ-p53 binding to p21 
and miR-34a probes were nearly identical, suggests that whatever is responsible for the 
differential binding profiles of WT-p53 and 2KQ-p53 to these sites in a ChIP assay is not 
recapitulated in vitro. Even though EMSA results do not always reflect cellular DNA binding, 32, 
49 it was nonetheless surprising that at high concentrations 2KQ-p53 appeared to bind DNA 
better than WT-p53, however it transactivated p53 targets to a lesser degree in vivo. It is 
possible that the differential binding of WT-p53 and 2KQ-p53 were related to the slight structural 
perturbations seen in our NMR spectra, as were the somewhat different display of p53:DNA 
complexes formed by WT and 2KQ p53 proteins on the miR-34a probe. Nonetheless, since the 
overall binding deficiency of 2KQ-p53 at high concentrations was not observed on naked DNA 
spanning the miR-34a binding site in vitro, these results suggest that the binding impairment of 
2KQ-p53 is not inherent to the sequence of the p53 RE at this locus.   
 
 Lysine 357 can be acetylated by p300/CBP 
Given our results with acetyl-mimicking mutants and previously reported findings 24, 26-27 
we sought to confirm that lysine residues 351 or 357 could be acetylated in vivo.  We first 
transfected constructs expressing WT-p53 alone or with either HA-tagged p300 or CBP, or Flag-
tagged pCAF into H1299 cells. The cells were harvested and subjected to immunoblot analysis 
with a rabbit polyclonal antibody that recognizes doubly acetylated p53 at K351 and K357 (anti-
Ac-351/7). Both p300 and CBP were able to acetylate these residues (Figure 5A). While pCAF 
was not apparently able to do so when expressed in these cells, it is acknowledged that a firm 
conclusion cannot be drawn since the version of pCAF we had available has a different epitope 
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tag and so we cannot compare its levels to those of p300 and CBP. Tip60, a HAT implicated in 
the acetylation of p53 at Lys120,50 was also apparently unable to acetylate these residues (data 
not shown). Although our p300 construct expressed poorly, on a per mole basis, it is possible 
that it could acetylate K351 and K357 to a similar extent as did CBP. 
To determine if the antibody was specific to these residues, we performed a similar 
transfection experiment in which either WT-p53 or 2KR-p53 was transfected with or without 
CBP. The signal from the Ac351/7 antibody was markedly reduced when 2KR-p53 
cotransfected with CBP was compared with WT-p53 cotransfected with CBP (Figure 5B). 
Mutations to arginine within these residues of the tetramerization domain did not appear to 
compromise p53 reactivity with a pan-acetyl antibody, while reactivity with an Ac-K382-specific 
antibody was decreased as compared to WT-p53 (Figure 5C).  
While the anti-Ac351/357 antibody could be used to detect ectopically overexpressed 
p53, unfortunately, it was not strong enough to detect endogenously expressed p53. A rabbit 
polyclonal antibody was generated that specifically recognized p53 acetylated at K357 (Ac357; 
Figure S5). HCT116 cells, which contain wild-type p53, were treated with either MG132, a 
proteasome inhibitor that stabilizes p53 in the absence of DNA damage, or with 5-FU, to induce 
damage-stabilized p53. The cells were harvested and subjected to immunoblot analysis with 
anti-Ac357 (Figure 5C). Acetylation of K357 was induced in response to damage by 5-FU, but 
was not visible when p53 was stabilized in the absence of damage by MG132, indicating that 5-
FU initiates a signaling pathway that results in acetylation of p53 at K357.  
Our results extend previous findings from mass spectrometric analysis that p53 can be 
acetylated at K357.26-27 Taken together, these data indicate that CBP (and likely p300), at least 
when they are overexpressed, are capable of acetylating p53 at K351 and/or K357 in 
mammalian cells, and that acetylation of K357 occurs endogenously in response to genotoxic 
stress, unlocking the exciting possibility of a physiological importance for these modifications.   
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Given that our data thus far demonstrated that 2KQ-p53 was largely defective in binding 
and transactivating p53 target genes (Figure 2), it was perhaps counterintuitive that acetylation 
of p53 at K357 was increased after DNA damage, when p53 function is amplified. We therefore 
constructed single mutants of p53-K351 (R or Q) and p53-K357 (R or Q). To determine whether 
the individual p53 mutants of these lysines gave rise to the same phenotype as the double 
mutant, their transactivation ability was assessed in a transient transfection assay (Figure 5D). 
Interestingly, at comparable levels of p53 protein (Fig 5D), both K351Q-p53 and K357R-p53 
showed reduced transcription of p21 mRNA when compared with WT-p53, while K351R-p53 
and K357Q-p53 could transactivate p21 as well as, or better than, WT-p53 (Figure 5E). To date, 
we have not yet been able to confirm whether K351 is also acetylated. These data indicate that 
if K351 is in fact acetylated such modification may be the reason for the defects in 2KQ binding 
and transactivation of select p53 targets. In that case, modification of K351 and K357 would 
play opposing roles in regulating p53 function, and the negative role of K351 modification would 




 While the extreme CTD of p53 is highly modified, few modifications have been described 
within p53’s tetramerization domain.19, 51 We sought to investigate the potential role of 
modification within this region by mutating the only two lysines in this domain of p53 (351 and 
357, Figure 1A) to either block all post-translational modification (lysine to arginine, 2KR-p53) or 
to neutralize basic charge (lysine to glutamine, 2KQ-p53). 
 Although mutation of other residues within this region can drastically impact p53 
tetramer formation and function, 52, 53 we found that neither 2KR-p53 nor 2KQ-p53 possessed 
unusual localization or tetramerization ability.  Our data strongly suggest that alteration of the 
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lysines in the tetramerization domain does not have a deleterious effect on the correct folding of 
p53.  To that end, the cellular phenotypes we observe seem to be a direct effect of the lysine 
mutations and not caused by perturbations in overall structure. 
 When examining the effects of lysines 351 and 357 mutation on p53’s role as a DNA-
binding transcription factor, some interesting results were observed.  Mutation to arginine did 
not have any observable impact on transactivation or in vivo DNA binding (Figure 2).  On the 
other hand, mutation to glutamine had a significant impact on both of these functions, reducing 
p53’s ability to bind response elements in vivo and induce mRNA production by about half.  
Although acetylation on lysines in regions flanking the tetramerization domain have been shown 
to enhance p53 transcriptional activity, our results point to a requirement of the positively 
charged residues in this region for proper recognition of DNA response elements by the core 
domain in the context of chromatin and efficient transcription. It is possible that even though 
neutralization of these lysines does not disrupt tetramerization and localization they could impart 
some subtle effects on the quaternary structure of p53 which impairs its access to DNA, as 
suggested by our NMR data. However, since at higher concentrations, the 2KQ-p53 mutant was 
not deficient in binding naked p21 or miR-34a response elements in an EMSA assay (Figure 
5C), it is also possible that the altered promoter specificity in vivo was due to the ability of 2KQ-
p53 to interact in an altered fashion with p53 binding partners. Many proteins have been shown 
to bind to p53 and to affect its propensity to bind select response elements,5, 20 and further 
experiments are underway to explore the differential association of WT-p53 and 2KQ-p53 with 
such proteins. Alternately, the chromatin landscape at p53 target promoters may account for 
different interactions of WT and 2KQ-p53.  
 How p53 discriminates between inducing cell-cycle arrest or apoptosis, the so-called 
“molecular switch,” has been attributed to a number of players, yet none of them are sufficient to 
drive this process in all cases.  In fact, mouse studies have conflictingly suggested that p53’s 
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arrest or apoptotic functions are individually dispensable for tumor suppression.54, 55 
Mechanisms underlying this decision making process could be as simple as levels of p53 
protein, presumably dictated by the extent of cellular stress, 32 or as complex as a coordination 
of modifications, interactions and conformational changes to the protein in a cell-type specific 
context.  A growing list of mutations within various regions of p53 has been shown to have an 
impact on the downstream function of p53.  Some of these mutations exhibit increased 
apoptotic activity (S121F, S46F), 56, 57 while others have been shown to drastically decrease the 
apoptotic potential of p53 (R213Q, A175P, A143P, ∆300-308).58-61 In these cases, the 
combined effect of the mutation on target gene activation, cell cycle arrest and apoptosis has 
been variable, supporting the idea that p53 serves as a “master gene” in which a single change 
can lead to simultaneous downstream changes.62 Even naturally-occurring polymorphisms 
within p53 can influence serine-46 phosphorylation (P47S)63 or cause a propensity for apoptosis 
by increasing p53’s export from the nucleus (P72R) and binding to the mitochondria which 
activates a transcription-independent death pathway (reviewed in ref. 64).  Other interacting 
proteins such as the ASPP family of proteins which bind to the core and proline-rich regions of 
p53, 65, 66 or kinases such as PKCdelta and HIPK2 which are recruited to p53 by p53DINP1 can 
selectively upregulate genes involved in cell death.67-69 
 With 2KQ-p53, a global defect in transcriptional ability could certainly explain the lack of 
arrest.  However, since p21 is thought to be the major effector of p53-mediated G1 arrest, our 
findings that 2KQ-p53 still failed to arrest cells even after inducing wild-type (or greater) levels of 
p21 induction were surprising.  That 2KQ-p53 was still capable of killing cells after 5-FU 
treatment was also unexpected, considering that apoptotic targets like PIG3 are known to 
possess generally weaker binding sites70 and that in our hands 2KQ-p53 was less capable of 
inducing a number of apoptotic targets.  This is a rare instance of a version of p53 incapable of 
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arrest yet still functional for programmed cell death and implicates a role for this mutant in the 
transcription-independent apoptotic program of p53. The 2KQ mutant p53 that we describe here 
functions to the contrary of several previously described p53 mutants, including K120R, R175P 
and E177R, which are defective in apoptotic induction but are still able to regulate cell cycle 
arrest. 50, 71-73 It is also unknown whether our mutant would be incapable of senescence, since it 
cannot arrest, and future work will look into these capabilities.74, 75  
Data with the 2KQ-p53 mutants point to some exciting possibilities.  First, there may be 
additional p53 transcriptional targets required for inducing G1 arrest other than p21. Lending 
support to this notion, p21-null mice develop normally, but curiously only partially fail to arrest in 
response to irradiation, indicating that a parallel, p21-independent pathway for G1 arrest must 
also exist.41 Based on data described herein and elsewhere, it is possible that this parallel 
pathway involves CCNG1 and/or miR34a as well as other targets that we have not identified. 
Along these lines, in certain contexts, miR-34a can inhibit cellular proliferation even when p21 is 
absent. 43  Notably, miR-34a functions by downregulating various cell-cycle related targets, 
including CDK4, CDK6, c-Myc, cyclin D1 and cyclin E2 mRNA, leading to decreased levels of 
phosphorylated Rb.43 CCNG1 was one of the earliest p53 targets to be discovered,74 yet its 
function remains controversial. It is known that CCNG1 can either induce a G1 arrest or 
apoptosis when expressed at high levels, in a fashion partially dependent on the Rb protein.45 
However, at low levels of expression, CCNG1 appears to promote proliferation.47 Also of note, a 
p21-independent, p53-mediated repression of c-Myc was shown to be necessary for human and 
mouse cells to arrest in G1.75 C-Myc is an oncogene that drives cellular proliferation,76 and can 
function by overcoming p53-mediated activation of p21 and GADD45.77, 78 It is possible that 
while WT-p53 can effect this repression of c-Myc, 2KQ-p53 cannot, thus preventing an efficient 
arrest of cells in G1. Another possibility is the existence of a pathway activated by 2KQ-p53 
which can selectively block p21’s inhibition of cyclin/CDK complexes.  Next-generation 
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sequencing studies would undoubtedly be worthwhile to look for additional targets induced or 
repressed by these mutants and to find novel targets directly involved in these phenotypes.   
An impetus for this study was the discovery that p53 can be modified on lysines 351 and 
357, however except for in the case of ubiquitination, the implications of this are largely 
unknown.24, 26-27 Here, we show that p53 can be acetylated in vivo on K357, although the 
functional significance of this modification alone is not yet clear. While our finding that 
acetylation of K357 increases after 5-FU treatment might seem at odds with our results that 
2KQ is impaired in transactivating p53 target genes, we cannot exclude the possibility that 
modification of K351 negatively regulates p53 target gene expression and is dominant over 
K357. Indeed, given our transfection data with the tetramerization domain single mutants 
(Figure 5D, E), this appears to be the case, at least for p21. It is also possible that there are 
differential kinetics and outcomes of modification of these residues. Such possibilities await 
future experimentation and further work is required to elucidate how these and potentially other 
modifications on lysines 351 and 357 can essentially “flip the molecular switch” of p53 to drive 
either cell cycle arrest or apoptosis.   
 
 
MATERIALS & METHODS 
 
Cell line creation and cell culture 
H1299 cells expressing tetracycline (tet) regulated (“tet-off”) WT-p53 were previously 
described.30, 31 Mammalian expression constructs in the pTRE2 backbone (Invitrogen) 
expressing p53-(K351R/K357R; 2KR) and p53-(K351Q/K351Q; 2KQ) were mutated from the 
wild-type sequence using the QuikChange protocol (Qiagen) according to the manufacturer’s 
specifications. H1299-derived inducible cell lines expressing 2KR-p53 and 2KQ-p53 were then 
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created using a two-step tetracycline-regulated system and clonally selected with 400 µg/ml 
Hygromycin B (Invitrogen) as previously described.31 The cells were grown in Dulbecco’s 
Modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum, 5 µg/ml 
tetracycline (Sigma), 100 µg/ml Hygromycin B (BD Biosciences), and 200 µg/ml G418 (Gibco).  
At least 25 clones were picked and screened for each line and all lines used in this study had 
their p53 sequence confirmed. Transfection experiments were performed with Lipofectamine 
2000 (Invitrogen), according to the manufacturer’s protocols.  
 
Immunofluorescence (IF) 
Cells were plated without drugs to 90% confluency in a 35-mm dish with a glass coverslip, 
washed twice 22 hours after seeding, and induced to express p53 (with tetracycline amounts 
indicated in the figure legends).  Twenty four hours after induction, cells were washed twice with 
PBS followed by incubation with 4% paraformaldehyde (Sigma-Aldrich) for 15 minutes then 
washed three times with PBS, treated with PBS/0.5% Triton X-100 for one and a half minutes 
and blocked with 0.5% BSA (Sigma-Aldrich) in PBS for 30 minutes prior to the incubation with 
the antibodies.  Samples were incubated with monoclonal antibodies PAb 1801 and PAb DO-1 
(50 µl) for one hour at room temperature.  The coverslips were then washed three times with 
PBS followed by incubation for another hour with 50 µl of diluted (1:100) secondary Cy5 goat 
anti-mouse IgG antibody (Jackson ImmunoResearch) and washed three times with PBS.  DNA 
staining was performed using 10 nM SYTOX Green nucleic acid dye (Molecular Probes) for 10 
minutes.  The coverslips were then mounted with 10 µl cold 50% glycerol. The images were 
collected using confocal laser scanning microscopy (Olympus Model 1X70) with Fluoview 
software. In order to directly visualize cells and nuclei, Differential Interference Contrast (DIC) 
images were taken in parallel. For p21 IF, the indicated cell lines were grown in tetracycline-free 
media for 48 hours before fixation, same as above. They were incubated with PAb p21 (F-5, 
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Santa Cruz Biotechnology) for one hour and then with Alexa Fluor 488 (sc-6246) for one hour. 
Cover slips were mounted with 20 μl Vectashield Mounting Medium with DAPI (Vector 
Laboratories, H-1200, Burlingame, CA) and visualized as above. 
 
Creation of acetyl-specific antibodies 
Polyclonal antibodies were generated by Cell Signaling Technologies and produced by 
immunizing animals with synthetic acetylated peptides (KLH-coupled) corresponding to residues 
surrounding lysine 351 and lysine 357 of human p53. Antibodies were purified using protein A 
and peptide affinity chromatography.  
 
Protein Purification and NMR Spectroscopy 
N-terminally Flag-tagged WT-p53 and 2KQ-p53 mutant proteins that contain an inserted site at 
their N-termini were affinity purified as previously described from Sf-9 cells infected with the 
corresponding baculovirus for p53.81 Constructs coding for p53 residues 310-362 were 
amplified from WT-p53, 2KQ-p53, and 2KR-p53 mutants respectively. The cDNAs were 
subcloned into pET32a (EMD Chemicals, Inc.) using EcoRI and XhoI sites.  A TEV protease 
recognition sequence (ENLYFQS) was created between the BamHI and EcoRI sites in pET32, 
at the C-terminus of Thioredoxin.  After TEV protease cleavage, p53 proteins contained Ser-
Glu-Phe at their N-termini.  For isotopic labeling, proteins were expressed in E. coli Rosetta 2 
(DE3), using 0.4 mM IPTG for induction and growth at 23 ºC for 16 h in modified minimal media 
using 15NH4Cl and U-13C6-Glucose or U-[13C6,2H7]-Glucose as sole nitrogen and/or carbon 
sources. Soluble forms of His-tagged proteins were first purified using 5 mL Ni-NTA columns 
and followed by gel-filtration column chromatography using Hi-Load Superdex200 16/60 (GE 
Healthcare) with a buffer containing 25 mM sodium phosphate, pH 7.5, 50 mM NaCl, 1 mM 
DTT, and 0.02 % sodium azide. After removal of Thioredoxin, final purifications of p53 proteins 
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were performed over a Hi-Trap QP column (GE Healthcare) at pH 7.5 using a 0 – 1 M NaCl 
gradient.  Buffer exchange was carried out using Amicon concentrators (Millipore).   
All NMR experiments were conducted at 17°C using protein samples in 25 mM sodium 
phosphate buffer, pH 7.5, 150 mM NaCl, 2 mM DTT, 0.02% sodium azide and 7% D2O, using a 
Bruker Avance 700 MHz spectrometer, equipped with 5 mm, triple resonance and z-axis 
gradient cryoprobes. For backbone chemical shift assignments of WT-p53(310-362), 2D 1H-
15N TROSY-HSQC and 3D TROSY-HNCACB and TROSY-HN(CO)CACB experiments were 
performed on a U-[13C,15N,2H]-labeled protein. The 1H-15N assignments of the 2KQ-p53 and 
2KR-p53 mutants were obtained by comparing the 2D 1H-15N TROSY-HSQC spectra of U-
[15N]-labeled mutant proteins to that of U-[13C,15N,2H]-labeled wild-type protein. 
 
Immunoblotting analysis  
Cells were seeded and induced as for immunofluorescence but on a 60 mm culture dish.  24 
hours after induction, cells were harvested and split into pellets for immunoblotting or RT-PCR. 
Lysis for immunoblotting was performed as previously described.82 p53 protein was visualized 
by separating 40 µg of whole-cell lysate on a 12% polyacrylamide gel, transferring to 
nitrocellulose followed by immunoblotting with DO-1 antibody (hybridoma supernatant, 1:1 
dilution with 5% milk) for 1 hour at room temperature.  Other antibodies used were anti-p21 
(C19, Oncogene Research Products), anti-pRb (XZ.131 supernatant), anti-HA (Covance), anti-
Flag (Sigma-Aldrich), anti-pan-acetyl lysine (Cell Signaling Technology), anti-p53 Ac382 (a gift 
from Y. Taya), and anti-actin (Sigma-Aldrich).   
 
Gluteraldehyde crosslinking  
H1299 cells were transfected with pCDNA3 vectors expressing WT-p53, or mutants 2KR-p53, 
or 2KQ-p53 (500 ng). 24 hours later, samples were harvested in TEGN buffer, and 
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gluteraldehyde was added to a final concentration of .005% to .020%. Samples were incubated 
on ice for 20 minutes, and the crosslinking reaction was stopped by the addition of protein 
sample buffer. Multimeric complexes were separated by SDS-PAGE and analyzed by Western 
Blotting. 
 
RT-PCR and qRT-PCR 
RNA was extracted from cell pellets using RNeasy Mini Kit (Qiagen) and quantitated by 
ultraviolet spectrophotometry.  cDNA was created from 1 µg of total RNA using the Superscript 
III First Strand Synthesis System for RT-PCR (Invitrogen), following the protocol for oligo-dT 
priming.  RT-PCR was performed using a dNTP mix (Roche) and Taq 2000 DNA Polymerase 
(Stratagene). Conditions for linear amplification were established through template and cycle 
curves. The cycling conditions were as follows: a denaturation step at 95°C for 5 min followed 
by 20 cycles (for p21, GADPH, and PIG3) or 19 cycles (for Mdm2) at 95°C for 30 sec, 56°C for 
30 sec and 70°C for 30 sec, with a final extension of 72°C for 7 min.  PCR products were then 
separated on 2.5% agarose gels and bands were visualized with ethidium bromide and the Gel 
Logix 100 imaging system (Kodak).  qRT-PCR was performed essentially as described. 83 
Sequences for the primers are available upon request.  
 
Electrophoretic mobility shift assay (EMSA) 
WT- p53 and 2KQ-p53 purified proteins from Sf9 cells (0 to 80 ug of total protein) were 
incubated for 25 minutes at room temperature in 1X EMSA buffer (12.5 mM Tris-HCl pH 6.8, 25 
mM KCl, 10% glycerol, 0.05% Triton-X, 0.5mg/ml BSA, 1 mM DTT, 250 ng mutant p21 
oligonucleotide) with 10 ng of a p21 5' binding site-containing 44 base pair oligonucleotide (5’-
AGC TAG TAG AGC GAA TAT ATC CCA ATA TAT TGG CGT GCT GCA GC-3’)or a miR-34a 
p53 binding site-containing 44- mer (5’-CGG GCT CTG CCT GGG CTT GCC TGG GCT TGT 
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TCC GAG CCG GGC TG-3’), labeled at the 5’ end with IRDye 800. Oligonucleotides were 
manufactured by Integrated DNA Technologies. The samples were run on a 4% native 
polyacrylamide gel at 200 Volts. The gel was visualized with a Licor Odyssey apparatus 
according to the manufacturer’s protocols.  Oligonucleotide sequences used for EMSA are 
available upon request.  
 
Chromatin immunoprecipitation (ChIP) 
Inducible cells were seeded to a 50% density in 10 cm plates and protein expression was 
induced for 24 hours as described above. Crosslinking, lysis, sonication, immunoprecipitation, 
purification, and semi-quantitative or qRT-PCR were performed as previously described. 82, 84 
Primer sequences are available upon request. 
 
Fluorescent-activated cell Sorting (FACS) analysis 
For cell cycle analysis, 2x105 cells were seeded per 60-mm plate without tetracycline.  22 hours 
after plating, the cells were washed and tetracycline added as needed to equilibrate protein 
levels. 0.5 mM 5-fluorouracil (5-FU) was added 24 hours after induction as indicated and 48 
hours after that, cells were harvested by trypsinization and fixed overnight with methanol at –
20°C as previously described.85 Fixed cells and fragmented DNA were spun down for 5 minutes 
at 1660 g, resuspended with 1 ml cold PBS, and rehydrated for 30 minutes on ice. 86 After 
another spin, cells were resuspended in 0.5 ml of PBS solution containing RNase (50 µg/ml) 
and propidium iodide (PI) (60 µg/ml, Sigma), and incubated in the dark for 20 minutes at room 
temperature.  Stained cells were analyzed in a fluorescence-activated cell sorter (FACSCalibur, 
Becton Dickinson), gating away the debris and aggregates.  Cell cycle profiles and apoptotic 
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Figure 1.  Mutation of the two lysine residues within the tetramerization domain of p53 
does not alter subcellular localization or oligomerization.   
A) Schematic representation of the domains of p53.  Location of tumor-derived mutations and 
relative frequency are indicated by the height of the line found at each amino acid position. 
The primary sequence encompassing lysine residues 351 and 357 in the tetramerization 
domain is listed and asterisks denote the positions of these residues within the sequence.   
(B) Subcellular localization of tetramerization domain mutants.  Cell lines listed on left were 
induced to express p53 by removal of tetracycline for 24 hours.  DNA was visualized by 
staining with Sytox Green (‘Sytox’) and p53 localization was detected by incubation with 
DO-1 monoclonal antibody followed by goat anti-mouse secondary antibody conjugated to 
Cy5 (‘p53’, red).  The ‘+ tet’ image shows p53 staining without protein induction.  DIC 
image of wild-type shows the whole cell including its nucleus and nucleoli.  
(C) H1299 cells were transfected with WT-p53, 2KR-p53, or 2KQ-p53 expression constructs. 
24 hours later, cells were harvested and crosslinked with 0.005%, 0.01%, or 0.02% 
gluteraldehyde. Complexes were separated by SDS-page and subjected to immunoblot 
analysis.  
(D) Superposition of the 1H-15N TROSY-HSQC spectra of WT-p53 (black) and the 2KQ-p53 
mutant (red).  
(E) Superposition of the 1H-15N TROSY-HSQC spectra of WT-p53 (black) and the 2KR-p53 
mutant (green).  
 
Figure 2.  2KQ-p53 mutants show reduced ability to bind to and transactivate canonical 
p53 target genes, while 2KR-p53 mutants behave similarly to WT-p53.   
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(A) Western Blot analysis. Tetracycline levels were regulated (as indicated) to express 
equivalent amounts of wild-type or mutant p53 protein, as determined by immunoblotting 
with 40 g of whole cell extract.  Levels of p21 protein induction were determined for each 
cell line and actin levels were assessed as a loading control.   
(B) mRNA induction by p53 variants.  Total cellular RNA was prepared with cells from the 
same plate as (A) and cDNA was generated from Poly-A mRNA by oligo-dT priming.  2 l 
of each cDNA reaction was then used as a template in semi-quantitative RT-PCR to 
amplify the indicated endogenous target.  20 l PCR reactions were resolved by agarose 
gel electrophoresis, stained with ethidium bromide, and visualized on a Kodak gel imaging 
system.   
(C) Summary chart showing the average of three independent RT-PCR experiments, graphing 
arbitrary mRNA induction after normalizing to GAPDH and uninduced basal levels.  Error 
bars indicate standard deviation.  
(D and E) Chromatin binding in vivo.  Wild-type p53 (WT-p53), 2KR-17, or 2KQ-12 cell lines 
were induced with indicated tet amounts for 24 hours, crosslinked, lysed, sonicated, and 
processed for immunoblotting of p53, actin, or p21 (D) or ChIP (E).  p53 
immunoprecipitations were performed using a mixture of protein A and protein G beads 
preincubated with 1801 and DO-1 antibodies.  In vivo DNA binding to p21 5’, PIG3 and 
Mdm2 response elements was determined by PCR using primers specific for regions 
within these genes.  An aliquot of chromatin was taken before the immunoprecipitation and 
amplified by PCR to determine the relative number of cells in each ChIP sample (‘Input’).   
(F) Chart representing the average binding of each cell line to the indicated promoter, 
normalized to input and uninduced (+ tet) basal levels.  Error bars indicate the standard 




Figure 3.  Even when overexpressed, 2KQ-p53 is unable to arrest but can induce cell 
death.  
 (A) FACS analysis of wild-type and mutant p53 cell lines, expressing either no p53 or 
equivalent levels of protein.  Percentage of cells in G1, S, or G2-phase and/or apoptotic 
sub-G1 is indicated.  S-phase is highlighted to indicate arrest.   
(B) FACS analysis of WT-p53 and 2KQ-p53 cell lines, expressing either no p53 or equivalent 
levels of protein as indicated.  Cells were treated for 48 hours with 0.5 mM 5-FU. Sub-G1 
content is indicated to highlight apoptosis.  
(C)  p21 localization in H1299 cell lines.  Cell lines listed at top were grown in tetracycline-free 
media for 48 hours.  DNA was visualized by staining with DAPI and p21 was detected by 
incubation with p21 antibody (Santa Cruz Biotechnology, F-5), then with Alexa Fluor 488 
(sc-6246). 
(D and E) Western blot (D) and FACS analysis (E) at low WT-p53 and maximal 2KQ-p53 
protein levels to determine relative p21 induction and cell cycle arrest respectively.  
(F) FACS analysis of other 2KQ-p53 clones induced to express maximal levels of p53 and p21.  
 
Figure 4.  When overexpressed in vivo, 2KQ-p53 is deficient in binding and inducing 
miR-34a and CCNG1.   
(A) mRNA induction at low WT-p53 and maximal 2KQ-p53 p53 protein levels (as in Fig 3C) to 
analyze transactivation potential of the 2KQ-p53 mutant. Cells were induced or not with tet 
for 24 hours, harvested, and RNA was extracted. After cDNA was synthesized, samples 
were amplified for indicated p53 target genes by qRT-PCR.  
(B) ChIP analysis at low WT-p53 and maximal 2KQ-p53 protein levels to assess in vivo DNA 
binding. Samples were processed for ChIP as in Figure 2D, except that immunoprecipitated 
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DNA was analyzed by qRT-PCR. For (A) and (B), the average of three experiments is 
shown, and error bars show standard deviation of three experiments. 
(C) Purified p53 WT-p53 or 2KQ-p53 protein was incubated with 10 ng of p21 5’ RE or miR34a 
RE fluorescently labeled 44mer probe, in the presence of excess 44mer mutant p21 
competitor. P53:DNA complexes were separated by electrophoresis and visualized by the 
Licor Odyssey system.  
 
Figure 5.  Lysine 357 can be acetylated in vivo.  
 (A) H1299 cells were transfected with WT-p53 and either p300-HA, CBP-HA, or pCAF-Flag 
expression plasmids. Cells were lysed and proteins were separated by SDS-PAGE and 
transferred to a nitrocellulose membrane. Immunoblot analysis with indicated antibodies 
was performed.  
(B) H1299 cells were transfected with CBP-HA and either WT-p53 or 2KR-p53. After 24 hours, 
cells were lysed and analyzed as in A.   
(C) HCT116 cells expressing p53 (+/+) were treated with 5FU (0.5 mM ) for 24 hours or 
MG132 (25 uM) for 6 hours, lysed, and subjected to immunoblot analysis with antibodies 
recognizing p53, p53-Ac357, or actin. HCT116 p53-null cells (-/-) were run alongside as a 
control.  
(D) H1299 cells were transfected with constructs expressing single tetramerization domain 
lysine p53 mutants as indicated. Cells were lysed and immunoblot analysis to detect p53 
level and actin as indicated. (E) Parallel cultures of H1299 cells were treated as in D. RNA 
was extracted and analyzed by qPCR for p21 expression, which was normalized to hprt1 



































































































































Cancer  Alteration(s)  Mut. Type  
Renal cell (RCC)  K351N  Missense  
Lung  K351*  Nonsense  
Melanoma  K351E  Missense 
Adrenocortical (ACC)  K351E  Missense  
Bladder  Δ349-351  In-frame deletion 
 
Table I. Mutations in p53 tetramerization domain.  Table showing selected mutations in p53 
tetramerization domain from cancers across all TCGA datasets (Accessed from cBioPortal Sept 
2015). 
 
Cell Line  # Positive  % Positive  
WT-p53* 13/37 35% 
2KR-p53 2/28 7% 
2KQ-p53 9/20 45% 
T123A-p53* 2/52 4% 
 
Table II. Isolation of inducible clones.  Table showing the number and percent positive of 





SUPPLEMENTAL FIGURES  
 
Figure S1. The two lysine residues within the tetramerization domain of p53 are solvent-
accessible and their mutation does not alter p53 stability or global structure. (A) Cartoon 
representation of the NMR structure of the tetramerization domain created with PyMOL (PDB = 
3SAK, (Clore et al., 1995)).  Location of lysines 351 and 357 on all four chains are represented 
by a ball-and-stick model.  (B) H1299 cells were transfected with WT-p53 or 2KQ-p53 
expression constructs. 24 hours later, cells were treated with cycloheximide for the indicated 
time points, harvested, and analyzed by immunoblotting. Quantification of bands was performed 
with the Odyssey Licor system.  (C)  Combined amide 1H,15N chemical shift differences are 
plotted versus residue number. The combined chemical shift difference () is calculated using  
22 )1.0(  NHN   with HN and N representing the 1HN and 15N chemical shift 








Figure S2. 2KQ-p53 is deficient in inducing pro-apoptotic targets. (A) WT-p53, 2KQ-12, or 2KQ-
5 tetracycline inducible cells were treated to express equivalent amounts of physiological levels 
of p53, lysed, separated by SDS-PAGE and analyzed by immunoblotting. (B) RNA was 











Figure S3. WT-p53 can effect a G1 arrest even if p21 has been downregulated. (A) WT-p53 
tetracycline inducible cells were exposed to p21 siRNA for 48 hours, and treated or not to 
express maximal amounts of p53 protein. Samples were lysed, separated by SDS-PAGE and 
analyzed by immunoblotting to check p21 knockdown. (B) WT-p53 tetracycline inducible cells 
were treated as in A, and subjected to FACS analysis. The cell cycle curves were analyzed by 










Figure S4. 2KQ-p53 is deficient in binding and inducing miR-34a and CCNG1. (A) mRNA was 
analyzed from cells expressing low physiological levels of WT-p53 and maximal supra-
physiological 2KQ-p53 protein that was expressed from another clone (2KQ-12) of H1299 2KQ 
inducible cells than shown in Figure 4. Cells were induced or not with tet for 24 hours, 
harvested, and RNA was extracted. After cDNA was synthesized, samples were amplified for 
indicated p53 target genes by qRT-PCR. Graph is representative of three independent 
experiments. (B, C) H1299 cells were transfected with pTRE2 empty vector or 1 ug of either 
WT-p53 or 2KQ-p53. 24 hours later, cells were harvested and processed for a ChIP assay. 
Samples were processed for ChIP as in Figure 2D, except that immunoprecipitated DNA was 







Figure S5. Specificity of rabbit polyclonal antibodies generated against acetylated p53-K357. 
H1299 cells were transfected with either WT-p53 or 2KR-p53 and with or without CBP-HA 
expression plasmids. Cells were lysed and proteins were separated by SDS-PAGE and 
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The p53-related gene p63 is required for epithelial cell establishment and its expression 
is often altered in tumor cells. Great strides have been made in understanding the pathways and 
mechanisms that regulate p63 levels, such as the Wnt, Hedgehog, Notch, and EGFR pathways. 
We discuss here the multiple signaling pathways that control p63 expression as well as 
transcription factors and post-transcriptional mechanisms that regulate p63 levels. While a 
unified picture has not emerged, it is clear that the fine-tuning of p63 has evolved to carefully 
control epithelial cell differentiation and fate. 
 
Introduction 
At first glance, the tumor suppressor p53 and its family member p63 seem quite similar 
in function and exhibit a high degree of evolutionary conservation. In particular, the DNA-binding 
domains are about 60% identical at the amino acid level; however, the adjacent domains and C-
termini diverge drastically (1). While it was first thought that p63 and p53 could regulate similar 
sets of genes, it has become clear that these potent transcription factors possess some partially 
redundant functions, and some that are entirely unique (2–4). 
p63 is also unlike its family member p53 in that it is rarely mutated in human cancers. 
Instead, mutations in p63 lead to disorders with ectodermal dysplasia such as ankyloblepharon-
ectodermal dysplasia-clefting (AEC)/Hay–Wells syndrome, which can include symptoms like 
cleft lip/palate and skin erosions (5, 6). Other p63 syndromes can include split hand/foot 
malformation and alopecia as symptoms, but cancer predisposition is generally not seen (7–9). 
Due to differential promoter usage and splicing, there are at least six common isoforms. 
There are two classes that arise from different promoters, one with the N-terminal 
transactivation domain (TA), and the other set lacking the N-terminal transactivation domain 
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(ΔN). While the ΔN form can be dominant negative to the TA isoforms (2), the ΔNp63α isoform 
has been shown to contain an alternate transcriptional activation domain, suggesting it can also 
directly activate target genes (3, 10). Alternative splicing of the 3′ end of the TA and ΔNp63 
mRNAs produces the α, β, and γ isoforms, although only the α isoforms contain the sterile-α 
motif (SAM) domain and the transcription-inhibitory (TI) domain. Mutations in these domains can 
disrupt binding to the target Apobec-1-binding protein-1 (ABBP1), and deletion of both domains 
led to increased p21Waf1/Cip1 signaling, indicating that these domains can modulate target gene 
specificity (11, 12). 
As to the specific functions of these isoforms, mouse models have been instrumental in 
providing us with clues. Two groups reported that p63−/− mice were found to have severe limb 
and epithelial defects, including partial or missing epithelial stratification, and truncated 
forelimbs (13, 14). More recently, both the whole animal- and epidermal-specific deletion of 
ΔNp63α in mice led to skin erosions and impaired terminal differentiation of keratinocytes, 
demonstrating the importance of this isoform in the epithelial stratification process (15–17). It is 
possible that deregulation of p63 targets linked to cell–matrix adhesion and epithelial 
morphogenesis causes these skin abnormalities (18–20). 
Furthermore, loss of epithelial cells in ΔNp63-null mice suggested that this isoform is 
essential for the establishment of epidermal progenitor cells (13). Pellegrini et al. (21) suggested 
that p63 is found in the stem cells of the proliferative compartment, but not in the transit 
amplifying keratinocytes that have exited the compartment. When it comes to the caudal 
endoderm, Pignon et al. (22) revealed that the p63-expressing cells are capable of 
differentiating into prostate, bladder, and colorectal epithelia. Another report found p63 to be 
essential for the proliferative ability and differentiation of the epidermis; however, in a thymic 
model, p63 was only required for clonogenicity but not for lineage commitment or differentiation 
(23, 24). Intriguingly, depletion of ΔNp63 or its target DGCR8, an miRNA processing factor, 
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allowed keratinocytes to enter a multipotent stem cell state, suggesting that ΔNp63 is needed to 
maintain the keratinocyte differentiation state (25). Finally, an AEC-like mutation in p63 led to 
reduced proliferative and clonogenic potential in epithelial cells (26). Together these studies 
make a compelling case for p63 in the maintenance and regulation of epithelial stem cells. 
Meanwhile, TAp63 ablation demonstrated that this isoform monitors the integrity of the 
germline after cellular stresses (27, 28). In particular, γ-irradiation was shown to induce 
tetramerization of TAp63α from inactive dimers, leading to greatly increased target binding 
ability (29), and inducing cell cycle arrest or an apoptotic response. 
Yet, p63 levels are sometimes altered in tumors. Many groups have reported increased 
expression in cancers, especially in head and neck squamous cell carcinomas (HNSCC) (30, 
31). Indeed, amplification or overexpression of p63 has frequently been observed in lung 
cancers, and more rarely in HNSCC (32–34). However, p63 expression is lost in more invasive 
prostate and breast cancers, and this loss is associated with worse prognosis in some cases 
(35, 36). It has been theorized that the tissue context, as well as the balance between TA and 
ΔN isoforms, could partially explain this dichotomy. 
So how does p63 impact cancer formation? The last decade has seen a preponderance 
of direct targets unearthed, including adhesion-related β4 integrin, the tissue integrity factor 
Perp, the Notch ligands Jagged1 and Jagged2, keratins 5 and 14, and EGF receptor (18, 19, 
37–41). Cancer-related targets like N-cadherin, Id3, MMP13, and Wnt-4 can be activated by 
p63; however, p63 can also induce Sharp1 and Cyclin G2 expression, which have been shown 
to be suppressors of breast cancer metastasis (42–45). Additionally, phosphorylated ΔNp63α 
was found to associate with components of the splicing machinery, as well as transcription 
factors SREBP1 and E2F1, in regulation of metabolic and cell cycle-related processes (46). 
p63 is also known to regulate a diverse set of microRNAs. A prominent target is miR-
205, a repressor of epithelial–mesenchymal transition (EMT) and metastasis in bladder and 
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pancreatic cancers (36, 47, 48). In contrast to the role of miR-205, members of the miR-17 
family (miR-17, miR-20b, and miR-106a) are regulated by p63 and Myc, and were found to 
target Rb, p21, and JNK2, suggesting that they are oncomirs (49–51). Additionally, p63 can 
repress the prominent cell cycle regulators miR-34a and miR-34c, thereby affecting cellular 
progression in a p53-independent manner (52). 
A data mining approach also identified p63 and the p53-related p73 gene as key 
regulators of microRNAs differentially expressed in ovarian carcinomas, including miR-200a, 
miR-200b, and miR-429 (53). Similarly, mir-193a was repressed by both p63 and p73, although 
its induction leads to p73 inhibition (54). For more on p63 regulation of microRNAs, see the 
review by Candi et al. (55). 
Taken together, p63, like p53 and p73, can regulate a host of processes, some of which 
are known regulators for or against tumor growth. As suggested by the opposite expression of 
p63 in different tumor types, the context of the cell type appears to be critical to which p63 
targets have the dominant effects in each cell. Whether targets are differentially expressed or 
have different activities in different cell types needs to be investigated further. 
As ΔNp63 is required for the formation of stratified epithelial layers and is the primary 
isoform expressed in the basal layer of epithelial tissues, it is subject to multiple modes of 
tissue-specific regulation (13, 14). As described below, a number of signaling pathways and 












Figure 1. Signaling pathway regulation of ΔNp63. Signaling pathways reported to 
regulate ΔNp63 levels are indicated. The thick, blue arrow indicates autoregulation. *Note 
that the Hedgehog and NF-κB pathways repress ΔNp63 levels while simultaneously 
activating expression from the TAp63 promoter. See text for feedback regulation where 
p63 regulates multiple components of these pathways (not shown here). 
 
Notch signaling 
One prominent pathway is Notch, which can control epidermal differentiation as well as 
other developmental pathways (56, 57). Notch activation was found to suppress p63 expression 
in keratinocytes, ectodermal progenitor cells, and mammary epithelial cells (58–60). The 
repression in keratinocytes was dependent on the IRF3 and IRF7 transcription factors (59). In 
mouse mammary epithelial cells, the Notch-mediated repression of p63 functions through the 
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CBF1/RBP-Jk transcription factor (60). In addition to these cases, there has been a report of 
Notch activation of p63 in fibroblasts (61), suggesting differing cell-specific modes of regulation. 
The Notch-to-p63 pathway is subject to feedback regulation by ΔNp63, as it can activate 
Notch pathway gene expression (58, 60, 62). This loop could delineate the boundary between 
basal and luminal mammary cells as well as allow for ectodermal specification during 
development (58, 60). 
As with p63 mutations, alterations in interferon regulatory factor 6 (IRF6) are associated 
with craniofacial abnormalities like cleft lip and/or palate (63, 64). Both IRF6 and p63 are 
required for normal palate development, so the finding that ΔNp63 induces IRF6 expression is 
logical, but surprisingly, IRF6 in turn causes proteasomal degradation of ΔNp63 (65, 66). Notch 
has also been found to activate IRF6 expression in keratinocytes (67). Together, these results 
suggest a Notch/p63/IRF6 axis regulates genes involved in epithelial development. Importantly, 
Notch, p63, and IRF6 genes were found mutated in about 30% of HNSCC cases, suggesting 
that this developmental pathway can be hijacked to promote tumor growth (68). 
 
Hedgehog signaling 
Hedgehog is another essential pathway for development (69, 70), and it is reported to 
regulate p63 expression. Hedgehog activation is seen in various cancers including lung, 
prostate, and breast (71, 72). Hedgehog ligands including Indian Hedgehog (IHH) can lead to 
activation of the Gli3 transcription factor, while absence of these ligands leads to a repressive 
form of the Gli3 transcription factor, termed Gli3R (73, 74). This balance of Gli3 forms can 
control p63 isoform formation, as IHH induction of Gli3 actually upregulates TAp63 expression 
while reducing ΔNp63 promoter usage (75). Again, there is a regulatory loop here since TAp63 
expression can increase IHH expression. Similarly, both TA and ΔNp63 β and γ isoforms can 
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activate Sonic Hedgehog (SHH) expression and recently ΔNp63 was found to induce 
expression of Gli2 and the Hedgehog receptor Ptch1, affecting mammary stem cell renewal (76, 
77). In addition, it was posited that some of the developmental defects observed in the p63−/− 
mice may occur due to subsequent repression of SHH and other Hedgehog pathway genes 
(76). Other connections between the p63 and Hedgehog pathways include ΔNp63 activation of 
Gli2 and Gli3 as well as suppressor of fused (SUFU) (78–80). As SUFU is an inhibitor of the Gli 
proteins, these contrasting effects show the complexity of this signaling system. Nevertheless, 
together these results suggest a strong connection between the Hedgehog and p63 signaling 
pathways that could control normal epithelial differentiation or cancer progression. 
 
Wnt signaling 
Strikingly, mutations in the WNT genes also cause similar craniofacial abnormalities as 
p63 and IRF6 mutations (81, 82). Moreover, mutations in the Pbx genes in mice resulted in a 
similar phenotype and perturbed Wnt signaling (82). Further analysis demonstrated a Pbx-
Wnt9b/Wnt3-p63-IRF6 signaling axis controlling development of the midfacial ectoderm (82). 
Chromatin immunoprecipitation and reporter genes suggested that p63 is directly regulated by 
the Wnt pathway through binding of Lef1/Tcf with β-catenin to a region between the TA and 
ΔNp63 promoters (82), although another report identified a β-catenin responsive site within the 
proximal ΔNp63 promoter (83). Recently, the Hedgehog pathway was also shown to be 
connected to craniofacial defects (84). Compound mutations in the Hedgehog pathway genes 
Hedgehog acyltransferase (Hhat) and Patched 1 (Ptch1) led to a cleft lip-like phenotype and 




Analysis of keratinocyte differentiation has led to a different characterization of the p63, 
Wnt, and Notch signaling pathways. Knockdown of p63 caused reduced Wnt and Notch 
signaling (50, 51), suggesting that they lie downstream of p63 in contrast to the models of 
craniofacial development. This could be reconciled as part of a feedback regulation pathway as 
described above for Notch and p63. Additionally, the activation of Wnt and Notch by p63 may be 
dependent upon the availability of other transcription factors. For instance, the depletion of p63 
led to reduced Myc gene expression via lowered Wnt/β-catenin and Notch signaling, and this is 
consistent with the requirement of both p63 and Myc for keratinocyte proliferation (50, 51). p63 
was also found to regulate the expression of Myc and β-catenin in esophageal squamous cell 
carcinomas, suggesting the general functioning of a p63/β-catenin/Myc pathway in 
tumorigenesis (85). Finally, ΔNp63 was shown to upregulate the Wnt receptor Fzd7, leading to 
enhanced mammary stem cell formation and clonogenic potential (86). 
 
FGFR2/EGFR signaling 
Mutations in the FRGR2 gene (also known as KGFR) can also lead to craniofacial 
disorders such as cleft lip and Crouzon’s syndrome (87, 88). The splice variant FGFR2-2b is an 
epithelial-specific receptor for ligands like FGF1 and FGF7 (KGF), and is required for 
embryogenesis and adult tissue homeostasis (89). FGFR signaling and ΔNp63 can influence 
each other, as ΔNp63 activates expression of FGFR2 in thymic epithelial cells (90) and KGF-
induced ΔNp63 expression in limbal epithelial cells (91). KGF’s effects on ΔNp63 require p38 
MAPK, suggesting a novel pathway for regulation of p63 (91). Furthermore, mutations in p63 
that cause AEC syndrome led to impaired FGFR2 gene expression and increased splicing of 
the mesenchymal FGFR2-2c isoform (11, 26). Together, the combination of FGFR2 activation of 
ΔNp63 and ΔNp63 induction of specific isoforms of FGFR2 are likely to lead to increased 
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proliferation of specific epithelial cell types. This could enhance proliferation of progenitor cells, 
but might block progression of specific epithelial cancers. 
Interestingly, FGFR2 can induce expression of the epithelial-specific transcription factor 
Elf5, and deletion of Elf5 causes altered expression of ΔNp63 in the luminal compartment of 
mouse mammary tissue (92–94). This suggests a pathway for cell type-specific expression of 
ΔNp63 mediated by Elf5. 
The tyrosine kinase receptor EGFR has also been found to induce ΔNp63 expression. In 
one case, this was through phosphatidylinositol-3-kinase (PI3K) signaling in keratinocytes (42), 
while in two types of carcinomas EGFR activation of ΔNp63 was found to be mediated by 
STAT3 (95, 96). STAT3 was also required for ΔNp63 expression in limbal keratinocytes (97). 
The inhibition of the STAT3 growth-stimulatory pathway allowed the concomitant differentiation 
of the limbal keratinocytes, further suggesting the importance of ΔNp63 regulation in these and 
likely other epithelial cells. The PI3K and STAT3 pathways may be connected through mTOR 
signaling, as Ma et al. (62) found that PI3K activation of mTOR led to mTOR-dependent 
activation of the STAT3-p63-Jagged pathway. This highlights the interconnectedness of these 
signaling pathways, and the role of STAT3 as a key regulator of p63. However, a clear 
mechanism for how STAT3 directly regulates p63 remains to be determined. 
 
Regulation of ΔNp63 during the Epithelial to Mesenchymal Transition 
 Epithelial cells can undergo an EMT during development and during carcinogenesis, 
progressing to a more invasive and metastatic phenotype. This differentiation is thought to allow 
the cancerous cells greater motility and increased metastatic potential [see reviews by Thiery 
(98) and Kang and Massagué (99)]. The expression of ΔNp63 is repressed during this transition 
(100, 101). Transcription factors that can induce EMT include Snail, Slug (also known as 
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Snail2), and Zeb1, and all of these can repress ΔNp63 in epithelial cells (100, 102–104). This 
inhibition, however, may be due to a feedback loop, as ΔNp63 expression can inhibit EMT by 
activation of miR-205, which suppresses Zeb1 and Zeb2 expression (36, 48). 
Other transcription factors involved in control of EMT are Ovol1 and Ovol2 (85, 105). 
These factors can repress Zeb1 expression; however, it was also found that ΔNp63 expression 
increased in Ovol1- and Ovol2-deficient cells, and that Ovol2 could bind to several sites within 
the ΔNp63 promoter (85). Ovol2 may be upstream of ΔNp63 in an EMT-inducing pathway; 
alternatively, there may be feedback of Ovol2 to ΔNp63 (as there is with Zeb1 and ΔNp63) with 
ΔNp63 being an activator of Ovol2. In general, it remains to be characterized how ΔNp63 is 
regulated during EMT in different epithelial cell types. 
 
Transcription Factor Control 
While we have mentioned a number of transcription factors as regulators of ΔNp63, a 
clear picture has yet to emerge on which factors are critical direct regulators of ΔNp63 and 
through which sequence elements they act near the ΔNp63 gene. 
It is possible that multiple pathways regulate p63 through the C/EBP family of 
transcription factors, as they have been repeatedly found to regulate p63. C/EBPδ was found to 
bind to multiple regions of the ΔNp63 gene in human keratinocytes (106, 107). Antonini et al. 
(108, 109) assayed all conserved regions throughout the p63 gene and identified two, termed as 
C38 and C40, in the second intron of the ΔNp63 gene that affect expression in mouse 
keratinocytes. The C40 region was needed for expression in keratinocytes, while C38 provided 
repression during calcium-dependent differentiation. They found that C/EBPα and β bound to 
the C38 and C40 regions, and that overexpression of these factors repressed reporter gene 
expression. In addition, siRNA depletion of C/EBPα and β slightly increased p63 mRNA levels in 
267 
 
differentiating cells, suggesting that C/EBPα and β are direct repressors of p63 expression. 
Furthermore, these investigators found AP-2 to be an activator of the C40 region and the POU 
domain protein Pou3f1 to be a repressor (108, 109). In contrast to the repression by C/EBPα 
and β described above, another group described a C/EBP site within the proximal human 
ΔNp63 promoter, which was required for expression in A431 epidermal carcinoma cells (100). 
C/EBPα was also found to positively activate a site within the mouse ΔNp63 promoter in mouse 
keratinocytes (110). Finally, after chemical stress, the cytosolic NAD(P)H:quinone 
oxidoreductase 1 (NQO1) was found to bind to and inhibit C/EBPα, partially accounting for its 
inhibition of ΔNp63 expression (110, 111). These contrasting effects of C/EBP may reflect 
different family members, DNA-binding sites or cell types used, suggesting that further studies 
are needed to better understanding of the roles these factors play in regulating p63. 
Other transcription factors have also been found to regulate the p63 gene. An OCT4 
binding site within the TAp63 promoter activates its expression, suggesting its involvement in 
stem cell regulation (112). Another pluripotency factor, Sox2, bound to p63 protein and localized 
with it to common gene loci in chromatin immunoprecipitation experiments. This binding 
occurred in squamous cell carcinoma cells, but not in embryonic stem cells, suggesting that p63 
may co-opt pluripotency factors for differentiated cell-specific expression (105). 
 
p63 Autoregulation and Interaction with p53 
p63 positively activates its own expression through binding to the C38 and C40 intronic 
enhancers as well as to its own proximal promoter (108, 109, 113). Overexpression of the 
ΔNp63γ isoform increased expression of ΔNp63α in HeLa cells, and of a promoter reporter 
gene in keratinocytes (108, 113). Overexpression of ΔNp63 was also found to increase 
expression of endogenous ΔNp63 in a nasopharyngeal carcinoma cell line where activation was 
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dependent upon the STAT3 transcription factor (95). Whether binding of p63 to its promoter is 
direct or through another transcription factor, the evidence consistently shows that it positively 
feeds back to augment its own expression. 
Initially, p63 expression was found to be suppressed by stresses, such as UV irradiation, 
that stimulate p53 expression (114–116). Binding of p53 to the ΔNp63 proximal promoter was 
detected in a mammary epithelial cell line, suggesting direct regulation by p53 of ΔNp63 
expression (116). Mutant p53 proteins could also bind to the p63 protein in tumor cell lines and 
inhibit its activity (117), while in carcinoma cells it was shown that mutant p53 together with 
SMADs could sequester p63, resulting in inhibition of p63 and increased metastatic potential 
(45). While these results suggest that wild-type and mutant p53 can repress p63 expression and 
function, more work is needed to demonstrate the significance of this effect in human cancers, 
and exactly how this could contribute to tumorigenesis. 
 
Post-Transcriptional Regulation 
p63 levels are also regulated by miRNA, ubiquitin-dependent proteasomal degradation, 
and protein phosphorylation. Notably, miR-203 can repress p63 expression in supra-basal 
epithelial cells, contributing to definition of the border between progenitor and differentiated 
epithelial cells (118, 119). In addition, miR-203 expression was activated during luminal 
mammary epithelial differentiation and ectopic expression of miR-203 stimulated EMT (120). 
These results suggest that miR-203 is an essential part of the epithelial differentiation pathway. 
Other miRNAs have also been found to regulate p63 expression. miR-92 targets 
ΔNp63α and β in the HaCaT keratinocyte cell line and in myeloid cells, respectively, and miR-
302 suppressed p63 expression in germ cells (121, 122). The apotosis stimulating protein of 
p53 (ASPP) family of p53 coactivators has similarities with protein phosphatases (123). A 
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related family member iASPP (also known as PPP1R13L) is an inhibitor of apoptosis and can 
also bind to p63 (124). The expression of iASPP in the basal layer of skin cells is strikingly 
similar to that of p63, and knockdown of iASPP promoted epithelial differentiation (125). 
However, rather than regulating p63 by protein–protein interaction, Chikh et al. (125) found that 
iASPP inhibits the expression of two miRNAs, miR-574-3p and miR-720, which inhibit p63 
expression. There is an auto-regulatory loop as p63 is needed for expression of these miRNAs 
and binds to the promoter of the iASPP gene. These experiments point to a critical role of 
iASPP and repression of its target miRNAs in maintenance of p63 expression and the epithelial 
phenotype. 
p63 protein stability is also regulated by the ubiquitin–proteasome system, adding 
another layer of regulation (126). One example is p53-induced RING-H2 (Pirh2), an E3 ubiquitin 
ligase, which can directly bind to p63 and cause its poly ubiquitination and degradation in 
keratinocytes (127, 128). Pirh2 was also a transcriptional target of ΔNp63, establishing an auto-
regulatory loop, and was required for epithelial differentiation. Another E3 ubiquitin ligase, 
Ring1B, part of the polycomb repressive complex 1 (PRC1), was found to target p63 (129). 
Ring1b is overexpressed in breast and pancreatic cancer cells (129, 130), suggesting a possible 
mechanism for p63 suppression in these tumors. 
While p53 is stabilized by DNA damaging agents, such as UV irradiation, ΔNp63 is 
degraded (115, 131, 132). Two mechanisms related to the NF-κB pathway have been found to 
mediate this degradation. In the first, IKKβ binds to ΔNp63 and phosphorylates it to induce 
ubiquitination and degradation (133). A second mechanism is direct binding of the p65 subunit 
of NF-κB to ΔNp63 in cisplatin-treated cells, leading to proteasomal degradation of ΔNp63 
(134). The reduction of ΔNp63 augmented activation of p53 target genes and may contribute to 
cell death in UV-damaged cells. NF-κB repression of p63 may also have a role in epithelial cell 
differentiation, as overexpression of the NF-κB factor p65 in epithelial cells led to p63 
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downregulation and increased EMT (103). ΔNp63 also bound to target genes with p65, 
suggesting that these two factors coordinately regulate a gene program promoting cell survival 
(135). 
NF-κB can also activate the TAp63 promoter, suggesting that a shift to the TAp63 form 
could also underlie the DNA damage response (136). Again, there is an auto-regulatory loop 
where TAp63 activates p65 expression as well as stabilizes p65 protein by direct binding (137, 
138). 
An alternative mechanism for ΔNp63 degradation as part of the DNA damage response 
is phosphorylation on threonine 397 by the protein kinase HIPK2 (139). HIPK2 has previously 
been identified as a DNA damage-induced kinase targeting p53 (140), such that it provides a 
mechanism to coordinate p63 levels with p53 and other aspects of the DNA damage response. 
For more regulators of p63 protein stability, see the review by Li and Xiao (126). 
 
Conclusion 
p63 has been termed a master regulator of epithelial cells, and it is often suppressed in 
order for these cells to differentiate (21, 141, 142). We now understand more about how p63 is 
regulated, uncovering a large array of signaling pathways (Figure 1) and feedback regulation 
that controls expression of components of the signaling pathway as well as p63. Besides the 
processes of differentiation and development, p63 is also regulated during the DNA damage 
response, suggesting that it can mediate the more immediate fate of cells. The regulation of 
ΔNp63 expression, the predominant form in epithelial cells, includes transcriptional and post-
transcriptional components. The relative importance of each pathway is still unclear and their 
usage will likely vary in different cell types and developmental stages. While there are multiple 
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reports of some pathways and mechanisms, common regulatory sequence element(s) for 
control of the p63 gene across systems have yet to be established. 
It will also be important to understand how modulation of p63 levels affects cancer 
formation. The combination of heterozygous p63 and p53 genotypes in mice yielded conflicting 
results, giving either greater or reduced tumor burdens (143, 144). Additionally, while ΔNp63 is 
often highly expressed or amplified in squamous carcinomas, other tumors such as esophageal 
adenocarcinomas and hepatocellular carcinomas generally lack expression (145–147). 
Naturally, these cancers arise from diverse tissues, but it is confounding that p63 can have 
oncogenic effects in some cases and tumor suppressive ones in others. As EMT is part of 
metastatic progression of some carcinomas, it is interesting that repression of p63 was seen 
during this differentiation process - is this regulation critical for progression of tumor cells to a 
more aggressive state? Further, which of the pathways described here, if any, are altered in 
cancer cells and modulate p63 levels in a critical manner? 
Other open questions concern p63 promoter usage and splicing – what factors 
determine the balance of usage of the TA and ΔN promoters, and what governs the presence of 
different 3′ splicing isoforms? How does the balance of these 3′ isoforms lead to differences in 
development or oncogenesis? Finally, can the signaling pathways that control p63 levels be 
controlled to provide a therapeutic benefit in specific cancers? We can hope that the following 
years will bring a greater understanding of this master regulator of epithelial biology. 
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